USUBJID,age,sex,racegr1,epas05fl,dctreas,trtsdt,trtdurm,weightbl,heightbl,bmibl,ecogbl,diagnos,tumstage,metast,sysregn,borirc,pfsirc,pfsirccn,borinv,pfsinv,pfsinvcn,osdur,oscnsr,VISITNUM,eqanx,eqcare,eqmob,eqpain,equact,eqvas,VISIT,QSDTC,timemth,male,utility
LOXO-TRK-15002-101-001,72,M,White,Y,Subject Decision,10/13/2015,53.32238193,81.7,165,30.00918274,1,Salivary gland,III,Metastatic,0,Complete response,52.20533881,1,Complete response,52.20533881,1,53.38809035,1,19,1,2,2,1,2,85,CYCLE 19 DAY 1,2/28/2017,16.591375,1,0.7310856
LOXO-TRK-15002-101-001,72,M,White,Y,Subject Decision,10/13/2015,53.32238193,81.7,165,30.00918274,1,Salivary gland,III,Metastatic,0,Complete response,52.20533881,1,Complete response,52.20533881,1,53.38809035,1,22,1,1,2,2,2,85,CYCLE 22 DAY 1,5/23/2017,19.35113,1,0.73012203
LOXO-TRK-15002-101-001,72,M,White,Y,Subject Decision,10/13/2015,53.32238193,81.7,165,30.00918274,1,Salivary gland,III,Metastatic,0,Complete response,52.20533881,1,Complete response,52.20533881,1,53.38809035,1,28,2,2,2,2,1,90,CYCLE 28 DAY 1,11/8/2017,24.90349,1,0.6263665
LOXO-TRK-15002-101-001,72,M,White,Y,Subject Decision,10/13/2015,53.32238193,81.7,165,30.00918274,1,Salivary gland,III,Metastatic,0,Complete response,52.20533881,1,Complete response,52.20533881,1,53.38809035,1,31,2,1,2,2,1,95,CYCLE 31 DAY 1,1/30/2018,27.63039,1,0.71091998
LOXO-TRK-15002-101-001,72,M,White,Y,Subject Decision,10/13/2015,53.32238193,81.7,165,30.00918274,1,Salivary gland,III,Metastatic,0,Complete response,52.20533881,1,Complete response,52.20533881,1,53.38809035,1,34,1,1,3,2,2,90,CYCLE 34 DAY 1,4/25/2018,30.422998,1,0.71290088
LOXO-TRK-15002-101-001,72,M,White,Y,Subject Decision,10/13/2015,53.32238193,81.7,165,30.00918274,1,Salivary gland,III,Metastatic,0,Complete response,52.20533881,1,Complete response,52.20533881,1,53.38809035,1,37,1,2,2,1,2,90,CYCLE 37 DAY 1,7/17/2018,33.149899,1,0.7310856
LOXO-TRK-15002-101-001,72,M,White,Y,Subject Decision,10/13/2015,53.32238193,81.7,165,30.00918274,1,Salivary gland,III,Metastatic,0,Complete response,52.20533881,1,Complete response,52.20533881,1,53.38809035,1,43,2,2,3,1,2,90,CYCLE 43 DAY 1,1/8/2019,38.899384,1,0.6560936
LOXO-TRK-15002-101-001,72,M,White,Y,Subject Decision,10/13/2015,53.32238193,81.7,165,30.00918274,1,Salivary gland,III,Metastatic,0,Complete response,52.20533881,1,Complete response,52.20533881,1,53.38809035,1,46,2,3,2,2,2,90,CYCLE 46 DAY 1,3/26/2019,41.429157,1,0.56548113
LOXO-TRK-15002-101-001,72,M,White,Y,Subject Decision,10/13/2015,53.32238193,81.7,165,30.00918274,1,Salivary gland,III,Metastatic,0,Complete response,52.20533881,1,Complete response,52.20533881,1,53.38809035,1,49,2,2,3,1,3,95,CYCLE 49 DAY 1,6/18/2019,44.188911,1,0.6349712
LOXO-TRK-15002-101-001,72,M,White,Y,Subject Decision,10/13/2015,53.32238193,81.7,165,30.00918274,1,Salivary gland,III,Metastatic,0,Complete response,52.20533881,1,Complete response,52.20533881,1,53.38809035,1,52,2,2,4,1,2,85,CYCLE 52 DAY 1,9/9/2019,46.91581,1,0.62992287
LOXO-TRK-15002-101-001,72,M,White,Y,Subject Decision,10/13/2015,53.32238193,81.7,165,30.00918274,1,Salivary gland,III,Metastatic,0,Complete response,52.20533881,1,Complete response,52.20533881,1,53.38809035,1,55,2,3,4,1,3,70,CYCLE 55 DAY 1,12/3/2019,49.70842,1,0.58001399
LOXO-TRK-15002-101-001,72,M,White,Y,Subject Decision,10/13/2015,53.32238193,81.7,165,30.00918274,1,Salivary gland,III,Metastatic,0,Complete response,52.20533881,1,Complete response,52.20533881,1,53.38809035,1,58,2,3,3,2,3,70,CYCLE 58 DAY 1,2/24/2020,52.435318,1,0.55006367
LOXO-TRK-15002-101-002,43,F,White,Y,Disease Progression,11/5/2015,0.952772074,66.6,165,24.46280992,1,Salivary gland,Not reported,Metastatic,5,Progressive disease,0.722792608,0,Progressive disease,0.722792608,0,12.38603696,0,,,,,,,,,,,0,
LOXO-TRK-15002-101-003,74,M,White,Y,Disease Progression,11/4/2015,3.679671458,63.8,170,22.07612457,1,Appendix,IV,Metastatic,2,Stable disease,3.482546201,0,Stable disease,3.482546201,0,7.655030801,1,,,,,,,,,,,1,
LOXO-TRK-15002-101-004,61,F,All others,Y,Adverse Event,12/2/2015,38.6036961,79.2,170,27.40484429,1,Soft tissue sarcoma,III,Metastatic,0,Surgical complete response,43.49897331,0,Partial response,41.724846,1,55.39219713,1,5,2,1,2,1,1,78,CYCLE 5 DAY 1,3/23/2016,3.7125256,0,0.80853075
LOXO-TRK-15002-101-004,61,F,All others,Y,Adverse Event,12/2/2015,38.6036961,79.2,170,27.40484429,1,Soft tissue sarcoma,III,Metastatic,0,Surgical complete response,43.49897331,0,Partial response,41.724846,1,55.39219713,1,7,1,1,2,1,1,90,CYCLE 7 DAY 1,5/18/2016,5.5523615,0,0.8935501
LOXO-TRK-15002-101-004,61,F,All others,Y,Adverse Event,12/2/2015,38.6036961,79.2,170,27.40484429,1,Soft tissue sarcoma,III,Metastatic,0,Surgical complete response,43.49897331,0,Partial response,41.724846,1,55.39219713,1,16,1,1,3,2,2,80,CYCLE 16 DAY 1,1/25/2017,13.831622,0,0.7081961
LOXO-TRK-15002-101-004,61,F,All others,Y,Adverse Event,12/2/2015,38.6036961,79.2,170,27.40484429,1,Soft tissue sarcoma,III,Metastatic,0,Surgical complete response,43.49897331,0,Partial response,41.724846,1,55.39219713,1,19,1,1,3,3,3,70,CYCLE 19 DAY 1,4/20/2017,16.624229,0,0.64754343
LOXO-TRK-15002-101-004,61,F,All others,Y,Adverse Event,12/2/2015,38.6036961,79.2,170,27.40484429,1,Soft tissue sarcoma,III,Metastatic,0,Surgical complete response,43.49897331,0,Partial response,41.724846,1,55.39219713,1,22,2,1,3,3,1,60,CYCLE 22 DAY 1,7/13/2017,19.383984,0,0.63176882
LOXO-TRK-15002-101-004,61,F,All others,Y,Adverse Event,12/2/2015,38.6036961,79.2,170,27.40484429,1,Soft tissue sarcoma,III,Metastatic,0,Surgical complete response,43.49897331,0,Partial response,41.724846,1,55.39219713,1,25,2,1,4,3,3,60,CYCLE 25 DAY 1,10/5/2017,22.143738,0,0.5867098
LOXO-TRK-15002-101-004,61,F,All others,Y,Adverse Event,12/2/2015,38.6036961,79.2,170,27.40484429,1,Soft tissue sarcoma,III,Metastatic,0,Surgical complete response,43.49897331,0,Partial response,41.724846,1,55.39219713,1,28,2,2,3,3,3,80,CYCLE 28 DAY 1,1/11/2018,25.363449,0,0.52991509
LOXO-TRK-15002-101-004,61,F,All others,Y,Adverse Event,12/2/2015,38.6036961,79.2,170,27.40484429,1,Soft tissue sarcoma,III,Metastatic,0,Surgical complete response,43.49897331,0,Partial response,41.724846,1,55.39219713,1,31,2,1,2,1,2,80,CYCLE 31 DAY 1,3/15/2018,27.433266,0,0.75890291
LOXO-TRK-15002-101-004,61,F,All others,Y,Adverse Event,12/2/2015,38.6036961,79.2,170,27.40484429,1,Soft tissue sarcoma,III,Metastatic,0,Surgical complete response,43.49897331,0,Partial response,41.724846,1,55.39219713,1,34,1,1,3,2,3,80,CYCLE 34 DAY 1,6/14/2018,30.422998,0,0.69158673
LOXO-TRK-15002-101-004,61,F,All others,Y,Adverse Event,12/2/2015,38.6036961,79.2,170,27.40484429,1,Soft tissue sarcoma,III,Metastatic,0,Surgical complete response,43.49897331,0,Partial response,41.724846,1,55.39219713,1,37,2,1,3,1,3,85,CYCLE 37 DAY 1,9/6/2018,33.182751,0,0.70313996
LOXO-TRK-15002-101-004,61,F,All others,Y,Adverse Event,12/2/2015,38.6036961,79.2,170,27.40484429,1,Soft tissue sarcoma,III,Metastatic,0,Surgical complete response,43.49897331,0,Partial response,41.724846,1,55.39219713,1,47,3,4,4,3,4,45,CYCLE 47 DAY 1,6/20/2019,42.611908,0,0.26964325
LOXO-TRK-15002-101-005,54,F,White,Y,Disease Progression,1/12/2016,9.166324435,62.3,157,25.27485902,1,Colon,II,Metastatic,2,Partial response,7.359342916,0,Partial response,5.519507187,0,36.46817249,0,,,,,,,,,,,0,
LOXO-TRK-15002-101-006,33,F,White,Y,Disease Progression,2/23/2016,0.919917865,56.3,156,23.13445102,1,Breast,III,Metastatic,9,Progressive disease,0.952772074,0,Progressive disease,0.952772074,0,0.952772074,1,0,1,2,4,4,3,45,CYCLE 1 DAY 1,2/23/2016,0,0,0.35899884
LOXO-TRK-15002-101-007,64,M,White,Y,Physician Decision,3/1/2016,36.79671458,91.6,163,34.47626934,0,Salivary gland,Not reported,Metastatic,1,Partial response,35.87679672,1,Partial response,35.87679672,1,36.82956879,1,0,3,2,2,3,3,50,CYCLE 1 DAY 1,3/1/2016,0,1,0.48979455
LOXO-TRK-15002-101-007,64,M,White,Y,Physician Decision,3/1/2016,36.79671458,91.6,163,34.47626934,0,Salivary gland,Not reported,Metastatic,1,Partial response,35.87679672,1,Partial response,35.87679672,1,36.82956879,1,3,2,2,3,1,2,75,CYCLE 3 DAY 1,4/26/2016,1.87269,1,0.65052086
LOXO-TRK-15002-101-007,64,M,White,Y,Physician Decision,3/1/2016,36.79671458,91.6,163,34.47626934,0,Salivary gland,Not reported,Metastatic,1,Partial response,35.87679672,1,Partial response,35.87679672,1,36.82956879,1,5,2,3,2,2,3,75,CYCLE 5 DAY 1,6/21/2016,3.7125256,1,0.55388218
LOXO-TRK-15002-101-007,64,M,White,Y,Physician Decision,3/1/2016,36.79671458,91.6,163,34.47626934,0,Salivary gland,Not reported,Metastatic,1,Partial response,35.87679672,1,Partial response,35.87679672,1,36.82956879,1,7,2,1,2,1,2,80,CYCLE 7 DAY 1,8/16/2016,5.5523615,1,0.76345956
LOXO-TRK-15002-101-007,64,M,White,Y,Physician Decision,3/1/2016,36.79671458,91.6,163,34.47626934,0,Salivary gland,Not reported,Metastatic,1,Partial response,35.87679672,1,Partial response,35.87679672,1,36.82956879,1,9,2,2,3,1,2,80,CYCLE 9 DAY 1,10/11/2016,7.3921971,1,0.65052086
LOXO-TRK-15002-101-007,64,M,White,Y,Physician Decision,3/1/2016,36.79671458,91.6,163,34.47626934,0,Salivary gland,Not reported,Metastatic,1,Partial response,35.87679672,1,Partial response,35.87679672,1,36.82956879,1,11,1,1,2,1,2,80,CYCLE 11 DAY 1,12/7/2016,9.2648869,1,0.82215941
LOXO-TRK-15002-101-007,64,M,White,Y,Physician Decision,3/1/2016,36.79671458,91.6,163,34.47626934,0,Salivary gland,Not reported,Metastatic,1,Partial response,35.87679672,1,Partial response,35.87679672,1,36.82956879,1,13,2,2,2,2,2,80,CYCLE 13 DAY 1,1/31/2017,11.071869,1,0.59451056
LOXO-TRK-15002-101-007,64,M,White,Y,Physician Decision,3/1/2016,36.79671458,91.6,163,34.47626934,0,Salivary gland,Not reported,Metastatic,1,Partial response,35.87679672,1,Partial response,35.87679672,1,36.82956879,1,19,2,1,2,1,2,80,CYCLE 19 DAY 1,7/18/2017,16.591375,1,0.76345956
LOXO-TRK-15002-101-007,64,M,White,Y,Physician Decision,3/1/2016,36.79671458,91.6,163,34.47626934,0,Salivary gland,Not reported,Metastatic,1,Partial response,35.87679672,1,Partial response,35.87679672,1,36.82956879,1,22,2,2,3,1,2,70,CYCLE 22 DAY 1,10/10/2017,19.35113,1,0.65052086
LOXO-TRK-15002-101-007,64,M,White,Y,Physician Decision,3/1/2016,36.79671458,91.6,163,34.47626934,0,Salivary gland,Not reported,Metastatic,1,Partial response,35.87679672,1,Partial response,35.87679672,1,36.82956879,1,25,3,1,3,2,3,70,CYCLE 25 DAY 1,1/3/2018,22.143738,1,0.59582269
LOXO-TRK-15002-101-007,64,M,White,Y,Physician Decision,3/1/2016,36.79671458,91.6,163,34.47626934,0,Salivary gland,Not reported,Metastatic,1,Partial response,35.87679672,1,Partial response,35.87679672,1,36.82956879,1,28,2,1,3,1,2,75,CYCLE 28 DAY 1,3/27/2018,24.870636,1,0.73858637
LOXO-TRK-15002-101-007,64,M,White,Y,Physician Decision,3/1/2016,36.79671458,91.6,163,34.47626934,0,Salivary gland,Not reported,Metastatic,1,Partial response,35.87679672,1,Partial response,35.87679672,1,36.82956879,1,31,2,1,3,1,2,70,CYCLE 31 DAY 1,6/19/2018,27.63039,1,0.73858637
LOXO-TRK-15002-101-007,64,M,White,Y,Physician Decision,3/1/2016,36.79671458,91.6,163,34.47626934,0,Salivary gland,Not reported,Metastatic,1,Partial response,35.87679672,1,Partial response,35.87679672,1,36.82956879,1,34,2,1,3,1,3,65,CYCLE 34 DAY 1,9/11/2018,30.390144,1,0.71452099
LOXO-TRK-15002-101-007,64,M,White,Y,Physician Decision,3/1/2016,36.79671458,91.6,163,34.47626934,0,Salivary gland,Not reported,Metastatic,1,Partial response,35.87679672,1,Partial response,35.87679672,1,36.82956879,1,37,2,1,3,2,3,70,CYCLE 37 DAY 1,12/4/2018,33.149899,1,0.64540988
LOXO-TRK-15002-101-007,64,M,White,Y,Physician Decision,3/1/2016,36.79671458,91.6,163,34.47626934,0,Salivary gland,Not reported,Metastatic,1,Partial response,35.87679672,1,Partial response,35.87679672,1,36.82956879,1,40,3,2,3,3,3,70,CYCLE 40 DAY 1,2/26/2019,35.909653,1,0.48316872
LOXO-TRK-15002-101-008,38,F,White,Y,Disease Progression,3/8/2016,1.412731006,53.9,143,26.35825713,1,Melanoma,III,Metastatic,2,Not evaluable,0.032854209,1,Progressive disease,1.412731006,0,1.412731006,1,0,3,2,3,4,4,25,CYCLE 1 DAY 1,3/8/2016,0,0,0.23509157
LOXO-TRK-15002-101-009,47,F,White,Y,Disease Progression,3/1/2016,14.45585216,54,166,19.59645812,1,Cholangiocarcinoma,I,Metastatic,1,Stable disease,33.41273101,0,Partial response,9.002053388,0,33.41273101,0,0,2,1,1,1,1,78,CYCLE 1 DAY 1,3/1/2016,0,0,0.87045294
LOXO-TRK-15002-101-009,47,F,White,Y,Disease Progression,3/1/2016,14.45585216,54,166,19.59645812,1,Cholangiocarcinoma,I,Metastatic,1,Stable disease,33.41273101,0,Partial response,9.002053388,0,33.41273101,0,3,2,1,1,1,1,90,CYCLE 3 DAY 1,4/26/2016,1.87269,0,0.87045294
LOXO-TRK-15002-101-009,47,F,White,Y,Disease Progression,3/1/2016,14.45585216,54,166,19.59645812,1,Cholangiocarcinoma,I,Metastatic,1,Stable disease,33.41273101,0,Partial response,9.002053388,0,33.41273101,0,5,2,1,1,2,1,87,CYCLE 5 DAY 1,6/21/2016,3.7125256,0,0.76422411
LOXO-TRK-15002-101-009,47,F,White,Y,Disease Progression,3/1/2016,14.45585216,54,166,19.59645812,1,Cholangiocarcinoma,I,Metastatic,1,Stable disease,33.41273101,0,Partial response,9.002053388,0,33.41273101,0,7,1,1,1,1,1,90,CYCLE 7 DAY 1,8/16/2016,5.5523615,0,0.97681606
LOXO-TRK-15002-101-009,47,F,White,Y,Disease Progression,3/1/2016,14.45585216,54,166,19.59645812,1,Cholangiocarcinoma,I,Metastatic,1,Stable disease,33.41273101,0,Partial response,9.002053388,0,33.41273101,0,9,2,1,1,1,1,90,CYCLE 9 DAY 1,10/7/2016,7.2607803,0,0.87045294
LOXO-TRK-15002-101-009,47,F,White,Y,Disease Progression,3/1/2016,14.45585216,54,166,19.59645812,1,Cholangiocarcinoma,I,Metastatic,1,Stable disease,33.41273101,0,Partial response,9.002053388,0,33.41273101,0,11,2,1,1,1,1,95,CYCLE 11 DAY 1,12/6/2016,9.2320328,0,0.87045294
LOXO-TRK-15002-101-009,47,F,White,Y,Disease Progression,3/1/2016,14.45585216,54,166,19.59645812,1,Cholangiocarcinoma,I,Metastatic,1,Stable disease,33.41273101,0,Partial response,9.002053388,0,33.41273101,0,13,2,1,1,1,1,93,CYCLE 13 DAY 1,1/31/2017,11.071869,0,0.87045294
LOXO-TRK-15002-101-009,47,F,White,Y,Disease Progression,3/1/2016,14.45585216,54,166,19.59645812,1,Cholangiocarcinoma,I,Metastatic,1,Stable disease,33.41273101,0,Partial response,9.002053388,0,33.41273101,0,16,2,1,1,1,1,93,CYCLE 16 DAY 1,4/25/2017,13.831622,0,0.87045294
LOXO-TRK-15002-101-009,47,F,White,Y,Disease Progression,3/1/2016,14.45585216,54,166,19.59645812,1,Cholangiocarcinoma,I,Metastatic,1,Stable disease,33.41273101,0,Partial response,9.002053388,0,33.41273101,0,96,2,1,1,1,1,92,END OF TREATMENT,5/15/2017,14.488707,0,0.87045294
LOXO-TRK-15002-101-010,73,F,White,Y,Subject Decision,3/16/2016,1.379876797,58.6,170,20.27681661,1,Colon,IV,Metastatic,2,Stable disease,1.478439425,1,Stable disease,1.478439425,1,2.168377823,1,0,2,1,2,2,3,60,CYCLE 1 DAY 1,3/16/2016,0,0,0.65505618
LOXO-TRK-15002-101-011,31,F,All others,Y,,3/15/2016,51.54825462,69.9,160,27.3046875,0,Lung,IV,Metastatic,4,Complete response,46.91581109,1,Complete response,16.55852156,1,52.20533881,1,0,2,1,1,2,1,90,CYCLE 1 DAY 1,3/15/2016,0,0,0.77420628
LOXO-TRK-15002-101-011,31,F,All others,Y,,3/15/2016,51.54825462,69.9,160,27.3046875,0,Lung,IV,Metastatic,4,Complete response,46.91581109,1,Complete response,16.55852156,1,52.20533881,1,3,2,1,1,1,2,85,CYCLE 3 DAY 1,5/10/2016,1.87269,0,0.83354527
LOXO-TRK-15002-101-011,31,F,All others,Y,,3/15/2016,51.54825462,69.9,160,27.3046875,0,Lung,IV,Metastatic,4,Complete response,46.91581109,1,Complete response,16.55852156,1,52.20533881,1,5,2,1,1,2,1,91,CYCLE 5 DAY 1,7/5/2016,3.7125256,0,0.77420628
LOXO-TRK-15002-101-011,31,F,All others,Y,,3/15/2016,51.54825462,69.9,160,27.3046875,0,Lung,IV,Metastatic,4,Complete response,46.91581109,1,Complete response,16.55852156,1,52.20533881,1,9,2,1,1,1,1,92,CYCLE 9 DAY 1,10/25/2016,7.3921971,0,0.87756276
LOXO-TRK-15002-101-011,31,F,All others,Y,,3/15/2016,51.54825462,69.9,160,27.3046875,0,Lung,IV,Metastatic,4,Complete response,46.91581109,1,Complete response,16.55852156,1,52.20533881,1,11,2,1,1,2,1,91,CYCLE 11 DAY 1,12/20/2016,9.2320328,0,0.77420628
LOXO-TRK-15002-101-011,31,F,All others,Y,,3/15/2016,51.54825462,69.9,160,27.3046875,0,Lung,IV,Metastatic,4,Complete response,46.91581109,1,Complete response,16.55852156,1,52.20533881,1,13,2,1,1,1,1,98,CYCLE 13 DAY 1,2/14/2017,11.071869,0,0.87756276
LOXO-TRK-15002-101-011,31,F,All others,Y,,3/15/2016,51.54825462,69.9,160,27.3046875,0,Lung,IV,Metastatic,4,Complete response,46.91581109,1,Complete response,16.55852156,1,52.20533881,1,16,2,1,1,2,1,90,CYCLE 16 DAY 1,5/9/2017,13.831622,0,0.77420628
LOXO-TRK-15002-101-011,31,F,All others,Y,,3/15/2016,51.54825462,69.9,160,27.3046875,0,Lung,IV,Metastatic,4,Complete response,46.91581109,1,Complete response,16.55852156,1,52.20533881,1,19,2,1,1,2,1,91,CYCLE 19 DAY 1,8/1/2017,16.591375,0,0.77420628
LOXO-TRK-15002-101-011,31,F,All others,Y,,3/15/2016,51.54825462,69.9,160,27.3046875,0,Lung,IV,Metastatic,4,Complete response,46.91581109,1,Complete response,16.55852156,1,52.20533881,1,22,2,1,2,2,1,85,CYCLE 22 DAY 1,10/24/2017,19.35113,0,0.73364699
LOXO-TRK-15002-101-011,31,F,All others,Y,,3/15/2016,51.54825462,69.9,160,27.3046875,0,Lung,IV,Metastatic,4,Complete response,46.91581109,1,Complete response,16.55852156,1,52.20533881,1,25,2,1,1,2,2,86,CYCLE 25 DAY 1,1/16/2018,22.110884,0,0.7412675
LOXO-TRK-15002-101-011,31,F,All others,Y,,3/15/2016,51.54825462,69.9,160,27.3046875,0,Lung,IV,Metastatic,4,Complete response,46.91581109,1,Complete response,16.55852156,1,52.20533881,1,28,1,1,1,2,1,86,CYCLE 28 DAY 1,4/10/2018,24.870636,0,0.8439613
LOXO-TRK-15002-101-011,31,F,All others,Y,,3/15/2016,51.54825462,69.9,160,27.3046875,0,Lung,IV,Metastatic,4,Complete response,46.91581109,1,Complete response,16.55852156,1,52.20533881,1,31,2,1,1,2,1,90,CYCLE 31 DAY 1,7/3/2018,27.63039,0,0.77420628
LOXO-TRK-15002-101-011,31,F,All others,Y,,3/15/2016,51.54825462,69.9,160,27.3046875,0,Lung,IV,Metastatic,4,Complete response,46.91581109,1,Complete response,16.55852156,1,52.20533881,1,34,2,1,1,2,2,85,CYCLE 34 DAY 1,9/25/2018,30.390144,0,0.7412675
LOXO-TRK-15002-101-011,31,F,All others,Y,,3/15/2016,51.54825462,69.9,160,27.3046875,0,Lung,IV,Metastatic,4,Complete response,46.91581109,1,Complete response,16.55852156,1,52.20533881,1,39,3,1,1,2,2,85,CYCLE 39 DAY 1,2/12/2019,34.989735,0,0.69357258
LOXO-TRK-15002-101-011,31,F,All others,Y,,3/15/2016,51.54825462,69.9,160,27.3046875,0,Lung,IV,Metastatic,4,Complete response,46.91581109,1,Complete response,16.55852156,1,52.20533881,1,40,2,1,1,1,1,96,CYCLE 40 DAY 1,3/12/2019,35.909653,0,0.87756276
LOXO-TRK-15002-101-011,31,F,All others,Y,,3/15/2016,51.54825462,69.9,160,27.3046875,0,Lung,IV,Metastatic,4,Complete response,46.91581109,1,Complete response,16.55852156,1,52.20533881,1,43,1,1,1,1,1,83,CYCLE 43 DAY 1,6/4/2019,38.669403,0,0.9812879
LOXO-TRK-15002-101-011,31,F,All others,Y,,3/15/2016,51.54825462,69.9,160,27.3046875,0,Lung,IV,Metastatic,4,Complete response,46.91581109,1,Complete response,16.55852156,1,52.20533881,1,49,1,1,2,3,1,85,CYCLE 49 DAY 1,11/19/2019,44.188911,0,0.71736985
LOXO-TRK-15002-101-011,31,F,All others,Y,,3/15/2016,51.54825462,69.9,160,27.3046875,0,Lung,IV,Metastatic,4,Complete response,46.91581109,1,Complete response,16.55852156,1,52.20533881,1,52,2,1,2,2,2,75,CYCLE 52 DAY 1,2/11/2020,46.948666,0,0.69545436
LOXO-TRK-15002-101-013,55,M,White,Y,Subject Decision,5/24/2016,30.29158111,153.5,181,46.85449162,1,Melanoma,III,Metastatic,4,Complete response,24.83778234,1,Complete response,24.83778234,1,37.51950719,1,0,2,1,3,3,3,65,CYCLE 1 DAY 1,5/24/2016,0,1,0.60315722
LOXO-TRK-15002-101-013,55,M,White,Y,Subject Decision,5/24/2016,30.29158111,153.5,181,46.85449162,1,Melanoma,III,Metastatic,4,Complete response,24.83778234,1,Complete response,24.83778234,1,37.51950719,1,3,2,1,4,2,3,30,CYCLE 3 DAY 1,7/14/2016,1.7084188,1,0.62732136
LOXO-TRK-15002-101-013,55,M,White,Y,Subject Decision,5/24/2016,30.29158111,153.5,181,46.85449162,1,Melanoma,III,Metastatic,4,Complete response,24.83778234,1,Complete response,24.83778234,1,37.51950719,1,5,1,1,4,3,3,60,CYCLE 5 DAY 1,9/13/2016,3.7125256,1,0.62939525
LOXO-TRK-15002-101-013,55,M,White,Y,Subject Decision,5/24/2016,30.29158111,153.5,181,46.85449162,1,Melanoma,III,Metastatic,4,Complete response,24.83778234,1,Complete response,24.83778234,1,37.51950719,1,7,1,1,4,1,4,70,CYCLE 7 DAY 1,11/8/2016,5.5523615,1,0.62167919
LOXO-TRK-15002-101-013,55,M,White,Y,Subject Decision,5/24/2016,30.29158111,153.5,181,46.85449162,1,Melanoma,III,Metastatic,4,Complete response,24.83778234,1,Complete response,24.83778234,1,37.51950719,1,9,3,2,4,3,4,75,CYCLE 9 DAY 1,1/4/2017,7.4250512,1,0.37763071
LOXO-TRK-15002-101-013,55,M,White,Y,Subject Decision,5/24/2016,30.29158111,153.5,181,46.85449162,1,Melanoma,III,Metastatic,4,Complete response,24.83778234,1,Complete response,24.83778234,1,37.51950719,1,11,3,3,4,3,4,75,CYCLE 11 DAY 1,2/28/2017,9.2320328,1,0.34946507
LOXO-TRK-15002-101-013,55,M,White,Y,Subject Decision,5/24/2016,30.29158111,153.5,181,46.85449162,1,Melanoma,III,Metastatic,4,Complete response,24.83778234,1,Complete response,24.83778234,1,37.51950719,1,13,2,3,4,2,5,55,CYCLE 13 DAY 1,4/25/2017,11.071869,1,0.25232843
LOXO-TRK-15002-101-013,55,M,White,Y,Subject Decision,5/24/2016,30.29158111,153.5,181,46.85449162,1,Melanoma,III,Metastatic,4,Complete response,24.83778234,1,Complete response,24.83778234,1,37.51950719,1,16,1,3,4,3,4,60,CYCLE 16 DAY 1,7/12/2017,13.634497,1,0.42263478
LOXO-TRK-15002-101-013,55,M,White,Y,Subject Decision,5/24/2016,30.29158111,153.5,181,46.85449162,1,Melanoma,III,Metastatic,4,Complete response,24.83778234,1,Complete response,24.83778234,1,37.51950719,1,19,2,2,4,2,4,60,CYCLE 19 DAY 1,10/10/2017,16.591375,1,0.45326629
LOXO-TRK-15002-101-013,55,M,White,Y,Subject Decision,5/24/2016,30.29158111,153.5,181,46.85449162,1,Melanoma,III,Metastatic,4,Complete response,24.83778234,1,Complete response,24.83778234,1,37.51950719,1,22,2,1,4,2,4,75,CYCLE 22 DAY 1,12/29/2017,19.219713,1,0.53438419
LOXO-TRK-15002-101-013,55,M,White,Y,Subject Decision,5/24/2016,30.29158111,153.5,181,46.85449162,1,Melanoma,III,Metastatic,4,Complete response,24.83778234,1,Complete response,24.83778234,1,37.51950719,1,25,2,3,4,2,3,70,CYCLE 25 DAY 1,3/27/2018,22.110884,1,0.53571332
LOXO-TRK-15002-101-013,55,M,White,Y,Subject Decision,5/24/2016,30.29158111,153.5,181,46.85449162,1,Melanoma,III,Metastatic,4,Complete response,24.83778234,1,Complete response,24.83778234,1,37.51950719,1,28,2,1,4,3,3,80,CYCLE 28 DAY 1,6/19/2018,24.870636,1,0.58341688
LOXO-TRK-15002-101-016,28,M,White,Y,,10/18/2016,45.07597536,64.8,176,20.91942149,1,Soft tissue sarcoma,I,Metastatic,0,Partial response,29.43737166,0,Partial response,22.07802875,1,45.07597536,1,0,2,2,3,4,3,50,CYCLE 1 DAY 1,10/18/2016,0,1,0.38237339
LOXO-TRK-15002-101-016,28,M,White,Y,,10/18/2016,45.07597536,64.8,176,20.91942149,1,Soft tissue sarcoma,I,Metastatic,0,Partial response,29.43737166,0,Partial response,22.07802875,1,45.07597536,1,3,1,1,2,3,2,90,CYCLE 3 DAY 1,12/13/2016,1.87269,1,0.68584728
LOXO-TRK-15002-101-016,28,M,White,Y,,10/18/2016,45.07597536,64.8,176,20.91942149,1,Soft tissue sarcoma,I,Metastatic,0,Partial response,29.43737166,0,Partial response,22.07802875,1,45.07597536,1,5,1,1,1,2,1,90,CYCLE 5 DAY 1,2/7/2017,3.7125256,1,0.85958147
LOXO-TRK-15002-101-016,28,M,White,Y,,10/18/2016,45.07597536,64.8,176,20.91942149,1,Soft tissue sarcoma,I,Metastatic,0,Partial response,29.43737166,0,Partial response,22.07802875,1,45.07597536,1,7,2,1,2,2,1,85,CYCLE 7 DAY 1,4/4/2017,5.5523615,1,0.7387768
LOXO-TRK-15002-101-016,28,M,White,Y,,10/18/2016,45.07597536,64.8,176,20.91942149,1,Soft tissue sarcoma,I,Metastatic,0,Partial response,29.43737166,0,Partial response,22.07802875,1,45.07597536,1,9,2,1,2,2,1,95,CYCLE 9 DAY 1,5/30/2017,7.3921971,1,0.7387768
LOXO-TRK-15002-101-016,28,M,White,Y,,10/18/2016,45.07597536,64.8,176,20.91942149,1,Soft tissue sarcoma,I,Metastatic,0,Partial response,29.43737166,0,Partial response,22.07802875,1,45.07597536,1,11,2,1,1,2,1,90,CYCLE 11 DAY 1,7/25/2017,9.2320328,1,0.78784996
LOXO-TRK-15002-101-016,28,M,White,Y,,10/18/2016,45.07597536,64.8,176,20.91942149,1,Soft tissue sarcoma,I,Metastatic,0,Partial response,29.43737166,0,Partial response,22.07802875,1,45.07597536,1,13,2,1,2,2,1,90,CYCLE 13 DAY 1,9/19/2017,11.071869,1,0.7387768
LOXO-TRK-15002-101-016,28,M,White,Y,,10/18/2016,45.07597536,64.8,176,20.91942149,1,Soft tissue sarcoma,I,Metastatic,0,Partial response,29.43737166,0,Partial response,22.07802875,1,45.07597536,1,16,2,1,1,2,1,90,CYCLE 16 DAY 1,12/12/2017,13.831622,1,0.78784996
LOXO-TRK-15002-101-016,28,M,White,Y,,10/18/2016,45.07597536,64.8,176,20.91942149,1,Soft tissue sarcoma,I,Metastatic,0,Partial response,29.43737166,0,Partial response,22.07802875,1,45.07597536,1,25,2,1,2,2,1,90,CYCLE 25 DAY 1,8/21/2018,22.110884,1,0.7387768
LOXO-TRK-15002-101-016,28,M,White,Y,,10/18/2016,45.07597536,64.8,176,20.91942149,1,Soft tissue sarcoma,I,Metastatic,0,Partial response,29.43737166,0,Partial response,22.07802875,1,45.07597536,1,28,2,1,1,2,1,95,CYCLE 28 DAY 1,11/19/2018,25.067762,1,0.78784996
LOXO-TRK-15002-101-016,28,M,White,Y,,10/18/2016,45.07597536,64.8,176,20.91942149,1,Soft tissue sarcoma,I,Metastatic,0,Partial response,29.43737166,0,Partial response,22.07802875,1,45.07597536,1,30,3,1,1,2,1,90,CYCLE 30 DAY 1,1/8/2019,26.710472,1,0.72677904
LOXO-TRK-15002-101-016,28,M,White,Y,,10/18/2016,45.07597536,64.8,176,20.91942149,1,Soft tissue sarcoma,I,Metastatic,0,Partial response,29.43737166,0,Partial response,22.07802875,1,45.07597536,1,34,2,1,1,2,1,90,CYCLE 34 DAY 1,5/7/2019,30.620123,1,0.78784996
LOXO-TRK-15002-101-016,28,M,White,Y,,10/18/2016,45.07597536,64.8,176,20.91942149,1,Soft tissue sarcoma,I,Metastatic,0,Partial response,29.43737166,0,Partial response,22.07802875,1,45.07597536,1,37,2,1,2,2,1,85,CYCLE 37 DAY 1,7/23/2019,33.149899,1,0.7387768
LOXO-TRK-15002-101-016,28,M,White,Y,,10/18/2016,45.07597536,64.8,176,20.91942149,1,Soft tissue sarcoma,I,Metastatic,0,Partial response,29.43737166,0,Partial response,22.07802875,1,45.07597536,1,40,3,1,1,3,1,85,CYCLE 40 DAY 1,10/15/2019,35.909653,1,0.67018872
LOXO-TRK-15002-101-016,28,M,White,Y,,10/18/2016,45.07597536,64.8,176,20.91942149,1,Soft tissue sarcoma,I,Metastatic,0,Partial response,29.43737166,0,Partial response,22.07802875,1,45.07597536,1,43,3,1,1,2,1,90,CYCLE 43 DAY 1,1/7/2020,38.669403,1,0.72677904
LOXO-TRK-15002-101-017,63,F,White,Y,Disease Progression,11/8/2016,7.950718686,69,158,27.63980131,1,Pancreas,IV,Metastatic,4,Stable disease,7.195071869,0,Partial response,5.32238193,0,14.12731006,0,0,1,1,1,3,1,85,CYCLE 1 DAY 1,11/8/2016,0,0,0.76024365
LOXO-TRK-15002-101-017,63,F,White,Y,Disease Progression,11/8/2016,7.950718686,69,158,27.63980131,1,Pancreas,IV,Metastatic,4,Stable disease,7.195071869,0,Partial response,5.32238193,0,14.12731006,0,3,1,1,1,1,1,95,CYCLE 3 DAY 1,1/4/2017,1.9055442,0,0.97467208
LOXO-TRK-15002-101-017,63,F,White,Y,Disease Progression,11/8/2016,7.950718686,69,158,27.63980131,1,Pancreas,IV,Metastatic,4,Stable disease,7.195071869,0,Partial response,5.32238193,0,14.12731006,0,5,1,1,1,2,1,95,CYCLE 5 DAY 1,2/28/2017,3.7125256,0,0.82914978
LOXO-TRK-15002-101-017,63,F,White,Y,Disease Progression,11/8/2016,7.950718686,69,158,27.63980131,1,Pancreas,IV,Metastatic,4,Stable disease,7.195071869,0,Partial response,5.32238193,0,14.12731006,0,7,1,1,1,1,1,91,CYCLE 7 DAY 1,4/25/2017,5.5523615,0,0.97467208
LOXO-TRK-15002-101-017,63,F,White,Y,Disease Progression,11/8/2016,7.950718686,69,158,27.63980131,1,Pancreas,IV,Metastatic,4,Stable disease,7.195071869,0,Partial response,5.32238193,0,14.12731006,0,9,2,1,1,2,1,90,CYCLE 9 DAY 1,6/21/2017,7.4250512,0,0.76115876
LOXO-TRK-15002-101-020,66,M,White,Y,Subject Decision,2/8/2017,7.457905544,117.5,177,37.50518689,1,Melanoma,III,Locally advanced,1,Partial response,3.482546201,1,Complete response,3.712525667,1,8.31211499,1,0,1,1,1,2,1,80,CYCLE 1 DAY 1,2/8/2017,0,1,0.83839017
LOXO-TRK-15002-101-020,66,M,White,Y,Subject Decision,2/8/2017,7.457905544,117.5,177,37.50518689,1,Melanoma,III,Locally advanced,1,Partial response,3.482546201,1,Complete response,3.712525667,1,8.31211499,1,3,1,1,2,1,1,75,CYCLE 3 DAY 1,4/5/2017,1.87269,1,0.88827306
LOXO-TRK-15002-101-020,66,M,White,Y,Subject Decision,2/8/2017,7.457905544,117.5,177,37.50518689,1,Melanoma,III,Locally advanced,1,Partial response,3.482546201,1,Complete response,3.712525667,1,8.31211499,1,5,1,1,2,2,1,85,CYCLE 5 DAY 1,5/31/2017,3.7125256,1,0.77073562
LOXO-TRK-15002-101-020,66,M,White,Y,Subject Decision,2/8/2017,7.457905544,117.5,177,37.50518689,1,Melanoma,III,Locally advanced,1,Partial response,3.482546201,1,Complete response,3.712525667,1,8.31211499,1,7,1,1,4,4,3,70,CYCLE 7 DAY 1,7/26/2017,5.5523615,1,0.46797577
LOXO-TRK-15002-101-024,76,F,White,Y,Physician Decision,8/1/2017,19.84394251,71.6,161,27.62239111,1,Lung,IV,Metastatic,4,Partial response,19.31827515,1,Partial response,19.31827515,1,19.84394251,1,0,1,1,2,3,2,70,CYCLE 1 DAY 1,8/1/2017,0,0,0.67563242
LOXO-TRK-15002-101-024,76,F,White,Y,Physician Decision,8/1/2017,19.84394251,71.6,161,27.62239111,1,Lung,IV,Metastatic,4,Partial response,19.31827515,1,Partial response,19.31827515,1,19.84394251,1,3,1,1,2,1,2,65,CYCLE 3 DAY 1,9/29/2017,1.9712526,0,0.82161647
LOXO-TRK-15002-101-024,76,F,White,Y,Physician Decision,8/1/2017,19.84394251,71.6,161,27.62239111,1,Lung,IV,Metastatic,4,Partial response,19.31827515,1,Partial response,19.31827515,1,19.84394251,1,5,1,2,2,1,2,70,CYCLE 5 DAY 1,11/17/2017,3.5811088,0,0.73387361
LOXO-TRK-15002-101-024,76,F,White,Y,Physician Decision,8/1/2017,19.84394251,71.6,161,27.62239111,1,Lung,IV,Metastatic,4,Partial response,19.31827515,1,Partial response,19.31827515,1,19.84394251,1,9,2,2,3,3,2,65,CYCLE 9 DAY 1,3/13/2018,7.3921971,0,0.54013163
LOXO-TRK-15002-101-024,76,F,White,Y,Physician Decision,8/1/2017,19.84394251,71.6,161,27.62239111,1,Lung,IV,Metastatic,4,Partial response,19.31827515,1,Partial response,19.31827515,1,19.84394251,1,11,1,2,2,1,2,55,CYCLE 11 DAY 1,5/8/2018,9.2320328,0,0.73387361
LOXO-TRK-15002-101-024,76,F,White,Y,Physician Decision,8/1/2017,19.84394251,71.6,161,27.62239111,1,Lung,IV,Metastatic,4,Partial response,19.31827515,1,Partial response,19.31827515,1,19.84394251,1,13,1,1,2,1,2,60,CYCLE 13 DAY 1,7/3/2018,11.071869,0,0.82161647
LOXO-TRK-15002-101-024,76,F,White,Y,Physician Decision,8/1/2017,19.84394251,71.6,161,27.62239111,1,Lung,IV,Metastatic,4,Partial response,19.31827515,1,Partial response,19.31827515,1,19.84394251,1,16,2,3,4,2,4,30,CYCLE 16 DAY 1,9/25/2018,13.831622,0,0.41709468
LOXO-TRK-15002-101-025,47,F,White,Y,Adverse Event,10/24/2017,0.755646817,58,178,18.30576947,0,Melanoma,III,Metastatic,2,Not evaluable,0.032854209,1,Not determined,0.032854209,1,32.09856263,1,0,2,1,1,2,1,95,CYCLE 1 DAY 1,10/24/2017,0,0,0.76422411
LOXO-TRK-15002-101-028,78,M,White,Y,,2/8/2018,28.55030801,68.7,161,26.50360711,1,Salivary gland,I,Metastatic,0,Partial response,27.40041068,1,Partial response,27.40041068,1,28.55030801,1,0,1,1,1,1,1,90,CYCLE 1 DAY 1,2/8/2018,0,1,0.97858673
LOXO-TRK-15002-101-028,78,M,White,Y,,2/8/2018,28.55030801,68.7,161,26.50360711,1,Salivary gland,I,Metastatic,0,Partial response,27.40041068,1,Partial response,27.40041068,1,28.55030801,1,3,1,1,1,2,2,80,CYCLE 3 DAY 1,4/5/2018,1.87269,1,0.79020578
LOXO-TRK-15002-101-028,78,M,White,Y,,2/8/2018,28.55030801,68.7,161,26.50360711,1,Salivary gland,I,Metastatic,0,Partial response,27.40041068,1,Partial response,27.40041068,1,28.55030801,1,5,1,1,1,1,1,90,CYCLE 5 DAY 1,5/31/2018,3.7125256,1,0.97858673
LOXO-TRK-15002-101-028,78,M,White,Y,,2/8/2018,28.55030801,68.7,161,26.50360711,1,Salivary gland,I,Metastatic,0,Partial response,27.40041068,1,Partial response,27.40041068,1,28.55030801,1,7,1,1,1,1,1,75,CYCLE 7 DAY 1,7/26/2018,5.5523615,1,0.97858673
LOXO-TRK-15002-101-028,78,M,White,Y,,2/8/2018,28.55030801,68.7,161,26.50360711,1,Salivary gland,I,Metastatic,0,Partial response,27.40041068,1,Partial response,27.40041068,1,28.55030801,1,9,1,1,2,3,1,70,CYCLE 9 DAY 1,10/4/2018,7.8521562,1,0.70466632
LOXO-TRK-15002-101-028,78,M,White,Y,,2/8/2018,28.55030801,68.7,161,26.50360711,1,Salivary gland,I,Metastatic,0,Partial response,27.40041068,1,Partial response,27.40041068,1,28.55030801,1,11,1,1,1,3,1,90,CYCLE 11 DAY 1,11/19/2018,9.3634501,1,0.76622874
LOXO-TRK-15002-101-028,78,M,White,Y,,2/8/2018,28.55030801,68.7,161,26.50360711,1,Salivary gland,I,Metastatic,0,Partial response,27.40041068,1,Partial response,27.40041068,1,28.55030801,1,13,1,1,1,2,2,90,CYCLE 13 DAY 1,1/10/2019,11.071869,1,0.79020578
LOXO-TRK-15002-101-028,78,M,White,Y,,2/8/2018,28.55030801,68.7,161,26.50360711,1,Salivary gland,I,Metastatic,0,Partial response,27.40041068,1,Partial response,27.40041068,1,28.55030801,1,16,1,1,2,2,1,85,CYCLE 16 DAY 1,4/4/2019,13.831622,1,0.76887447
LOXO-TRK-15002-101-028,78,M,White,Y,,2/8/2018,28.55030801,68.7,161,26.50360711,1,Salivary gland,I,Metastatic,0,Partial response,27.40041068,1,Partial response,27.40041068,1,28.55030801,1,22,2,1,2,2,2,60,CYCLE 22 DAY 1,9/19/2019,19.35113,1,0.67849678
LOXO-TRK-15002-101-028,78,M,White,Y,,2/8/2018,28.55030801,68.7,161,26.50360711,1,Salivary gland,I,Metastatic,0,Partial response,27.40041068,1,Partial response,27.40041068,1,28.55030801,1,25,1,1,2,2,2,60,CYCLE 25 DAY 1,12/10/2019,22.045174,1,0.7294513
LOXO-TRK-15002-101-028,78,M,White,Y,,2/8/2018,28.55030801,68.7,161,26.50360711,1,Salivary gland,I,Metastatic,0,Partial response,27.40041068,1,Partial response,27.40041068,1,28.55030801,1,28,1,2,3,4,2,75,CYCLE 28 DAY 1,3/5/2020,24.870636,1,0.47770387
LOXO-TRK-15002-101-029,68,M,White,Y,,3/8/2018,27.63039014,87.1,194,23.14273568,1,Thyroid,III,Metastatic,5,Partial response,26.71047228,1,Partial response,26.71047228,1,28.45174538,1,0,3,3,4,3,3,60,CYCLE 1 DAY 1,3/8/2018,0,1,0.45254415
LOXO-TRK-15002-101-029,68,M,White,Y,,3/8/2018,27.63039014,87.1,194,23.14273568,1,Thyroid,III,Metastatic,5,Partial response,26.71047228,1,Partial response,26.71047228,1,28.45174538,1,3,2,2,2,1,2,60,CYCLE 3 DAY 1,5/3/2018,1.87269,1,0.67153639
LOXO-TRK-15002-101-029,68,M,White,Y,,3/8/2018,27.63039014,87.1,194,23.14273568,1,Thyroid,III,Metastatic,5,Partial response,26.71047228,1,Partial response,26.71047228,1,28.45174538,1,5,3,2,2,1,2,70,CYCLE 5 DAY 1,6/28/2018,3.7125256,1,0.61511052
LOXO-TRK-15002-101-029,68,M,White,Y,,3/8/2018,27.63039014,87.1,194,23.14273568,1,Thyroid,III,Metastatic,5,Partial response,26.71047228,1,Partial response,26.71047228,1,28.45174538,1,7,3,1,2,1,2,70,CYCLE 7 DAY 1,8/23/2018,5.5523615,1,0.7055732
LOXO-TRK-15002-101-029,68,M,White,Y,,3/8/2018,27.63039014,87.1,194,23.14273568,1,Thyroid,III,Metastatic,5,Partial response,26.71047228,1,Partial response,26.71047228,1,28.45174538,1,9,3,2,3,4,2,55,CYCLE 9 DAY 1,10/18/2018,7.3921971,1,0.35031489
LOXO-TRK-15002-101-029,68,M,White,Y,,3/8/2018,27.63039014,87.1,194,23.14273568,1,Thyroid,III,Metastatic,5,Partial response,26.71047228,1,Partial response,26.71047228,1,28.45174538,1,11,2,1,2,2,2,70,CYCLE 11 DAY 1,12/14/2018,9.2648869,1,0.67761844
LOXO-TRK-15002-101-029,68,M,White,Y,,3/8/2018,27.63039014,87.1,194,23.14273568,1,Thyroid,III,Metastatic,5,Partial response,26.71047228,1,Partial response,26.71047228,1,28.45174538,1,13,3,2,3,1,3,65,CYCLE 13 DAY 1,2/7/2019,11.071869,1,0.57989126
LOXO-TRK-15002-101-029,68,M,White,Y,,3/8/2018,27.63039014,87.1,194,23.14273568,1,Thyroid,III,Metastatic,5,Partial response,26.71047228,1,Partial response,26.71047228,1,28.45174538,1,19,3,2,3,3,3,75,CYCLE 19 DAY 1,7/25/2019,16.591375,1,0.48373616
LOXO-TRK-15002-101-029,68,M,White,Y,,3/8/2018,27.63039014,87.1,194,23.14273568,1,Thyroid,III,Metastatic,5,Partial response,26.71047228,1,Partial response,26.71047228,1,28.45174538,1,22,2,1,2,1,2,70,CYCLE 22 DAY 1,10/17/2019,19.35113,1,0.76466411
LOXO-TRK-15002-101-029,68,M,White,Y,,3/8/2018,27.63039014,87.1,194,23.14273568,1,Thyroid,III,Metastatic,5,Partial response,26.71047228,1,Partial response,26.71047228,1,28.45174538,1,25,2,1,3,2,2,70,CYCLE 25 DAY 1,1/10/2020,22.143738,1,0.66196901
LOXO-TRK-15002-101-030,69,F,White,Y,,4/5/2018,26.71047228,74.4,158,29.8029162,0,Thyroid,II,Metastatic,1,Non-CR/Non-PD,24.77207392,1,Partial response,27.43326489,1,27.43326489,1,0,3,2,4,3,3,35,CYCLE 1 DAY 1,4/5/2018,0,0,0.47657776
LOXO-TRK-15002-101-030,69,F,White,Y,,4/5/2018,26.71047228,74.4,158,29.8029162,0,Thyroid,II,Metastatic,1,Non-CR/Non-PD,24.77207392,1,Partial response,27.43326489,1,27.43326489,1,3,2,3,4,3,3,50,CYCLE 3 DAY 1,5/31/2018,1.87269,0,0.49921411
LOXO-TRK-15002-101-030,69,F,White,Y,,4/5/2018,26.71047228,74.4,158,29.8029162,0,Thyroid,II,Metastatic,1,Non-CR/Non-PD,24.77207392,1,Partial response,27.43326489,1,27.43326489,1,5,2,2,4,2,3,60,CYCLE 5 DAY 1,7/26/2018,3.7125256,0,0.55536962
LOXO-TRK-15002-101-030,69,F,White,Y,,4/5/2018,26.71047228,74.4,158,29.8029162,0,Thyroid,II,Metastatic,1,Non-CR/Non-PD,24.77207392,1,Partial response,27.43326489,1,27.43326489,1,7,2,2,4,2,3,70,CYCLE 7 DAY 1,9/20/2018,5.5523615,0,0.55536962
LOXO-TRK-15002-101-030,69,F,White,Y,,4/5/2018,26.71047228,74.4,158,29.8029162,0,Thyroid,II,Metastatic,1,Non-CR/Non-PD,24.77207392,1,Partial response,27.43326489,1,27.43326489,1,9,2,1,4,2,3,70,CYCLE 9 DAY 1,11/15/2018,7.3921971,0,0.62548375
LOXO-TRK-15002-101-030,69,F,White,Y,,4/5/2018,26.71047228,74.4,158,29.8029162,0,Thyroid,II,Metastatic,1,Non-CR/Non-PD,24.77207392,1,Partial response,27.43326489,1,27.43326489,1,11,2,1,4,2,3,80,CYCLE 11 DAY 1,1/10/2019,9.2320328,0,0.62548375
LOXO-TRK-15002-101-030,69,F,White,Y,,4/5/2018,26.71047228,74.4,158,29.8029162,0,Thyroid,II,Metastatic,1,Non-CR/Non-PD,24.77207392,1,Partial response,27.43326489,1,27.43326489,1,13,2,1,4,2,3,75,CYCLE 13 DAY 1,3/7/2019,11.071869,0,0.62548375
LOXO-TRK-15002-101-030,69,F,White,Y,,4/5/2018,26.71047228,74.4,158,29.8029162,0,Thyroid,II,Metastatic,1,Non-CR/Non-PD,24.77207392,1,Partial response,27.43326489,1,27.43326489,1,16,2,1,4,2,3,70,CYCLE 16 DAY 1,5/30/2019,13.831622,0,0.62548375
LOXO-TRK-15002-101-030,69,F,White,Y,,4/5/2018,26.71047228,74.4,158,29.8029162,0,Thyroid,II,Metastatic,1,Non-CR/Non-PD,24.77207392,1,Partial response,27.43326489,1,27.43326489,1,19,3,3,4,2,3,55,CYCLE 19 DAY 1,8/22/2019,16.591375,0,0.49491474
LOXO-TRK-15002-101-030,69,F,White,Y,,4/5/2018,26.71047228,74.4,158,29.8029162,0,Thyroid,II,Metastatic,1,Non-CR/Non-PD,24.77207392,1,Partial response,27.43326489,1,27.43326489,1,22,3,2,4,2,3,45,CYCLE 22 DAY 1,11/14/2019,19.35113,0,0.5117687
LOXO-TRK-15002-101-030,69,F,White,Y,,4/5/2018,26.71047228,74.4,158,29.8029162,0,Thyroid,II,Metastatic,1,Non-CR/Non-PD,24.77207392,1,Partial response,27.43326489,1,27.43326489,1,25,2,2,4,2,3,65,CYCLE 25 DAY 1,2/6/2020,22.110884,0,0.55536962
LOXO-TRK-15002-101-031,29,F,All others,Y,,7/16/2018,23.95071869,112,164,41.64187983,0,Thyroid,IV,Metastatic,0,Non-CR/Non-PD,22.01232033,1,Stable disease,22.01232033,1,23.95071869,1,1,1,1,2,1,2,60,CYCLE 1 DAY 8,7/23/2018,0.26283368,0,0.83596259
LOXO-TRK-15002-101-031,29,F,All others,Y,,7/16/2018,23.95071869,112,164,41.64187983,0,Thyroid,IV,Metastatic,0,Non-CR/Non-PD,22.01232033,1,Stable disease,22.01232033,1,23.95071869,1,3,1,1,2,3,3,80,CYCLE 3 DAY 1,9/10/2018,1.87269,0,0.66478127
LOXO-TRK-15002-101-031,29,F,All others,Y,,7/16/2018,23.95071869,112,164,41.64187983,0,Thyroid,IV,Metastatic,0,Non-CR/Non-PD,22.01232033,1,Stable disease,22.01232033,1,23.95071869,1,5,1,2,2,3,2,55,CYCLE 5 DAY 1,11/5/2018,3.7125256,0,0.59869516
LOXO-TRK-15002-101-031,29,F,All others,Y,,7/16/2018,23.95071869,112,164,41.64187983,0,Thyroid,IV,Metastatic,0,Non-CR/Non-PD,22.01232033,1,Stable disease,22.01232033,1,23.95071869,1,7,3,1,3,3,3,45,CYCLE 7 DAY 1,1/3/2019,5.6509242,0,0.57885361
LOXO-TRK-15002-101-031,29,F,All others,Y,,7/16/2018,23.95071869,112,164,41.64187983,0,Thyroid,IV,Metastatic,0,Non-CR/Non-PD,22.01232033,1,Stable disease,22.01232033,1,23.95071869,1,11,2,1,2,2,2,63,CYCLE 11 DAY 1,4/22/2019,9.2320328,0,0.69896668
LOXO-TRK-15002-101-031,29,F,All others,Y,,7/16/2018,23.95071869,112,164,41.64187983,0,Thyroid,IV,Metastatic,0,Non-CR/Non-PD,22.01232033,1,Stable disease,22.01232033,1,23.95071869,1,13,3,1,3,3,3,50,CYCLE 13 DAY 1,6/17/2019,11.071869,0,0.57885361
LOXO-TRK-15002-101-031,29,F,All others,Y,,7/16/2018,23.95071869,112,164,41.64187983,0,Thyroid,IV,Metastatic,0,Non-CR/Non-PD,22.01232033,1,Stable disease,22.01232033,1,23.95071869,1,16,2,1,4,3,3,45,CYCLE 16 DAY 1,9/9/2019,13.831622,0,0.60156065
LOXO-TRK-15002-101-031,29,F,All others,Y,,7/16/2018,23.95071869,112,164,41.64187983,0,Thyroid,IV,Metastatic,0,Non-CR/Non-PD,22.01232033,1,Stable disease,22.01232033,1,23.95071869,1,19,3,1,1,2,2,50,CYCLE 19 DAY 1,12/2/2019,16.591375,0,0.69592273
LOXO-TRK-15002-101-031,29,F,All others,Y,,7/16/2018,23.95071869,112,164,41.64187983,0,Thyroid,IV,Metastatic,0,Non-CR/Non-PD,22.01232033,1,Stable disease,22.01232033,1,23.95071869,1,22,4,1,3,2,3,55,CYCLE 22 DAY 1,2/24/2020,19.35113,0,0.41812596
LOXO-TRK-15002-101-032,76,F,All others,Y,Disease Progression,6/26/2018,20.20533881,48.5,150,21.55555556,0,Lung,IV,Metastatic,0,Partial response,11.30184805,0,Partial response,19.21971253,0,23.95071869,1,0,2,1,2,2,3,65,CYCLE 1 DAY 1,6/26/2018,0,0,0.6552453
LOXO-TRK-15002-101-032,76,F,All others,Y,Disease Progression,6/26/2018,20.20533881,48.5,150,21.55555556,0,Lung,IV,Metastatic,0,Partial response,11.30184805,0,Partial response,19.21971253,0,23.95071869,1,3,3,1,1,3,1,85,CYCLE 3 DAY 1,8/21/2018,1.87269,0,0.64983839
LOXO-TRK-15002-101-032,76,F,All others,Y,Disease Progression,6/26/2018,20.20533881,48.5,150,21.55555556,0,Lung,IV,Metastatic,0,Partial response,11.30184805,0,Partial response,19.21971253,0,23.95071869,1,5,2,1,2,2,2,85,CYCLE 5 DAY 1,10/17/2018,3.7453799,0,0.6746797
LOXO-TRK-15002-101-032,76,F,All others,Y,Disease Progression,6/26/2018,20.20533881,48.5,150,21.55555556,0,Lung,IV,Metastatic,0,Partial response,11.30184805,0,Partial response,19.21971253,0,23.95071869,1,9,3,1,2,2,2,80,CYCLE 9 DAY 1,2/5/2019,7.3921971,0,0.61788946
LOXO-TRK-15002-101-032,76,F,All others,Y,Disease Progression,6/26/2018,20.20533881,48.5,150,21.55555556,0,Lung,IV,Metastatic,0,Partial response,11.30184805,0,Partial response,19.21971253,0,23.95071869,1,11,2,1,1,2,1,85,CYCLE 11 DAY 1,4/1/2019,9.1991787,0,0.76363945
LOXO-TRK-15002-101-032,76,F,All others,Y,Disease Progression,6/26/2018,20.20533881,48.5,150,21.55555556,0,Lung,IV,Metastatic,0,Partial response,11.30184805,0,Partial response,19.21971253,0,23.95071869,1,13,2,1,2,3,2,75,CYCLE 13 DAY 1,6/5/2019,11.334702,0,0.62362403
LOXO-TRK-15002-101-032,76,F,All others,Y,Disease Progression,6/26/2018,20.20533881,48.5,150,21.55555556,0,Lung,IV,Metastatic,0,Partial response,11.30184805,0,Partial response,19.21971253,0,23.95071869,1,16,2,1,2,2,2,87,CYCLE 16 DAY 1,8/20/2019,13.831622,0,0.6746797
LOXO-TRK-15002-101-032,76,F,All others,Y,Disease Progression,6/26/2018,20.20533881,48.5,150,21.55555556,0,Lung,IV,Metastatic,0,Partial response,11.30184805,0,Partial response,19.21971253,0,23.95071869,1,22,2,1,2,2,2,85,CYCLE 22 DAY 1,2/4/2020,19.35113,0,0.6746797
LOXO-TRK-15002-101-032,76,F,All others,Y,Disease Progression,6/26/2018,20.20533881,48.5,150,21.55555556,0,Lung,IV,Metastatic,0,Partial response,11.30184805,0,Partial response,19.21971253,0,23.95071869,1,96,2,1,3,3,3,75,END OF TREATMENT,3/3/2020,20.271048,0,0.60153639
LOXO-TRK-15002-101-033,45,F,All others,Y,Disease Progression,8/17/2018,9.560574949,59.2,163,22.28160638,0,Breast,III,Metastatic,8,Complete response,16.06570842,0,Partial response,9.133470226,0,16.06570842,0,0,2,1,1,1,1,80,CYCLE 1 DAY 1,8/17/2018,0,0,0.87095642
LOXO-TRK-15002-101-033,45,F,All others,Y,Disease Progression,8/17/2018,9.560574949,59.2,163,22.28160638,0,Breast,III,Metastatic,8,Complete response,16.06570842,0,Partial response,9.133470226,0,16.06570842,0,2,1,1,1,1,1,95,CYCLE 2 DAY 1,9/18/2018,1.0841889,0,0.97725827
LOXO-TRK-15002-101-033,45,F,All others,Y,Disease Progression,8/17/2018,9.560574949,59.2,163,22.28160638,0,Breast,III,Metastatic,8,Complete response,16.06570842,0,Partial response,9.133470226,0,16.06570842,0,3,1,1,1,1,1,100,CYCLE 3 DAY 1,10/15/2018,1.9712526,0,0.97725827
LOXO-TRK-15002-101-033,45,F,All others,Y,Disease Progression,8/17/2018,9.560574949,59.2,163,22.28160638,0,Breast,III,Metastatic,8,Complete response,16.06570842,0,Partial response,9.133470226,0,16.06570842,0,5,2,1,1,1,1,90,CYCLE 5 DAY 1,12/10/2018,3.8110883,0,0.87095642
LOXO-TRK-15002-101-033,45,F,All others,Y,Disease Progression,8/17/2018,9.560574949,59.2,163,22.28160638,0,Breast,III,Metastatic,8,Complete response,16.06570842,0,Partial response,9.133470226,0,16.06570842,0,7,1,1,1,1,1,95,CYCLE 7 DAY 1,2/4/2019,5.6509242,0,0.97725827
LOXO-TRK-15002-101-033,45,F,All others,Y,Disease Progression,8/17/2018,9.560574949,59.2,163,22.28160638,0,Breast,III,Metastatic,8,Complete response,16.06570842,0,Partial response,9.133470226,0,16.06570842,0,9,2,1,1,2,1,100,CYCLE 9 DAY 1,4/1/2019,7.4907598,0,0.76503861
LOXO-TRK-15002-101-033,45,F,All others,Y,Disease Progression,8/17/2018,9.560574949,59.2,163,22.28160638,0,Breast,III,Metastatic,8,Complete response,16.06570842,0,Partial response,9.133470226,0,16.06570842,0,11,2,1,1,2,1,90,CYCLE 11 DAY 1,5/29/2019,9.3963041,0,0.76503861
LOXO-TRK-15002-101-034,32,M,White,Y,Disease Progression,10/15/2018,21.15811088,.,.,.,2,Breast,I,Metastatic,5,Partial response,12.74743327,0,Partial response,12.74743327,0,21.19096509,1,0,4,4,5,4,4,45,CYCLE 1 DAY 1,10/15/2018,0,1,-0.12446339
LOXO-TRK-15002-101-034,32,M,White,Y,Disease Progression,10/15/2018,21.15811088,.,.,.,2,Breast,I,Metastatic,5,Partial response,12.74743327,0,Partial response,12.74743327,0,21.19096509,1,3,1,2,5,2,3,65,CYCLE 3 DAY 1,12/10/2018,1.87269,1,0.58713585
LOXO-TRK-15002-101-034,32,M,White,Y,Disease Progression,10/15/2018,21.15811088,.,.,.,2,Breast,I,Metastatic,5,Partial response,12.74743327,0,Partial response,12.74743327,0,21.19096509,1,5,1,2,5,1,3,75,CYCLE 5 DAY 1,2/4/2019,3.7125256,1,0.64158171
LOXO-TRK-15002-101-034,32,M,White,Y,Disease Progression,10/15/2018,21.15811088,.,.,.,2,Breast,I,Metastatic,5,Partial response,12.74743327,0,Partial response,12.74743327,0,21.19096509,1,7,1,2,5,1,3,75,CYCLE 7 DAY 1,4/1/2019,5.5523615,1,0.64158171
LOXO-TRK-15002-101-034,32,M,White,Y,Disease Progression,10/15/2018,21.15811088,.,.,.,2,Breast,I,Metastatic,5,Partial response,12.74743327,0,Partial response,12.74743327,0,21.19096509,1,9,1,2,5,1,3,85,CYCLE 9 DAY 1,5/29/2019,7.4579058,1,0.64158171
LOXO-TRK-15002-101-034,32,M,White,Y,Disease Progression,10/15/2018,21.15811088,.,.,.,2,Breast,I,Metastatic,5,Partial response,12.74743327,0,Partial response,12.74743327,0,21.19096509,1,11,3,3,5,2,4,45,CYCLE 11 DAY 1,7/22/2019,9.2320328,1,0.34693789
LOXO-TRK-15002-101-034,32,M,White,Y,Disease Progression,10/15/2018,21.15811088,.,.,.,2,Breast,I,Metastatic,5,Partial response,12.74743327,0,Partial response,12.74743327,0,21.19096509,1,13,3,3,5,2,4,45,CYCLE 13 DAY 1,9/16/2019,11.071869,1,0.34693789
LOXO-TRK-15002-101-034,32,M,White,Y,Disease Progression,10/15/2018,21.15811088,.,.,.,2,Breast,I,Metastatic,5,Partial response,12.74743327,0,Partial response,12.74743327,0,21.19096509,1,16,2,2,5,2,2,75,CYCLE 16 DAY 1,12/9/2019,13.831622,1,0.57403547
LOXO-TRK-15002-101-034,32,M,White,Y,Disease Progression,10/15/2018,21.15811088,.,.,.,2,Breast,I,Metastatic,5,Partial response,12.74743327,0,Partial response,12.74743327,0,21.19096509,1,19,3,2,5,2,5,60,CYCLE 19 DAY 1,3/2/2020,16.591375,1,0.22278233
LOXO-TRK-15002-104-001,73,F,Black,Y,Adverse Event,2/26/2016,2.694045175,38,152,16.44736842,2,Colon,Not reported,Metastatic,1,Stable disease,2.759753593,0,Stable disease,2.694045175,0,2.759753593,0,,,,,,,,,,,0,
LOXO-TRK-15002-104-002,69,F,All others,Y,Disease Progression,5/20/2016,28.5174538,43.7,154,18.42637882,1,Salivary gland,Not reported,Metastatic,0,Partial response,28.5174538,1,Partial response,25.75770021,0,49.24845996,1,-1,1,1,1,3,1,95,SCREENING,5/18/2016,0,0,0.76011175
LOXO-TRK-15002-104-002,69,F,All others,Y,Disease Progression,5/20/2016,28.5174538,43.7,154,18.42637882,1,Salivary gland,Not reported,Metastatic,0,Partial response,28.5174538,1,Partial response,25.75770021,0,49.24845996,1,3,1,1,1,2,1,95,CYCLE 3 DAY 1,7/29/2016,2.3326488,0,0.82903987
LOXO-TRK-15002-104-002,69,F,All others,Y,Disease Progression,5/20/2016,28.5174538,43.7,154,18.42637882,1,Salivary gland,Not reported,Metastatic,0,Partial response,28.5174538,1,Partial response,25.75770021,0,49.24845996,1,5,2,1,1,3,1,75,CYCLE 5 DAY 1,9/23/2016,4.1724844,0,0.70368475
LOXO-TRK-15002-104-002,69,F,All others,Y,Disease Progression,5/20/2016,28.5174538,43.7,154,18.42637882,1,Salivary gland,Not reported,Metastatic,0,Partial response,28.5174538,1,Partial response,25.75770021,0,49.24845996,1,7,2,1,1,3,1,80,CYCLE 7 DAY 1,11/17/2016,5.979466,0,0.70368475
LOXO-TRK-15002-104-002,69,F,All others,Y,Disease Progression,5/20/2016,28.5174538,43.7,154,18.42637882,1,Salivary gland,Not reported,Metastatic,0,Partial response,28.5174538,1,Partial response,25.75770021,0,49.24845996,1,9,1,1,1,2,1,75,CYCLE 9 DAY 1,1/13/2017,7.8521562,0,0.82903987
LOXO-TRK-15002-104-002,69,F,All others,Y,Disease Progression,5/20/2016,28.5174538,43.7,154,18.42637882,1,Salivary gland,Not reported,Metastatic,0,Partial response,28.5174538,1,Partial response,25.75770021,0,49.24845996,1,11,2,1,1,3,1,80,CYCLE 11 DAY 1,3/10/2017,9.6919918,0,0.70368475
LOXO-TRK-15002-104-002,69,F,All others,Y,Disease Progression,5/20/2016,28.5174538,43.7,154,18.42637882,1,Salivary gland,Not reported,Metastatic,0,Partial response,28.5174538,1,Partial response,25.75770021,0,49.24845996,1,13,3,1,1,3,1,50,CYCLE 13 DAY 1,5/5/2017,11.531828,0,0.64892673
LOXO-TRK-15002-104-002,69,F,All others,Y,Disease Progression,5/20/2016,28.5174538,43.7,154,18.42637882,1,Salivary gland,Not reported,Metastatic,0,Partial response,28.5174538,1,Partial response,25.75770021,0,49.24845996,1,16,2,1,2,2,1,70,CYCLE 16 DAY 1,7/28/2017,14.291581,0,0.70920837
LOXO-TRK-15002-104-002,69,F,All others,Y,Disease Progression,5/20/2016,28.5174538,43.7,154,18.42637882,1,Salivary gland,Not reported,Metastatic,0,Partial response,28.5174538,1,Partial response,25.75770021,0,49.24845996,1,19,1,1,1,2,1,90,CYCLE 19 DAY 1,10/20/2017,17.051334,0,0.82903987
LOXO-TRK-15002-104-002,69,F,All others,Y,Disease Progression,5/20/2016,28.5174538,43.7,154,18.42637882,1,Salivary gland,Not reported,Metastatic,0,Partial response,28.5174538,1,Partial response,25.75770021,0,49.24845996,1,22,2,1,2,3,2,80,CYCLE 22 DAY 1,1/12/2018,19.811089,0,0.62483883
LOXO-TRK-15002-104-002,69,F,All others,Y,Disease Progression,5/20/2016,28.5174538,43.7,154,18.42637882,1,Salivary gland,Not reported,Metastatic,0,Partial response,28.5174538,1,Partial response,25.75770021,0,49.24845996,1,25,2,1,1,2,1,85,CYCLE 25 DAY 1,4/6/2018,22.570843,0,0.76166981
LOXO-TRK-15002-104-002,69,F,All others,Y,Disease Progression,5/20/2016,28.5174538,43.7,154,18.42637882,1,Salivary gland,Not reported,Metastatic,0,Partial response,28.5174538,1,Partial response,25.75770021,0,49.24845996,1,28,2,1,1,2,2,50,CYCLE 28 DAY 1,7/13/2018,25.790554,0,0.72839749
LOXO-TRK-15002-104-002,69,F,All others,Y,Disease Progression,5/20/2016,28.5174538,43.7,154,18.42637882,1,Salivary gland,Not reported,Metastatic,0,Partial response,28.5174538,1,Partial response,25.75770021,0,49.24845996,1,96,1,1,1,3,1,80,END OF TREATMENT,10/5/2018,28.550308,0,0.76011175
LOXO-TRK-15002-104-004,57,F,White,Y,Disease Progression,12/6/2016,7.72073922,69.1,156,28.39414859,1,Thyroid,III,Metastatic,1,Partial response,5.519507187,0,Partial response,5.519507187,0,16.72279261,0,0,1,1,1,1,1,95,CYCLE 1 DAY 1,12/6/2016,0,0,0.9751386
LOXO-TRK-15002-104-004,57,F,White,Y,Disease Progression,12/6/2016,7.72073922,69.1,156,28.39414859,1,Thyroid,III,Metastatic,1,Partial response,5.519507187,0,Partial response,5.519507187,0,16.72279261,0,3,1,1,1,1,1,95,CYCLE 3 DAY 1,1/31/2017,1.87269,0,0.9751386
LOXO-TRK-15002-104-004,57,F,White,Y,Disease Progression,12/6/2016,7.72073922,69.1,156,28.39414859,1,Thyroid,III,Metastatic,1,Partial response,5.519507187,0,Partial response,5.519507187,0,16.72279261,0,5,1,1,1,1,1,95,CYCLE 5 DAY 1,3/28/2017,3.7125256,0,0.9751386
LOXO-TRK-15002-104-004,57,F,White,Y,Disease Progression,12/6/2016,7.72073922,69.1,156,28.39414859,1,Thyroid,III,Metastatic,1,Partial response,5.519507187,0,Partial response,5.519507187,0,16.72279261,0,7,1,1,1,1,1,95,CYCLE 7 DAY 1,5/23/2017,5.5523615,0,0.9751386
LOXO-TRK-15002-104-004,57,F,White,Y,Disease Progression,12/6/2016,7.72073922,69.1,156,28.39414859,1,Thyroid,III,Metastatic,1,Partial response,5.519507187,0,Partial response,5.519507187,0,16.72279261,0,9,1,1,2,2,1,95,CYCLE 9 DAY 1,7/18/2017,7.3921971,0,0.77500576
LOXO-TRK-15002-104-005,48,M,Asian,Y,Disease Progression,1/3/2017,15.44147844,63.7,170,22.04152249,0,Salivary gland,Not reported,Metastatic,0,Complete response,15.17864476,0,Complete response,15.17864476,0,38.66940452,0,0,2,1,1,1,1,70,CYCLE 1 DAY 1,1/3/2017,0,1,0.87912565
LOXO-TRK-15002-104-005,48,M,Asian,Y,Disease Progression,1/3/2017,15.44147844,63.7,170,22.04152249,0,Salivary gland,Not reported,Metastatic,0,Complete response,15.17864476,0,Complete response,15.17864476,0,38.66940452,0,3,1,1,1,2,1,80,CYCLE 3 DAY 1,3/2/2017,1.9383984,1,0.8427676
LOXO-TRK-15002-104-005,48,M,Asian,Y,Disease Progression,1/3/2017,15.44147844,63.7,170,22.04152249,0,Salivary gland,Not reported,Metastatic,0,Complete response,15.17864476,0,Complete response,15.17864476,0,38.66940452,0,5,1,1,1,1,1,80,CYCLE 5 DAY 1,5/2/2017,3.9425051,1,0.98043764
LOXO-TRK-15002-104-005,48,M,Asian,Y,Disease Progression,1/3/2017,15.44147844,63.7,170,22.04152249,0,Salivary gland,Not reported,Metastatic,0,Complete response,15.17864476,0,Complete response,15.17864476,0,38.66940452,0,7,1,1,1,1,1,80,CYCLE 7 DAY 1,7/6/2017,6.0780287,1,0.98043764
LOXO-TRK-15002-104-005,48,M,Asian,Y,Disease Progression,1/3/2017,15.44147844,63.7,170,22.04152249,0,Salivary gland,Not reported,Metastatic,0,Complete response,15.17864476,0,Complete response,15.17864476,0,38.66940452,0,9,1,1,1,1,1,90,CYCLE 9 DAY 1,9/5/2017,8.0821352,1,0.98043764
LOXO-TRK-15002-104-005,48,M,Asian,Y,Disease Progression,1/3/2017,15.44147844,63.7,170,22.04152249,0,Salivary gland,Not reported,Metastatic,0,Complete response,15.17864476,0,Complete response,15.17864476,0,38.66940452,0,11,1,1,1,1,1,90,CYCLE 11 DAY 1,11/7/2017,10.151951,1,0.98043764
LOXO-TRK-15002-104-005,48,M,Asian,Y,Disease Progression,1/3/2017,15.44147844,63.7,170,22.04152249,0,Salivary gland,Not reported,Metastatic,0,Complete response,15.17864476,0,Complete response,15.17864476,0,38.66940452,0,13,1,1,2,1,1,90,CYCLE 13 DAY 1,1/9/2018,12.221766,1,0.90262133
LOXO-TRK-15002-104-006,59,M,White,Y,,1/13/2017,41.62628337,83.5,170,28.89273356,0,Salivary gland,III,Metastatic,0,Complete response,41.56057495,1,Partial response,41.59342916,1,41.62628337,1,0,1,1,1,3,1,85,CYCLE 1 DAY 1,1/13/2017,0,1,0.7651031
LOXO-TRK-15002-104-006,59,M,White,Y,,1/13/2017,41.62628337,83.5,170,28.89273356,0,Salivary gland,III,Metastatic,0,Complete response,41.56057495,1,Partial response,41.59342916,1,41.62628337,1,3,1,1,1,2,1,85,CYCLE 3 DAY 1,3/9/2017,1.8398358,1,0.83926487
LOXO-TRK-15002-104-006,59,M,White,Y,,1/13/2017,41.62628337,83.5,170,28.89273356,0,Salivary gland,III,Metastatic,0,Complete response,41.56057495,1,Partial response,41.59342916,1,41.62628337,1,5,1,1,1,3,1,88,CYCLE 5 DAY 1,5/4/2017,3.6796715,1,0.7651031
LOXO-TRK-15002-104-006,59,M,White,Y,,1/13/2017,41.62628337,83.5,170,28.89273356,0,Salivary gland,III,Metastatic,0,Complete response,41.56057495,1,Partial response,41.59342916,1,41.62628337,1,7,1,1,1,2,1,85,CYCLE 7 DAY 1,6/27/2017,5.4537988,1,0.83926487
LOXO-TRK-15002-104-006,59,M,White,Y,,1/13/2017,41.62628337,83.5,170,28.89273356,0,Salivary gland,III,Metastatic,0,Complete response,41.56057495,1,Partial response,41.59342916,1,41.62628337,1,9,1,1,1,2,1,80,CYCLE 9 DAY 1,8/24/2017,7.3593431,1,0.83926487
LOXO-TRK-15002-104-006,59,M,White,Y,,1/13/2017,41.62628337,83.5,170,28.89273356,0,Salivary gland,III,Metastatic,0,Complete response,41.56057495,1,Partial response,41.59342916,1,41.62628337,1,11,1,1,1,2,1,85,CYCLE 11 DAY 1,10/19/2017,9.1991787,1,0.83926487
LOXO-TRK-15002-104-006,59,M,White,Y,,1/13/2017,41.62628337,83.5,170,28.89273356,0,Salivary gland,III,Metastatic,0,Complete response,41.56057495,1,Partial response,41.59342916,1,41.62628337,1,13,1,1,1,3,1,88,CYCLE 13 DAY 1,12/14/2017,11.039015,1,0.7651031
LOXO-TRK-15002-104-006,59,M,White,Y,,1/13/2017,41.62628337,83.5,170,28.89273356,0,Salivary gland,III,Metastatic,0,Complete response,41.56057495,1,Partial response,41.59342916,1,41.62628337,1,16,1,1,1,2,2,80,CYCLE 16 DAY 1,3/8/2018,13.798768,1,0.79138309
LOXO-TRK-15002-104-006,59,M,White,Y,,1/13/2017,41.62628337,83.5,170,28.89273356,0,Salivary gland,III,Metastatic,0,Complete response,41.56057495,1,Partial response,41.59342916,1,41.62628337,1,19,1,1,1,3,2,68,CYCLE 19 DAY 1,5/31/2018,16.558521,1,0.73023117
LOXO-TRK-15002-104-006,59,M,White,Y,,1/13/2017,41.62628337,83.5,170,28.89273356,0,Salivary gland,III,Metastatic,0,Complete response,41.56057495,1,Partial response,41.59342916,1,41.62628337,1,25,1,1,1,3,3,70,CYCLE 25 DAY 1,11/15/2018,22.07803,1,0.7069639
LOXO-TRK-15002-104-006,59,M,White,Y,,1/13/2017,41.62628337,83.5,170,28.89273356,0,Salivary gland,III,Metastatic,0,Complete response,41.56057495,1,Partial response,41.59342916,1,41.62628337,1,28,1,1,1,3,3,55,CYCLE 28 DAY 1,2/7/2019,24.837782,1,0.7069639
LOXO-TRK-15002-104-006,59,M,White,Y,,1/13/2017,41.62628337,83.5,170,28.89273356,0,Salivary gland,III,Metastatic,0,Complete response,41.56057495,1,Partial response,41.59342916,1,41.62628337,1,31,1,1,1,3,1,90,CYCLE 31 DAY 1,5/7/2019,27.761806,1,0.7651031
LOXO-TRK-15002-104-006,59,M,White,Y,,1/13/2017,41.62628337,83.5,170,28.89273356,0,Salivary gland,III,Metastatic,0,Complete response,41.56057495,1,Partial response,41.59342916,1,41.62628337,1,34,1,1,1,2,1,83,CYCLE 34 DAY 1,7/30/2019,30.521561,1,0.83926487
LOXO-TRK-15002-104-006,59,M,White,Y,,1/13/2017,41.62628337,83.5,170,28.89273356,0,Salivary gland,III,Metastatic,0,Complete response,41.56057495,1,Partial response,41.59342916,1,41.62628337,1,37,2,1,1,3,1,82,CYCLE 37 DAY 1,10/24/2019,33.347023,1,0.70840889
LOXO-TRK-15002-104-006,59,M,White,Y,,1/13/2017,41.62628337,83.5,170,28.89273356,0,Salivary gland,III,Metastatic,0,Complete response,41.56057495,1,Partial response,41.59342916,1,41.62628337,1,40,1,1,1,3,1,75,CYCLE 40 DAY 1,1/15/2020,36.073921,1,0.7651031
LOXO-TRK-15002-104-006,59,M,White,Y,,1/13/2017,41.62628337,83.5,170,28.89273356,0,Salivary gland,III,Metastatic,0,Complete response,41.56057495,1,Partial response,41.59342916,1,41.62628337,1,43,1,1,1,3,1,90,CYCLE 43 DAY 1,4/9/2020,38.866531,1,0.7651031
LOXO-TRK-15002-104-006,59,M,White,Y,,1/13/2017,41.62628337,83.5,170,28.89273356,0,Salivary gland,III,Metastatic,0,Complete response,41.56057495,1,Partial response,41.59342916,1,41.62628337,1,46,2,1,1,3,1,90,CYCLE 46 DAY 1,7/2/2020,41.626282,1,0.70840889
LOXO-TRK-15002-104-007,66,F,White,Y,Death,4/5/2017,21.88090349,47.9,164,17.80933968,2,Thyroid,III,Metastatic,1,Partial response,23.35934292,0,Partial response,23.35934292,0,23.35934292,0,-1,1,2,2,1,3,70,SCREENING,4/4/2017,0,0,0.68828475
LOXO-TRK-15002-104-007,66,F,White,Y,Death,4/5/2017,21.88090349,47.9,164,17.80933968,2,Thyroid,III,Metastatic,1,Partial response,23.35934292,0,Partial response,23.35934292,0,23.35934292,0,3,2,1,1,2,1,90,CYCLE 3 DAY 1,5/30/2017,1.8398358,0,0.76127106
LOXO-TRK-15002-104-007,66,F,White,Y,Death,4/5/2017,21.88090349,47.9,164,17.80933968,2,Thyroid,III,Metastatic,1,Partial response,23.35934292,0,Partial response,23.35934292,0,23.35934292,0,5,1,1,1,2,1,90,CYCLE 5 DAY 1,7/25/2017,3.6796715,0,0.82898903
LOXO-TRK-15002-104-007,66,F,White,Y,Death,4/5/2017,21.88090349,47.9,164,17.80933968,2,Thyroid,III,Metastatic,1,Partial response,23.35934292,0,Partial response,23.35934292,0,23.35934292,0,7,2,1,2,3,3,65,CYCLE 7 DAY 1,9/19/2017,5.5195074,0,0.60885501
LOXO-TRK-15002-104-007,66,F,White,Y,Death,4/5/2017,21.88090349,47.9,164,17.80933968,2,Thyroid,III,Metastatic,1,Partial response,23.35934292,0,Partial response,23.35934292,0,23.35934292,0,9,3,1,1,3,2,80,CYCLE 9 DAY 1,11/28/2017,7.8193021,0,0.62037462
LOXO-TRK-15002-104-007,66,F,White,Y,Death,4/5/2017,21.88090349,47.9,164,17.80933968,2,Thyroid,III,Metastatic,1,Partial response,23.35934292,0,Partial response,23.35934292,0,23.35934292,0,11,2,1,1,2,2,95,CYCLE 11 DAY 1,1/23/2018,9.6591377,0,0.72846001
LOXO-TRK-15002-104-007,66,F,White,Y,Death,4/5/2017,21.88090349,47.9,164,17.80933968,2,Thyroid,III,Metastatic,1,Partial response,23.35934292,0,Partial response,23.35934292,0,23.35934292,0,13,3,1,2,3,2,40,CYCLE 13 DAY 1,3/20/2018,11.498973,0,0.57242304
LOXO-TRK-15002-104-007,66,F,White,Y,Death,4/5/2017,21.88090349,47.9,164,17.80933968,2,Thyroid,III,Metastatic,1,Partial response,23.35934292,0,Partial response,23.35934292,0,23.35934292,0,16,3,1,2,3,3,50,CYCLE 16 DAY 1,6/19/2018,14.488707,0,0.55882335
LOXO-TRK-15002-104-007,66,F,White,Y,Death,4/5/2017,21.88090349,47.9,164,17.80933968,2,Thyroid,III,Metastatic,1,Partial response,23.35934292,0,Partial response,23.35934292,0,23.35934292,0,19,3,3,3,4,3,60,CYCLE 19 DAY 1,9/18/2018,17.478439,0,0.2648775
LOXO-TRK-15002-104-007,66,F,White,Y,Death,4/5/2017,21.88090349,47.9,164,17.80933968,2,Thyroid,III,Metastatic,1,Partial response,23.35934292,0,Partial response,23.35934292,0,23.35934292,0,22,3,1,3,4,4,80,CYCLE 22 DAY 1,12/11/2018,20.238194,0,0.28948587
LOXO-TRK-15002-104-008,35,M,White,Y,,5/8/2017,38.43942505,125.9,174,41.58409301,1,Salivary gland,Not reported,Metastatic,0,Partial response,38.43942505,1,Partial response,38.43942505,1,38.43942505,1,-1,2,1,1,1,1,75,SCREENING,5/5/2017,0,1,0.88344198
LOXO-TRK-15002-104-008,35,M,White,Y,,5/8/2017,38.43942505,125.9,174,41.58409301,1,Salivary gland,Not reported,Metastatic,0,Partial response,38.43942505,1,Partial response,38.43942505,1,38.43942505,1,3,2,1,1,2,3,60,CYCLE 3 DAY 1,6/30/2017,1.7741274,1,0.72134042
LOXO-TRK-15002-104-008,35,M,White,Y,,5/8/2017,38.43942505,125.9,174,41.58409301,1,Salivary gland,Not reported,Metastatic,0,Partial response,38.43942505,1,Partial response,38.43942505,1,38.43942505,1,5,1,1,2,2,3,75,CYCLE 5 DAY 1,9/7/2017,4.0410676,1,0.7115463
LOXO-TRK-15002-104-008,35,M,White,Y,,5/8/2017,38.43942505,125.9,174,41.58409301,1,Salivary gland,Not reported,Metastatic,0,Partial response,38.43942505,1,Partial response,38.43942505,1,38.43942505,1,7,1,2,5,3,5,50,CYCLE 7 DAY 1,11/29/2017,6.7679672,1,0.20845853
LOXO-TRK-15002-104-008,35,M,White,Y,,5/8/2017,38.43942505,125.9,174,41.58409301,1,Salivary gland,Not reported,Metastatic,0,Partial response,38.43942505,1,Partial response,38.43942505,1,38.43942505,1,9,1,1,1,2,2,58,CYCLE 9 DAY 1,1/26/2018,8.6735115,1,0.79945654
LOXO-TRK-15002-104-008,35,M,White,Y,,5/8/2017,38.43942505,125.9,174,41.58409301,1,Salivary gland,Not reported,Metastatic,0,Partial response,38.43942505,1,Partial response,38.43942505,1,38.43942505,1,11,1,1,1,1,1,80,CYCLE 11 DAY 1,3/23/2018,10.513347,1,0.9834457
LOXO-TRK-15002-104-008,35,M,White,Y,,5/8/2017,38.43942505,125.9,174,41.58409301,1,Salivary gland,Not reported,Metastatic,0,Partial response,38.43942505,1,Partial response,38.43942505,1,38.43942505,1,13,1,1,1,1,2,75,CYCLE 13 DAY 1,5/25/2018,12.583162,1,0.91108906
LOXO-TRK-15002-104-008,35,M,White,Y,,5/8/2017,38.43942505,125.9,174,41.58409301,1,Salivary gland,Not reported,Metastatic,0,Partial response,38.43942505,1,Partial response,38.43942505,1,38.43942505,1,16,1,1,1,2,2,75,CYCLE 16 DAY 1,8/17/2018,15.342916,1,0.79945654
LOXO-TRK-15002-104-008,35,M,White,Y,,5/8/2017,38.43942505,125.9,174,41.58409301,1,Salivary gland,Not reported,Metastatic,0,Partial response,38.43942505,1,Partial response,38.43942505,1,38.43942505,1,19,1,1,2,2,1,85,CYCLE 19 DAY 1,11/20/2018,18.464066,1,0.79079729
LOXO-TRK-15002-104-008,35,M,White,Y,,5/8/2017,38.43942505,125.9,174,41.58409301,1,Salivary gland,Not reported,Metastatic,0,Partial response,38.43942505,1,Partial response,38.43942505,1,38.43942505,1,22,1,1,1,3,2,85,CYCLE 22 DAY 1,2/13/2019,21.256674,1,0.73516196
LOXO-TRK-15002-104-008,35,M,White,Y,,5/8/2017,38.43942505,125.9,174,41.58409301,1,Salivary gland,Not reported,Metastatic,0,Partial response,38.43942505,1,Partial response,38.43942505,1,38.43942505,1,25,1,1,2,3,2,85,CYCLE 25 DAY 1,4/30/2019,23.753593,1,0.68242913
LOXO-TRK-15002-104-008,35,M,White,Y,,5/8/2017,38.43942505,125.9,174,41.58409301,1,Salivary gland,Not reported,Metastatic,0,Partial response,38.43942505,1,Partial response,38.43942505,1,38.43942505,1,28,1,1,1,2,2,80,CYCLE 28 DAY 1,7/23/2019,26.513348,1,0.79945654
LOXO-TRK-15002-104-008,35,M,White,Y,,5/8/2017,38.43942505,125.9,174,41.58409301,1,Salivary gland,Not reported,Metastatic,0,Partial response,38.43942505,1,Partial response,38.43942505,1,38.43942505,1,31,1,1,1,1,2,85,CYCLE 31 DAY 1,11/12/2019,30.193018,1,0.91108906
LOXO-TRK-15002-104-008,35,M,White,Y,,5/8/2017,38.43942505,125.9,174,41.58409301,1,Salivary gland,Not reported,Metastatic,0,Partial response,38.43942505,1,Partial response,38.43942505,1,38.43942505,1,34,2,1,1,3,1,85,CYCLE 34 DAY 1,2/4/2020,32.95277,1,0.71609008
LOXO-TRK-15002-104-009,71,M,White,Y,Death,7/7/2017,29.33880904,97.4,173,32.54368673,1,Colon,Not reported,Metastatic,2,Complete response,29.37166324,0,Complete response,29.37166324,0,29.37166324,0,-1,2,1,1,1,1,100,SCREENING,7/5/2017,0,1,0.88408798
LOXO-TRK-15002-104-009,71,M,White,Y,Death,7/7/2017,29.33880904,97.4,173,32.54368673,1,Colon,Not reported,Metastatic,2,Complete response,29.37166324,0,Complete response,29.37166324,0,29.37166324,0,3,1,1,1,1,1,100,CYCLE 3 DAY 1,9/8/2017,2.1026695,1,0.97830981
LOXO-TRK-15002-104-009,71,M,White,Y,Death,7/7/2017,29.33880904,97.4,173,32.54368673,1,Colon,Not reported,Metastatic,2,Complete response,29.37166324,0,Complete response,29.37166324,0,29.37166324,0,5,2,1,1,1,1,100,CYCLE 5 DAY 1,10/25/2017,3.6468172,1,0.88408798
LOXO-TRK-15002-104-009,71,M,White,Y,Death,7/7/2017,29.33880904,97.4,173,32.54368673,1,Colon,Not reported,Metastatic,2,Complete response,29.37166324,0,Complete response,29.37166324,0,29.37166324,0,7,2,1,1,2,1,95,CYCLE 7 DAY 1,12/20/2017,5.4866529,1,0.77121663
LOXO-TRK-15002-104-009,71,M,White,Y,Death,7/7/2017,29.33880904,97.4,173,32.54368673,1,Colon,Not reported,Metastatic,2,Complete response,29.37166324,0,Complete response,29.37166324,0,29.37166324,0,9,1,1,1,1,1,100,CYCLE 9 DAY 1,2/13/2018,7.2936344,1,0.97830981
LOXO-TRK-15002-104-009,71,M,White,Y,Death,7/7/2017,29.33880904,97.4,173,32.54368673,1,Colon,Not reported,Metastatic,2,Complete response,29.37166324,0,Complete response,29.37166324,0,29.37166324,0,13,3,1,1,1,1,99,CYCLE 13 DAY 1,6/13/2018,11.236139,1,0.81542575
LOXO-TRK-15002-104-009,71,M,White,Y,Death,7/7/2017,29.33880904,97.4,173,32.54368673,1,Colon,Not reported,Metastatic,2,Complete response,29.37166324,0,Complete response,29.37166324,0,29.37166324,0,16,2,1,2,2,1,50,CYCLE 16 DAY 1,9/6/2018,14.028748,1,0.71099275
LOXO-TRK-15002-104-009,71,M,White,Y,Death,7/7/2017,29.33880904,97.4,173,32.54368673,1,Colon,Not reported,Metastatic,2,Complete response,29.37166324,0,Complete response,29.37166324,0,29.37166324,0,22,1,1,,1,1,90,CYCLE 22 DAY 1,3/6/2019,19.975359,1,
LOXO-TRK-15002-104-009,71,M,White,Y,Death,7/7/2017,29.33880904,97.4,173,32.54368673,1,Colon,Not reported,Metastatic,2,Complete response,29.37166324,0,Complete response,29.37166324,0,29.37166324,0,25,3,1,2,2,1,85,CYCLE 25 DAY 1,5/29/2019,22.735113,1,0.65236211
LOXO-TRK-15002-104-009,71,M,White,Y,Death,7/7/2017,29.33880904,97.4,173,32.54368673,1,Colon,Not reported,Metastatic,2,Complete response,29.37166324,0,Complete response,29.37166324,0,29.37166324,0,28,2,1,1,1,1,85,CYCLE 28 DAY 1,8/28/2019,25.724846,1,0.88408798
LOXO-TRK-15002-104-009,71,M,White,Y,Death,7/7/2017,29.33880904,97.4,173,32.54368673,1,Colon,Not reported,Metastatic,2,Complete response,29.37166324,0,Complete response,29.37166324,0,29.37166324,0,31,2,1,3,3,1,50,CYCLE 31 DAY 1,11/19/2019,28.451746,1,0.63415849
LOXO-TRK-15002-104-010,43,M,White,Y,,11/17/2017,31.90143737,102.7,179,32.0526825,0,Salivary gland,Not reported,Metastatic,2,Partial response,30.9486653,1,Partial response,30.9486653,1,31.90143737,1,-1,1,1,1,2,1,75,SCREENING,11/14/2017,0,1,0.8456279
LOXO-TRK-15002-104-010,43,M,White,Y,,11/17/2017,31.90143737,102.7,179,32.0526825,0,Salivary gland,Not reported,Metastatic,2,Partial response,30.9486653,1,Partial response,30.9486653,1,31.90143737,1,3,1,1,1,1,1,90,CYCLE 3 DAY 1,1/11/2018,1.8398358,1,0.98146659
LOXO-TRK-15002-104-010,43,M,White,Y,,11/17/2017,31.90143737,102.7,179,32.0526825,0,Salivary gland,Not reported,Metastatic,2,Partial response,30.9486653,1,Partial response,30.9486653,1,31.90143737,1,5,1,1,1,1,1,90,CYCLE 5 DAY 1,3/8/2018,3.6796715,1,0.98146659
LOXO-TRK-15002-104-010,43,M,White,Y,,11/17/2017,31.90143737,102.7,179,32.0526825,0,Salivary gland,Not reported,Metastatic,2,Partial response,30.9486653,1,Partial response,30.9486653,1,31.90143737,1,7,1,1,1,1,1,95,CYCLE 7 DAY 1,5/1/2018,5.4537988,1,0.98146659
LOXO-TRK-15002-104-010,43,M,White,Y,,11/17/2017,31.90143737,102.7,179,32.0526825,0,Salivary gland,Not reported,Metastatic,2,Partial response,30.9486653,1,Partial response,30.9486653,1,31.90143737,1,9,1,1,1,1,1,95,CYCLE 9 DAY 1,6/26/2018,7.2936344,1,0.98146659
LOXO-TRK-15002-104-010,43,M,White,Y,,11/17/2017,31.90143737,102.7,179,32.0526825,0,Salivary gland,Not reported,Metastatic,2,Partial response,30.9486653,1,Partial response,30.9486653,1,31.90143737,1,11,1,1,1,1,1,90,CYCLE 11 DAY 1,8/21/2018,9.1334705,1,0.98146659
LOXO-TRK-15002-104-010,43,M,White,Y,,11/17/2017,31.90143737,102.7,179,32.0526825,0,Salivary gland,Not reported,Metastatic,2,Partial response,30.9486653,1,Partial response,30.9486653,1,31.90143737,1,13,1,1,1,1,1,96,CYCLE 13 DAY 1,10/23/2018,11.203285,1,0.98146659
LOXO-TRK-15002-104-010,43,M,White,Y,,11/17/2017,31.90143737,102.7,179,32.0526825,0,Salivary gland,Not reported,Metastatic,2,Partial response,30.9486653,1,Partial response,30.9486653,1,31.90143737,1,16,1,1,1,1,1,97,CYCLE 16 DAY 1,1/15/2019,13.963039,1,0.98146659
LOXO-TRK-15002-104-010,43,M,White,Y,,11/17/2017,31.90143737,102.7,179,32.0526825,0,Salivary gland,Not reported,Metastatic,2,Partial response,30.9486653,1,Partial response,30.9486653,1,31.90143737,1,19,1,1,1,1,1,95,CYCLE 19 DAY 1,4/9/2019,16.722792,1,0.98146659
LOXO-TRK-15002-104-010,43,M,White,Y,,11/17/2017,31.90143737,102.7,179,32.0526825,0,Salivary gland,Not reported,Metastatic,2,Partial response,30.9486653,1,Partial response,30.9486653,1,31.90143737,1,22,1,1,1,1,1,95,CYCLE 22 DAY 1,7/16/2019,19.942505,1,0.98146659
LOXO-TRK-15002-104-010,43,M,White,Y,,11/17/2017,31.90143737,102.7,179,32.0526825,0,Salivary gland,Not reported,Metastatic,2,Partial response,30.9486653,1,Partial response,30.9486653,1,31.90143737,1,25,1,1,1,1,1,99,CYCLE 25 DAY 1,10/8/2019,22.702259,1,0.98146659
LOXO-TRK-15002-104-010,43,M,White,Y,,11/17/2017,31.90143737,102.7,179,32.0526825,0,Salivary gland,Not reported,Metastatic,2,Partial response,30.9486653,1,Partial response,30.9486653,1,31.90143737,1,28,1,1,1,1,1,97,CYCLE 28 DAY 1,12/31/2019,25.462013,1,0.98146659
LOXO-TRK-15002-104-010,43,M,White,Y,,11/17/2017,31.90143737,102.7,179,32.0526825,0,Salivary gland,Not reported,Metastatic,2,Partial response,30.9486653,1,Partial response,30.9486653,1,31.90143737,1,34,1,1,1,1,1,97,CYCLE 34 DAY 1,6/16/2020,30.98152,1,0.98146659
LOXO-TRK-15002-104-011,37,M,White,Y,,11/29/2017,31.34291581,85.5,182,25.81209999,1,Salivary gland,Not reported,Metastatic,0,Complete response,23.91786448,1,Partial response,30.09445585,1,31.34291581,1,-1,3,1,1,1,1,15,SCREENING,11/16/2017,0,1,0.80621129
LOXO-TRK-15002-104-011,37,M,White,Y,,11/29/2017,31.34291581,85.5,182,25.81209999,1,Salivary gland,Not reported,Metastatic,0,Complete response,23.91786448,1,Partial response,30.09445585,1,31.34291581,1,3,1,1,1,1,1,95,CYCLE 3 DAY 1,1/25/2018,1.9055442,1,0.98291826
LOXO-TRK-15002-104-011,37,M,White,Y,,11/29/2017,31.34291581,85.5,182,25.81209999,1,Salivary gland,Not reported,Metastatic,0,Complete response,23.91786448,1,Partial response,30.09445585,1,31.34291581,1,5,,,,,,88,CYCLE 5 DAY 1,3/22/2018,3.7453799,1,
LOXO-TRK-15002-104-011,37,M,White,Y,,11/29/2017,31.34291581,85.5,182,25.81209999,1,Salivary gland,Not reported,Metastatic,0,Complete response,23.91786448,1,Partial response,30.09445585,1,31.34291581,1,7,1,1,1,1,1,90,CYCLE 7 DAY 1,5/17/2018,5.5852156,1,0.98291826
LOXO-TRK-15002-104-011,37,M,White,Y,,11/29/2017,31.34291581,85.5,182,25.81209999,1,Salivary gland,Not reported,Metastatic,0,Complete response,23.91786448,1,Partial response,30.09445585,1,31.34291581,1,9,2,1,1,1,1,80,CYCLE 9 DAY 1,7/12/2018,7.4250512,1,0.88248539
LOXO-TRK-15002-104-011,37,M,White,Y,,11/29/2017,31.34291581,85.5,182,25.81209999,1,Salivary gland,Not reported,Metastatic,0,Complete response,23.91786448,1,Partial response,30.09445585,1,31.34291581,1,11,1,1,1,1,1,85,CYCLE 11 DAY 1,9/7/2018,9.2977409,1,0.98291826
LOXO-TRK-15002-104-011,37,M,White,Y,,11/29/2017,31.34291581,85.5,182,25.81209999,1,Salivary gland,Not reported,Metastatic,0,Complete response,23.91786448,1,Partial response,30.09445585,1,31.34291581,1,13,1,1,1,1,1,92,CYCLE 13 DAY 1,11/2/2018,11.137577,1,0.98291826
LOXO-TRK-15002-104-011,37,M,White,Y,,11/29/2017,31.34291581,85.5,182,25.81209999,1,Salivary gland,Not reported,Metastatic,0,Complete response,23.91786448,1,Partial response,30.09445585,1,31.34291581,1,16,2,1,1,1,1,70,CYCLE 16 DAY 1,1/17/2019,13.634497,1,0.88248539
LOXO-TRK-15002-104-011,37,M,White,Y,,11/29/2017,31.34291581,85.5,182,25.81209999,1,Salivary gland,Not reported,Metastatic,0,Complete response,23.91786448,1,Partial response,30.09445585,1,31.34291581,1,19,2,1,1,1,1,80,CYCLE 19 DAY 1,4/11/2019,16.394251,1,0.88248539
LOXO-TRK-15002-104-011,37,M,White,Y,,11/29/2017,31.34291581,85.5,182,25.81209999,1,Salivary gland,Not reported,Metastatic,0,Complete response,23.91786448,1,Partial response,30.09445585,1,31.34291581,1,22,1,1,1,1,1,75,CYCLE 22 DAY 1,7/9/2019,19.318275,1,0.98291826
LOXO-TRK-15002-104-011,37,M,White,Y,,11/29/2017,31.34291581,85.5,182,25.81209999,1,Salivary gland,Not reported,Metastatic,0,Complete response,23.91786448,1,Partial response,30.09445585,1,31.34291581,1,27,2,1,1,1,1,70,CYCLE 27 DAY 1,12/3/2019,24.147844,1,0.88248539
LOXO-TRK-15002-104-011,37,M,White,Y,,11/29/2017,31.34291581,85.5,182,25.81209999,1,Salivary gland,Not reported,Metastatic,0,Complete response,23.91786448,1,Partial response,30.09445585,1,31.34291581,1,28,1,1,1,1,1,85,CYCLE 28 DAY 1,1/6/2020,25.264887,1,0.98291826
LOXO-TRK-15002-104-012,64,M,White,Y,Disease Progression,12/15/2017,0.919917865,69.1,176,22.30759298,2,Thyroid,IV,Metastatic,1,Progressive disease,0.919917865,0,Progressive disease,0.919917865,0,3.022587269,0,-1,1,3,3,3,3,80,SCREENING,12/4/2017,0,1,0.55188829
LOXO-TRK-15002-104-013,27,F,All others,Y,,12/15/2017,25.85626283,36.8,152,15.92797784,2,Thyroid,II,Metastatic,4,Partial response,28.09034908,1,Partial response,28.09034908,1,28.09034908,1,-1,1,2,1,3,3,45,SCREENING,12/6/2017,0,0,0.63714737
LOXO-TRK-15002-104-013,27,F,All others,Y,,12/15/2017,25.85626283,36.8,152,15.92797784,2,Thyroid,II,Metastatic,4,Partial response,28.09034908,1,Partial response,28.09034908,1,28.09034908,1,3,2,1,1,4,2,95,CYCLE 3 DAY 1,2/7/2018,1.8069816,0,0.616678
LOXO-TRK-15002-104-013,27,F,All others,Y,,12/15/2017,25.85626283,36.8,152,15.92797784,2,Thyroid,II,Metastatic,4,Partial response,28.09034908,1,Partial response,28.09034908,1,28.09034908,1,7,1,1,1,3,2,70,CYCLE 7 DAY 1,7/27/2018,7.3921971,0,0.73376656
LOXO-TRK-15002-104-013,27,F,All others,Y,,12/15/2017,25.85626283,36.8,152,15.92797784,2,Thyroid,II,Metastatic,4,Partial response,28.09034908,1,Partial response,28.09034908,1,28.09034908,1,9,1,1,3,4,3,85,CYCLE 9 DAY 1,11/7/2018,10.77618,0,0.49250707
LOXO-TRK-15002-104-013,27,F,All others,Y,,12/15/2017,25.85626283,36.8,152,15.92797784,2,Thyroid,II,Metastatic,4,Partial response,28.09034908,1,Partial response,28.09034908,1,28.09034908,1,11,1,1,2,4,3,80,CYCLE 11 DAY 1,1/11/2019,12.911704,0,0.52527511
LOXO-TRK-15002-104-013,27,F,All others,Y,,12/15/2017,25.85626283,36.8,152,15.92797784,2,Thyroid,II,Metastatic,4,Partial response,28.09034908,1,Partial response,28.09034908,1,28.09034908,1,12,2,1,1,3,2,60,CYCLE 12 DAY 1,5/3/2019,16.591375,0,0.68871951
LOXO-TRK-15002-104-013,27,F,All others,Y,,12/15/2017,25.85626283,36.8,152,15.92797784,2,Thyroid,II,Metastatic,4,Partial response,28.09034908,1,Partial response,28.09034908,1,28.09034908,1,13,1,1,1,1,2,70,CYCLE 13 DAY 1,6/24/2019,18.299795,0,0.9094094
LOXO-TRK-15002-104-013,27,F,All others,Y,,12/15/2017,25.85626283,36.8,152,15.92797784,2,Thyroid,II,Metastatic,4,Partial response,28.09034908,1,Partial response,28.09034908,1,28.09034908,1,15,1,2,2,3,2,60,CYCLE 15 DAY 1,10/25/2019,22.340862,0,0.59681261
LOXO-TRK-15002-104-013,27,F,All others,Y,,12/15/2017,25.85626283,36.8,152,15.92797784,2,Thyroid,II,Metastatic,4,Partial response,28.09034908,1,Partial response,28.09034908,1,28.09034908,1,16,1,1,1,3,2,60,CYCLE 16 DAY 1,1/10/2020,24.870636,0,0.73376656
LOXO-TRK-15002-104-015,50,F,White,Y,Disease Progression,4/11/2018,9.691991786,57.9,162,22.06218564,0,Soft tissue sarcoma,Not reported,Metastatic,1,Complete response,9.659137577,0,Complete response,7.589322382,0,26.74332649,1,0,1,1,1,2,1,100,CYCLE 1 DAY 1,4/11/2018,0,0,0.83201945
LOXO-TRK-15002-104-015,50,F,White,Y,Disease Progression,4/11/2018,9.691991786,57.9,162,22.06218564,0,Soft tissue sarcoma,Not reported,Metastatic,1,Complete response,9.659137577,0,Complete response,7.589322382,0,26.74332649,1,5,1,1,1,1,1,95,CYCLE 5 DAY 1,8/8/2018,3.9425051,0,0.97622776
LOXO-TRK-15002-104-015,50,F,White,Y,Disease Progression,4/11/2018,9.691991786,57.9,162,22.06218564,0,Soft tissue sarcoma,Not reported,Metastatic,1,Complete response,9.659137577,0,Complete response,7.589322382,0,26.74332649,1,9,1,1,1,1,1,100,CYCLE 9 DAY 1,11/28/2018,7.6221766,0,0.97622776
LOXO-TRK-15002-104-015,50,F,White,Y,Disease Progression,4/11/2018,9.691991786,57.9,162,22.06218564,0,Soft tissue sarcoma,Not reported,Metastatic,1,Complete response,9.659137577,0,Complete response,7.589322382,0,26.74332649,1,96,1,1,1,2,1,80,END OF TREATMENT,1/30/2019,9.6919918,0,0.83201945
LOXO-TRK-15002-104-016,13,M,White,Y,,4/9/2018,26.34907598,68.6,176,22.14617769,0,Thyroid,Not reported,Metastatic,0,Complete response,27.26899384,1,Partial response,24.41067762,1,27.30184805,1,,,,,,,,,,,1,
LOXO-TRK-15002-104-017,72,F,White,Y,Subject Decision,4/27/2018,11.92607803,95.1,.,.,1,Thyroid,Not reported,Locally advanced,1,Not evaluable,0.032854209,1,Partial response,12.84599589,1,26.34907598,1,0,1,1,3,3,3,80,CYCLE 1 DAY 1,4/27/2018,0,0,0.65027446
LOXO-TRK-15002-104-017,72,F,White,Y,Subject Decision,4/27/2018,11.92607803,95.1,.,.,1,Thyroid,Not reported,Locally advanced,1,Not evaluable,0.032854209,1,Partial response,12.84599589,1,26.34907598,1,3,1,1,3,3,1,50,CYCLE 3 DAY 1,6/21/2018,1.8398358,0,0.68375129
LOXO-TRK-15002-104-017,72,F,White,Y,Subject Decision,4/27/2018,11.92607803,95.1,.,.,1,Thyroid,Not reported,Locally advanced,1,Not evaluable,0.032854209,1,Partial response,12.84599589,1,26.34907598,1,5,2,1,2,3,3,40,CYCLE 5 DAY 1,8/16/2018,3.6796715,0,0.60930932
LOXO-TRK-15002-104-017,72,F,White,Y,Subject Decision,4/27/2018,11.92607803,95.1,.,.,1,Thyroid,Not reported,Locally advanced,1,Not evaluable,0.032854209,1,Partial response,12.84599589,1,26.34907598,1,7,2,1,3,3,4,70,CYCLE 7 DAY 1,10/11/2018,5.5195074,0,0.52192259
LOXO-TRK-15002-104-017,72,F,White,Y,Subject Decision,4/27/2018,11.92607803,95.1,.,.,1,Thyroid,Not reported,Locally advanced,1,Not evaluable,0.032854209,1,Partial response,12.84599589,1,26.34907598,1,9,1,1,1,3,1,32,CYCLE 9 DAY 1,12/6/2018,7.3593431,0,0.76024991
LOXO-TRK-15002-104-017,72,F,White,Y,Subject Decision,4/27/2018,11.92607803,95.1,.,.,1,Thyroid,Not reported,Locally advanced,1,Not evaluable,0.032854209,1,Partial response,12.84599589,1,26.34907598,1,11,2,1,3,3,3,75,CYCLE 11 DAY 1,1/31/2019,9.1991787,0,0.60088301
LOXO-TRK-15002-104-017,72,F,White,Y,Subject Decision,4/27/2018,11.92607803,95.1,.,.,1,Thyroid,Not reported,Locally advanced,1,Not evaluable,0.032854209,1,Partial response,12.84599589,1,26.34907598,1,13,2,1,3,3,2,40,CYCLE 13 DAY 1,3/28/2019,11.039015,0,0.61235398
LOXO-TRK-15002-104-017,72,F,White,Y,Subject Decision,4/27/2018,11.92607803,95.1,.,.,1,Thyroid,Not reported,Locally advanced,1,Not evaluable,0.032854209,1,Partial response,12.84599589,1,26.34907598,1,96,2,1,4,3,5,50,END OF TREATMENT,5/23/2019,12.87885,0,0.28890583
LOXO-TRK-15002-104-018,69,F,White,Y,,6/20/2018,24.37782341,106.5,160,41.6015625,1,Salivary gland,Not reported,Locally advanced,0,Complete response,24.11498973,1,Partial response,24.37782341,1,24.37782341,1,-1,2,1,2,2,2,80,SCREENING,5/29/2018,0,0,0.67505825
LOXO-TRK-15002-104-018,69,F,White,Y,,6/20/2018,24.37782341,106.5,160,41.6015625,1,Salivary gland,Not reported,Locally advanced,0,Complete response,24.11498973,1,Partial response,24.37782341,1,24.37782341,1,3,1,1,1,1,1,90,CYCLE 3 DAY 1,8/14/2018,1.8398358,0,0.97473931
LOXO-TRK-15002-104-018,69,F,White,Y,,6/20/2018,24.37782341,106.5,160,41.6015625,1,Salivary gland,Not reported,Locally advanced,0,Complete response,24.11498973,1,Partial response,24.37782341,1,24.37782341,1,6,2,1,1,2,2,95,CYCLE 6 DAY 1,11/6/2018,4.5995893,0,0.72839749
LOXO-TRK-15002-104-018,69,F,White,Y,,6/20/2018,24.37782341,106.5,160,41.6015625,1,Salivary gland,Not reported,Locally advanced,0,Complete response,24.11498973,1,Partial response,24.37782341,1,24.37782341,1,8,1,1,2,2,1,96,CYCLE 8 DAY 1,1/8/2019,6.6694045,0,0.77055043
LOXO-TRK-15002-104-018,69,F,White,Y,,6/20/2018,24.37782341,106.5,160,41.6015625,1,Salivary gland,Not reported,Locally advanced,0,Complete response,24.11498973,1,Partial response,24.37782341,1,24.37782341,1,10,1,1,2,1,1,75,CYCLE 10 DAY 1,3/4/2019,8.4763861,0,0.89157081
LOXO-TRK-15002-104-018,69,F,White,Y,,6/20/2018,24.37782341,106.5,160,41.6015625,1,Salivary gland,Not reported,Locally advanced,0,Complete response,24.11498973,1,Partial response,24.37782341,1,24.37782341,1,12,,,,,,85,CYCLE 12 DAY 1,4/30/2019,10.349076,0,
LOXO-TRK-15002-104-018,69,F,White,Y,,6/20/2018,24.37782341,106.5,160,41.6015625,1,Salivary gland,Not reported,Locally advanced,0,Complete response,24.11498973,1,Partial response,24.37782341,1,24.37782341,1,15,1,1,2,3,2,90,CYCLE 15 DAY 1,7/23/2019,13.108829,0,0.67711323
LOXO-TRK-15002-104-018,69,F,White,Y,,6/20/2018,24.37782341,106.5,160,41.6015625,1,Salivary gland,Not reported,Locally advanced,0,Complete response,24.11498973,1,Partial response,24.37782341,1,24.37782341,1,18,2,1,2,2,2,95,CYCLE 18 DAY 1,10/15/2019,15.868583,0,0.67505825
LOXO-TRK-15002-104-018,69,F,White,Y,,6/20/2018,24.37782341,106.5,160,41.6015625,1,Salivary gland,Not reported,Locally advanced,0,Complete response,24.11498973,1,Partial response,24.37782341,1,24.37782341,1,21,1,1,2,2,2,70,CYCLE 21 DAY 1,1/14/2020,18.858316,0,0.72934002
LOXO-TRK-15002-104-018,69,F,White,Y,,6/20/2018,24.37782341,106.5,160,41.6015625,1,Salivary gland,Not reported,Locally advanced,0,Complete response,24.11498973,1,Partial response,24.37782341,1,24.37782341,1,27,1,1,2,2,2,90,CYCLE 27 DAY 1,6/30/2020,24.377823,0,0.72934002
LOXO-TRK-15002-104-020,52,F,White,Y,,8/28/2018,22.17659138,68.1,.,.,0,Thyroid,IV,Metastatic,3,Partial response,22.14373717,1,Partial response,22.14373717,1,22.17659138,1,-1,1,1,1,1,1,80,SCREENING,8/7/2018,0,0,0.97587627
LOXO-TRK-15002-104-020,52,F,White,Y,,8/28/2018,22.17659138,68.1,.,.,0,Thyroid,IV,Metastatic,3,Partial response,22.14373717,1,Partial response,22.14373717,1,22.17659138,1,3,1,1,1,1,1,85,CYCLE 3 DAY 1,10/23/2018,1.87269,0,0.97587627
LOXO-TRK-15002-104-020,52,F,White,Y,,8/28/2018,22.17659138,68.1,.,.,0,Thyroid,IV,Metastatic,3,Partial response,22.14373717,1,Partial response,22.14373717,1,22.17659138,1,5,1,1,1,2,1,90,CYCLE 5 DAY 1,12/18/2018,3.7125256,0,0.83139122
LOXO-TRK-15002-104-020,52,F,White,Y,,8/28/2018,22.17659138,68.1,.,.,0,Thyroid,IV,Metastatic,3,Partial response,22.14373717,1,Partial response,22.14373717,1,22.17659138,1,7,1,1,1,1,1,97,CYCLE 7 DAY 1,2/12/2019,5.5523615,0,0.97587627
LOXO-TRK-15002-104-020,52,F,White,Y,,8/28/2018,22.17659138,68.1,.,.,0,Thyroid,IV,Metastatic,3,Partial response,22.14373717,1,Partial response,22.14373717,1,22.17659138,1,9,1,1,1,2,1,92,CYCLE 9 DAY 1,4/9/2019,7.3921971,0,0.83139122
LOXO-TRK-15002-104-020,52,F,White,Y,,8/28/2018,22.17659138,68.1,.,.,0,Thyroid,IV,Metastatic,3,Partial response,22.14373717,1,Partial response,22.14373717,1,22.17659138,1,11,1,1,1,1,1,95,CYCLE 11 DAY 1,6/4/2019,9.2320328,0,0.97587627
LOXO-TRK-15002-104-020,52,F,White,Y,,8/28/2018,22.17659138,68.1,.,.,0,Thyroid,IV,Metastatic,3,Partial response,22.14373717,1,Partial response,22.14373717,1,22.17659138,1,13,1,1,1,1,1,90,CYCLE 13 DAY 1,7/30/2019,11.071869,0,0.97587627
LOXO-TRK-15002-104-020,52,F,White,Y,,8/28/2018,22.17659138,68.1,.,.,0,Thyroid,IV,Metastatic,3,Partial response,22.14373717,1,Partial response,22.14373717,1,22.17659138,1,16,1,1,1,3,1,93,CYCLE 16 DAY 1,10/22/2019,13.831622,0,0.76130265
LOXO-TRK-15002-104-020,52,F,White,Y,,8/28/2018,22.17659138,68.1,.,.,0,Thyroid,IV,Metastatic,3,Partial response,22.14373717,1,Partial response,22.14373717,1,22.17659138,1,19,1,1,1,1,1,95,CYCLE 19 DAY 1,1/14/2020,16.591375,0,0.97587627
LOXO-TRK-15002-104-021,69,F,White,Y,Physician Decision,9/13/2018,0.887063655,109.7,.,.,3,Thyroid,Not reported,Metastatic,2,Not evaluable,0.032854209,1,Not determined,0.032854209,1,1.18275154,1,-1,3,4,4,3,4,75,SCREENING,8/30/2018,0,0,0.2642464
LOXO-TRK-15002-104-022,84,F,White,Y,,10/23/2018,20.33675565,58.1,163,21.86759005,1,Colon,Not reported,Metastatic,1,Partial response,20.27104723,1,Partial response,20.33675565,1,20.36960986,1,-1,1,1,1,1,1,100,SCREENING,10/9/2018,0,0,0.97591603
LOXO-TRK-15002-104-022,84,F,White,Y,,10/23/2018,20.33675565,58.1,163,21.86759005,1,Colon,Not reported,Metastatic,1,Partial response,20.27104723,1,Partial response,20.33675565,1,20.36960986,1,2,1,1,1,1,1,100,CYCLE 2 DAY 1,1/3/2019,2.3983574,0,0.97591603
LOXO-TRK-15002-104-022,84,F,White,Y,,10/23/2018,20.33675565,58.1,163,21.86759005,1,Colon,Not reported,Metastatic,1,Partial response,20.27104723,1,Partial response,20.33675565,1,20.36960986,1,3,1,1,1,1,1,100,CYCLE 3 DAY 1,2/5/2019,3.4825461,0,0.97591603
LOXO-TRK-15002-104-022,84,F,White,Y,,10/23/2018,20.33675565,58.1,163,21.86759005,1,Colon,Not reported,Metastatic,1,Partial response,20.27104723,1,Partial response,20.33675565,1,20.36960986,1,4,1,1,1,1,1,100,CYCLE 4 DAY 1,3/13/2019,4.6652975,0,0.97591603
LOXO-TRK-15002-104-022,84,F,White,Y,,10/23/2018,20.33675565,58.1,163,21.86759005,1,Colon,Not reported,Metastatic,1,Partial response,20.27104723,1,Partial response,20.33675565,1,20.36960986,1,6,1,1,1,1,1,100,CYCLE 6 DAY 1,5/7/2019,6.4722791,0,0.97591603
LOXO-TRK-15002-104-022,84,F,White,Y,,10/23/2018,20.33675565,58.1,163,21.86759005,1,Colon,Not reported,Metastatic,1,Partial response,20.27104723,1,Partial response,20.33675565,1,20.36960986,1,8,1,1,1,1,1,100,CYCLE 8 DAY 1,7/2/2019,8.3121147,0,0.97591603
LOXO-TRK-15002-104-022,84,F,White,Y,,10/23/2018,20.33675565,58.1,163,21.86759005,1,Colon,Not reported,Metastatic,1,Partial response,20.27104723,1,Partial response,20.33675565,1,20.36960986,1,10,1,2,3,1,2,100,CYCLE 10 DAY 1,8/29/2019,10.217659,0,0.71583629
LOXO-TRK-15002-104-022,84,F,White,Y,,10/23/2018,20.33675565,58.1,163,21.86759005,1,Colon,Not reported,Metastatic,1,Partial response,20.27104723,1,Partial response,20.33675565,1,20.36960986,1,12,1,1,3,1,1,100,CYCLE 12 DAY 1,10/24/2019,12.057495,0,0.83516681
LOXO-TRK-15002-104-022,84,F,White,Y,,10/23/2018,20.33675565,58.1,163,21.86759005,1,Colon,Not reported,Metastatic,1,Partial response,20.27104723,1,Partial response,20.33675565,1,20.36960986,1,15,1,1,3,2,2,95,CYCLE 15 DAY 1,1/21/2020,14.98152,0,0.71194226
LOXO-TRK-15002-104-022,84,F,White,Y,,10/23/2018,20.33675565,58.1,163,21.86759005,1,Colon,Not reported,Metastatic,1,Partial response,20.27104723,1,Partial response,20.33675565,1,20.36960986,1,21,1,1,2,1,1,95,CYCLE 21 DAY 1,7/2/2020,20.336756,0,0.88899314
LOXO-TRK-15002-104-023,47,F,White,Y,,11/6/2018,19.58110883,76.9,176,24.82567149,1,Thyroid,III,Metastatic,0,Partial response,19.54825462,1,Partial response,19.54825462,1,20.33675565,1,0,1,1,1,2,1,95,CYCLE 1 DAY 1,11/6/2018,0,0,0.83313304
LOXO-TRK-15002-104-023,47,F,White,Y,,11/6/2018,19.58110883,76.9,176,24.82567149,1,Thyroid,III,Metastatic,0,Partial response,19.54825462,1,Partial response,19.54825462,1,20.33675565,1,2,1,1,1,1,1,95,CYCLE 2 DAY 1,12/4/2018,0.95277208,0,0.97681606
LOXO-TRK-15002-104-023,47,F,White,Y,,11/6/2018,19.58110883,76.9,176,24.82567149,1,Thyroid,III,Metastatic,0,Partial response,19.54825462,1,Partial response,19.54825462,1,20.33675565,1,3,1,1,1,1,1,95,CYCLE 3 DAY 1,1/3/2019,1.9383984,0,0.97681606
LOXO-TRK-15002-104-023,47,F,White,Y,,11/6/2018,19.58110883,76.9,176,24.82567149,1,Thyroid,III,Metastatic,0,Partial response,19.54825462,1,Partial response,19.54825462,1,20.33675565,1,5,1,1,1,1,1,92,CYCLE 5 DAY 1,2/28/2019,3.778234,0,0.97681606
LOXO-TRK-15002-104-023,47,F,White,Y,,11/6/2018,19.58110883,76.9,176,24.82567149,1,Thyroid,III,Metastatic,0,Partial response,19.54825462,1,Partial response,19.54825462,1,20.33675565,1,7,1,1,1,1,1,96,CYCLE 7 DAY 1,4/30/2019,5.782341,0,0.97681606
LOXO-TRK-15002-104-023,47,F,White,Y,,11/6/2018,19.58110883,76.9,176,24.82567149,1,Thyroid,III,Metastatic,0,Partial response,19.54825462,1,Partial response,19.54825462,1,20.33675565,1,9,1,1,1,2,1,94,CYCLE 9 DAY 1,6/25/2019,7.6221766,0,0.83313304
LOXO-TRK-15002-104-023,47,F,White,Y,,11/6/2018,19.58110883,76.9,176,24.82567149,1,Thyroid,III,Metastatic,0,Partial response,19.54825462,1,Partial response,19.54825462,1,20.33675565,1,11,1,1,1,1,1,98,CYCLE 11 DAY 1,8/22/2019,9.5277205,0,0.97681606
LOXO-TRK-15002-104-023,47,F,White,Y,,11/6/2018,19.58110883,76.9,176,24.82567149,1,Thyroid,III,Metastatic,0,Partial response,19.54825462,1,Partial response,19.54825462,1,20.33675565,1,13,1,1,1,1,1,96,CYCLE 13 DAY 1,10/17/2019,11.367557,0,0.97681606
LOXO-TRK-15002-104-023,47,F,White,Y,,11/6/2018,19.58110883,76.9,176,24.82567149,1,Thyroid,III,Metastatic,0,Partial response,19.54825462,1,Partial response,19.54825462,1,20.33675565,1,16,1,1,1,1,1,98,CYCLE 16 DAY 1,1/9/2020,14.12731,0,0.97681606
LOXO-TRK-15002-104-023,47,F,White,Y,,11/6/2018,19.58110883,76.9,176,24.82567149,1,Thyroid,III,Metastatic,0,Partial response,19.54825462,1,Partial response,19.54825462,1,20.33675565,1,19,2,1,1,1,1,96,CYCLE 19 DAY 1,3/31/2020,16.821356,0,0.87045294
LOXO-TRK-15002-104-023,47,F,White,Y,,11/6/2018,19.58110883,76.9,176,24.82567149,1,Thyroid,III,Metastatic,0,Partial response,19.54825462,1,Partial response,19.54825462,1,20.33675565,1,22,1,1,1,1,1,98,CYCLE 22 DAY 1,6/23/2020,19.581108,0,0.97681606
LOXO-TRK-15002-105-001,65,M,White,Y,,11/29/2016,43.07186858,76.8,170,26.57439446,0,Thyroid,IV,Metastatic,3,Complete response,40.96919918,1,Complete response,40.96919918,1,43.07186858,1,43,1,1,1,1,1,90,CYCLE 43 DAY 1,2/12/2020,38.472279,1,0.97847062
LOXO-TRK-15002-105-002,25,F,All others,Y,Disease Progression,1/26/2018,2.069815195,46.6,160,18.203125,1,Lung,IV,Metastatic,1,Stable disease,7.556468173,0,Stable disease,1.80698152,0,7.556468173,0,0,1,1,2,3,3,60,CYCLE 1 DAY 1,1/26/2018,0,0,0.66457218
LOXO-TRK-15002-105-002,25,F,All others,Y,Disease Progression,1/26/2018,2.069815195,46.6,160,18.203125,1,Lung,IV,Metastatic,1,Stable disease,7.556468173,0,Stable disease,1.80698152,0,7.556468173,0,2,1,1,1,2,2,90,CYCLE 2 DAY 1,2/27/2018,1.0841889,0,0.79774106
LOXO-TRK-15002-105-002,25,F,All others,Y,Disease Progression,1/26/2018,2.069815195,46.6,160,18.203125,1,Lung,IV,Metastatic,1,Stable disease,7.556468173,0,Stable disease,1.80698152,0,7.556468173,0,3,2,1,1,2,1,80,CYCLE 3 DAY 1,3/27/2018,2.0041068,0,0.78034633
LOXO-TRK-15002-105-002,25,F,All others,Y,Disease Progression,1/26/2018,2.069815195,46.6,160,18.203125,1,Lung,IV,Metastatic,1,Stable disease,7.556468173,0,Stable disease,1.80698152,0,7.556468173,0,96,2,1,1,2,2,80,END OF TREATMENT,3/30/2018,2.1026695,0,0.74609184
LOXO-TRK-15002-105-003,74,F,White,Y,,3/14/2018,22.99794661,75.6,156,31.06508876,1,Thyroid,IV,Metastatic,1,Complete response,25.62628337,1,Partial response,25.62628337,1,27.63039014,1,0,2,1,1,1,3,40,CYCLE 1 DAY 1,3/14/2018,0,0,0.78794241
LOXO-TRK-15002-105-003,74,F,White,Y,,3/14/2018,22.99794661,75.6,156,31.06508876,1,Thyroid,IV,Metastatic,1,Complete response,25.62628337,1,Partial response,25.62628337,1,27.63039014,1,3,2,1,2,1,3,65,CYCLE 3 DAY 1,5/9/2018,1.87269,0,0.73119634
LOXO-TRK-15002-105-003,74,F,White,Y,,3/14/2018,22.99794661,75.6,156,31.06508876,1,Thyroid,IV,Metastatic,1,Complete response,25.62628337,1,Partial response,25.62628337,1,27.63039014,1,5,2,1,2,1,1,75,CYCLE 5 DAY 1,7/2/2018,3.6468172,0,0.81006259
LOXO-TRK-15002-105-003,74,F,White,Y,,3/14/2018,22.99794661,75.6,156,31.06508876,1,Thyroid,IV,Metastatic,1,Complete response,25.62628337,1,Partial response,25.62628337,1,27.63039014,1,7,1,1,2,2,3,70,CYCLE 7 DAY 1,8/29/2018,5.5523615,0,0.70648855
LOXO-TRK-15002-105-003,74,F,White,Y,,3/14/2018,22.99794661,75.6,156,31.06508876,1,Thyroid,IV,Metastatic,1,Complete response,25.62628337,1,Partial response,25.62628337,1,27.63039014,1,9,2,2,3,3,3,65,CYCLE 9 DAY 1,10/24/2018,7.3921971,0,0.52732009
LOXO-TRK-15002-105-003,74,F,White,Y,,3/14/2018,22.99794661,75.6,156,31.06508876,1,Thyroid,IV,Metastatic,1,Complete response,25.62628337,1,Partial response,25.62628337,1,27.63039014,1,11,2,1,2,1,3,80,CYCLE 11 DAY 1,12/19/2018,9.2320328,0,0.73119634
LOXO-TRK-15002-105-003,74,F,White,Y,,3/14/2018,22.99794661,75.6,156,31.06508876,1,Thyroid,IV,Metastatic,1,Complete response,25.62628337,1,Partial response,25.62628337,1,27.63039014,1,13,2,1,3,1,3,75,CYCLE 13 DAY 1,2/12/2019,11.039015,0,0.70976758
LOXO-TRK-15002-105-003,74,F,White,Y,,3/14/2018,22.99794661,75.6,156,31.06508876,1,Thyroid,IV,Metastatic,1,Complete response,25.62628337,1,Partial response,25.62628337,1,27.63039014,1,16,2,1,2,1,2,85,CYCLE 16 DAY 1,5/8/2019,13.831622,0,0.76029164
LOXO-TRK-15002-105-003,74,F,White,Y,,3/14/2018,22.99794661,75.6,156,31.06508876,1,Thyroid,IV,Metastatic,1,Complete response,25.62628337,1,Partial response,25.62628337,1,27.63039014,1,19,2,1,2,2,2,75,CYCLE 19 DAY 1,7/31/2019,16.591375,0,0.67442483
LOXO-TRK-15002-105-003,74,F,White,Y,,3/14/2018,22.99794661,75.6,156,31.06508876,1,Thyroid,IV,Metastatic,1,Complete response,25.62628337,1,Partial response,25.62628337,1,27.63039014,1,22,2,1,3,1,3,50,CYCLE 22 DAY 1,10/23/2019,19.35113,0,0.70976758
LOXO-TRK-15002-105-003,74,F,White,Y,,3/14/2018,22.99794661,75.6,156,31.06508876,1,Thyroid,IV,Metastatic,1,Complete response,25.62628337,1,Partial response,25.62628337,1,27.63039014,1,25,3,3,3,1,4,40,CYCLE 25 DAY 1,1/15/2020,22.110884,0,0.43645748
LOXO-TRK-15002-105-004,53,F,White,Y,,6/21/2018,19.31827515,49.8,168,17.64455782,1,Breast,I,Metastatic,3,Partial response,24.64065708,1,Partial response,24.64065708,1,24.87063655,1,0,1,1,1,1,1,80,CYCLE 1 DAY 1,6/21/2018,0,0,0.97571182
LOXO-TRK-15002-105-004,53,F,White,Y,,6/21/2018,19.31827515,49.8,168,17.64455782,1,Breast,I,Metastatic,3,Partial response,24.64065708,1,Partial response,24.64065708,1,24.87063655,1,5,2,1,1,1,1,85,CYCLE 5 DAY 1,10/11/2018,3.7125256,0,0.86967421
LOXO-TRK-15002-105-004,53,F,White,Y,,6/21/2018,19.31827515,49.8,168,17.64455782,1,Breast,I,Metastatic,3,Partial response,24.64065708,1,Partial response,24.64065708,1,24.87063655,1,7,2,1,1,1,1,78,CYCLE 7 DAY 1,12/6/2018,5.5523615,0,0.86967421
LOXO-TRK-15002-105-004,53,F,White,Y,,6/21/2018,19.31827515,49.8,168,17.64455782,1,Breast,I,Metastatic,3,Partial response,24.64065708,1,Partial response,24.64065708,1,24.87063655,1,9,2,1,1,1,1,80,CYCLE 9 DAY 1,1/31/2019,7.3921971,0,0.86967421
LOXO-TRK-15002-105-004,53,F,White,Y,,6/21/2018,19.31827515,49.8,168,17.64455782,1,Breast,I,Metastatic,3,Partial response,24.64065708,1,Partial response,24.64065708,1,24.87063655,1,13,1,1,1,1,2,90,CYCLE 13 DAY 1,5/23/2019,11.071869,0,0.89630741
LOXO-TRK-15002-105-004,53,F,White,Y,,6/21/2018,19.31827515,49.8,168,17.64455782,1,Breast,I,Metastatic,3,Partial response,24.64065708,1,Partial response,24.64065708,1,24.87063655,1,16,1,1,1,1,1,80,CYCLE 16 DAY 1,8/15/2019,13.831622,0,0.97571182
LOXO-TRK-15002-105-004,53,F,White,Y,,6/21/2018,19.31827515,49.8,168,17.64455782,1,Breast,I,Metastatic,3,Partial response,24.64065708,1,Partial response,24.64065708,1,24.87063655,1,19,1,1,1,2,1,87,CYCLE 19 DAY 1,11/7/2019,16.591375,0,0.83110344
LOXO-TRK-15002-105-004,53,F,White,Y,,6/21/2018,19.31827515,49.8,168,17.64455782,1,Breast,I,Metastatic,3,Partial response,24.64065708,1,Partial response,24.64065708,1,24.87063655,1,22,1,1,1,1,1,50,CYCLE 22 DAY 1,1/30/2020,19.35113,0,0.97571182
LOXO-TRK-15002-105-005,63,M,White,Y,,11/13/2018,20.04106776,90.3,166,32.76963275,0,Thyroid,IV,Metastatic,2,Partial response,18.95687885,1,Partial response,18.95687885,1,20.04106776,1,0,1,1,1,1,1,95,CYCLE 1 DAY 1,11/13/2018,0,1,0.97861469
LOXO-TRK-15002-105-005,63,M,White,Y,,11/13/2018,20.04106776,90.3,166,32.76963275,0,Thyroid,IV,Metastatic,2,Partial response,18.95687885,1,Partial response,18.95687885,1,20.04106776,1,3,1,1,1,1,1,85,CYCLE 3 DAY 1,1/8/2019,1.87269,1,0.97861469
LOXO-TRK-15002-105-005,63,M,White,Y,,11/13/2018,20.04106776,90.3,166,32.76963275,0,Thyroid,IV,Metastatic,2,Partial response,18.95687885,1,Partial response,18.95687885,1,20.04106776,1,5,1,1,2,2,2,85,CYCLE 5 DAY 1,3/5/2019,3.7125256,1,0.73034918
LOXO-TRK-15002-105-005,63,M,White,Y,,11/13/2018,20.04106776,90.3,166,32.76963275,0,Thyroid,IV,Metastatic,2,Partial response,18.95687885,1,Partial response,18.95687885,1,20.04106776,1,7,2,1,1,1,1,87,CYCLE 7 DAY 1,4/30/2019,5.5523615,1,0.88055396
LOXO-TRK-15002-105-005,63,M,White,Y,,11/13/2018,20.04106776,90.3,166,32.76963275,0,Thyroid,IV,Metastatic,2,Partial response,18.95687885,1,Partial response,18.95687885,1,20.04106776,1,9,2,1,3,3,2,88,CYCLE 9 DAY 1,6/26/2019,7.4250512,1,0.61300504
LOXO-TRK-15002-105-005,63,M,White,Y,,11/13/2018,20.04106776,90.3,166,32.76963275,0,Thyroid,IV,Metastatic,2,Partial response,18.95687885,1,Partial response,18.95687885,1,20.04106776,1,11,3,1,4,4,4,85,CYCLE 11 DAY 1,8/27/2019,9.4620123,1,0.2459359
LOXO-TRK-15002-105-005,63,M,White,Y,,11/13/2018,20.04106776,90.3,166,32.76963275,0,Thyroid,IV,Metastatic,2,Partial response,18.95687885,1,Partial response,18.95687885,1,20.04106776,1,13,2,2,3,2,3,80,CYCLE 13 DAY 1,10/22/2019,11.301848,1,0.56940484
LOXO-TRK-15002-105-005,63,M,White,Y,,11/13/2018,20.04106776,90.3,166,32.76963275,0,Thyroid,IV,Metastatic,2,Partial response,18.95687885,1,Partial response,18.95687885,1,20.04106776,1,16,2,3,3,3,3,80,CYCLE 16 DAY 1,1/8/2020,13.864476,1,0.50621235
LOXO-TRK-15002-106-001,64,M,Black,Y,Disease Progression,3/21/2016,5.486652977,92.7,188,26.22793119,0,Colon,III,Metastatic,2,Stable disease,5.35523614,0,Partial response,5.35523614,0,7.786447639,1,0,1,1,2,3,2,75,CYCLE 1 DAY 1,3/21/2016,0,1,0.67545879
LOXO-TRK-15002-106-001,64,M,Black,Y,Disease Progression,3/21/2016,5.486652977,92.7,188,26.22793119,0,Colon,III,Metastatic,2,Stable disease,5.35523614,0,Partial response,5.35523614,0,7.786447639,1,2,1,1,2,1,1,95,CYCLE 2 DAY 1,4/18/2016,0.95277208,1,0.88925999
LOXO-TRK-15002-106-001,64,M,Black,Y,Disease Progression,3/21/2016,5.486652977,92.7,188,26.22793119,0,Colon,III,Metastatic,2,Stable disease,5.35523614,0,Partial response,5.35523614,0,7.786447639,1,5,3,1,1,3,1,85,CYCLE 5 DAY 1,7/11/2016,3.7125256,1,0.65247643
LOXO-TRK-15002-106-001,64,M,Black,Y,Disease Progression,3/21/2016,5.486652977,92.7,188,26.22793119,0,Colon,III,Metastatic,2,Stable disease,5.35523614,0,Partial response,5.35523614,0,7.786447639,1,96,3,2,4,5,4,10,END OF TREATMENT,9/7/2016,5.6180696,1,0.025504978
LOXO-TRK-15002-106-002,76,M,Asian,Y,Death,5/2/2018,0.919917865,58.5,178,18.46357783,3,Hepatic,IV,Metastatic,2,Not evaluable,1.117043121,0,Not determined,1.117043121,0,1.117043121,0,0,2,5,5,3,5,70,CYCLE 1 DAY 1,5/2/2018,0,1,-0.12632084
LOXO-TRK-15002-109-001,72,F,White,Y,Disease Progression,5/2/2016,3.679671458,59.8,160,23.359375,1,Melanoma,Not reported,Metastatic,7,Progressive disease,1.872689938,0,Stable disease,3.712525667,0,5.32238193,0,0,2,1,2,2,2,80,CYCLE 1 DAY 1,5/2/2016,0,0,0.67447555
LOXO-TRK-15002-109-001,72,F,White,Y,Disease Progression,5/2/2016,3.679671458,59.8,160,23.359375,1,Melanoma,Not reported,Metastatic,7,Progressive disease,1.872689938,0,Stable disease,3.712525667,0,5.32238193,0,3,2,1,1,2,2,80,CYCLE 3 DAY 1,6/27/2016,1.87269,0,0.72849858
LOXO-TRK-15002-109-001,72,F,White,Y,Disease Progression,5/2/2016,3.679671458,59.8,160,23.359375,1,Melanoma,Not reported,Metastatic,7,Progressive disease,1.872689938,0,Stable disease,3.712525667,0,5.32238193,0,96,2,1,1,2,2,80,END OF TREATMENT,8/22/2016,3.7125256,0,0.72849858
LOXO-TRK-15002-109-002,67,M,Black,Y,Disease Progression,5/22/2017,1.938398357,85.5,174,28.24019025,1,Colon,IV,Metastatic,2,Stable disease,2.759753593,0,Stable disease,2.168377823,0,2.759753593,0,0,1,1,1,3,2,75,CYCLE 1 DAY 1,5/22/2017,0,1,0.72868901
LOXO-TRK-15002-109-002,67,M,Black,Y,Disease Progression,5/22/2017,1.938398357,85.5,174,28.24019025,1,Colon,IV,Metastatic,2,Stable disease,2.759753593,0,Stable disease,2.168377823,0,2.759753593,0,3,1,1,1,2,1,90,CYCLE 3 DAY 1,7/19/2017,1.9383984,1,0.83834821
LOXO-TRK-15002-109-004,41,M,White,Y,Subject Decision,12/15/2017,11.69609856,73.6,178,23.22939023,0,Soft tissue sarcoma,II,Metastatic,2,Progressive disease,0.459958932,0,Partial response,11.07186858,1,23.85215606,0,0,1,1,1,1,1,95,CYCLE 1 DAY 1,12/15/2017,0,1,0.98193014
LOXO-TRK-15002-109-004,41,M,White,Y,Subject Decision,12/15/2017,11.69609856,73.6,178,23.22939023,0,Soft tissue sarcoma,II,Metastatic,2,Progressive disease,0.459958932,0,Partial response,11.07186858,1,23.85215606,0,3,1,1,1,1,1,0,CYCLE 3 DAY 1,2/9/2018,1.87269,1,0.98193014
LOXO-TRK-15002-109-004,41,M,White,Y,Subject Decision,12/15/2017,11.69609856,73.6,178,23.22939023,0,Soft tissue sarcoma,II,Metastatic,2,Progressive disease,0.459958932,0,Partial response,11.07186858,1,23.85215606,0,5,1,1,1,1,1,90,CYCLE 5 DAY 1,4/6/2018,3.7125256,1,0.98193014
LOXO-TRK-15002-109-004,41,M,White,Y,Subject Decision,12/15/2017,11.69609856,73.6,178,23.22939023,0,Soft tissue sarcoma,II,Metastatic,2,Progressive disease,0.459958932,0,Partial response,11.07186858,1,23.85215606,0,7,1,1,1,1,1,90,CYCLE 7 DAY 1,6/5/2018,5.6837783,1,0.98193014
LOXO-TRK-15002-109-004,41,M,White,Y,Subject Decision,12/15/2017,11.69609856,73.6,178,23.22939023,0,Soft tissue sarcoma,II,Metastatic,2,Progressive disease,0.459958932,0,Partial response,11.07186858,1,23.85215606,0,9,1,1,1,2,2,87,CYCLE 9 DAY 1,7/27/2018,7.3921971,1,0.79687768
LOXO-TRK-15002-109-004,41,M,White,Y,Subject Decision,12/15/2017,11.69609856,73.6,178,23.22939023,0,Soft tissue sarcoma,II,Metastatic,2,Progressive disease,0.459958932,0,Partial response,11.07186858,1,23.85215606,0,11,1,1,1,2,2,90,CYCLE 11 DAY 1,9/18/2018,9.1334705,1,0.79687768
LOXO-TRK-15002-109-004,41,M,White,Y,Subject Decision,12/15/2017,11.69609856,73.6,178,23.22939023,0,Soft tissue sarcoma,II,Metastatic,2,Progressive disease,0.459958932,0,Partial response,11.07186858,1,23.85215606,0,13,1,1,1,1,1,90,CYCLE 13 DAY 1,11/16/2018,11.071869,1,0.98193014
LOXO-TRK-15002-109-004,41,M,White,Y,Subject Decision,12/15/2017,11.69609856,73.6,178,23.22939023,0,Soft tissue sarcoma,II,Metastatic,2,Progressive disease,0.459958932,0,Partial response,11.07186858,1,23.85215606,0,96,1,1,1,2,2,87,END OF TREATMENT,12/13/2018,11.958932,1,0.79687768
LOXO-TRK-15002-109-005,41,M,White,Y,Disease Progression,11/9/2018,14.9486653,88.2,187,25.22233979,1,Salivary gland,IV,Metastatic,3,Partial response,9.232032854,0,Partial response,12.22176591,0,19.51540041,1,0,1,1,1,2,1,95,CYCLE 1 DAY 1,11/9/2018,0,1,0.84697938
LOXO-TRK-15002-109-005,41,M,White,Y,Disease Progression,11/9/2018,14.9486653,88.2,187,25.22233979,1,Salivary gland,IV,Metastatic,3,Partial response,9.232032854,0,Partial response,12.22176591,0,19.51540041,1,3,1,1,1,3,1,95,CYCLE 3 DAY 1,1/4/2019,1.87269,1,0.76985663
LOXO-TRK-15002-109-005,41,M,White,Y,Disease Progression,11/9/2018,14.9486653,88.2,187,25.22233979,1,Salivary gland,IV,Metastatic,3,Partial response,9.232032854,0,Partial response,12.22176591,0,19.51540041,1,5,1,1,3,3,1,90,CYCLE 5 DAY 1,3/1/2019,3.7125256,1,0.68800604
LOXO-TRK-15002-109-005,41,M,White,Y,Disease Progression,11/9/2018,14.9486653,88.2,187,25.22233979,1,Salivary gland,IV,Metastatic,3,Partial response,9.232032854,0,Partial response,12.22176591,0,19.51540041,1,7,1,1,1,3,1,96,CYCLE 7 DAY 1,4/26/2019,5.5523615,1,0.76985663
LOXO-TRK-15002-109-005,41,M,White,Y,Disease Progression,11/9/2018,14.9486653,88.2,187,25.22233979,1,Salivary gland,IV,Metastatic,3,Partial response,9.232032854,0,Partial response,12.22176591,0,19.51540041,1,9,1,1,2,3,1,95,CYCLE 9 DAY 1,6/21/2019,7.3921971,1,0.71337825
LOXO-TRK-15002-109-005,41,M,White,Y,Disease Progression,11/9/2018,14.9486653,88.2,187,25.22233979,1,Salivary gland,IV,Metastatic,3,Partial response,9.232032854,0,Partial response,12.22176591,0,19.51540041,1,11,1,1,2,2,1,95,CYCLE 11 DAY 1,8/16/2019,9.2320328,1,0.7845878
LOXO-TRK-15002-109-005,41,M,White,Y,Disease Progression,11/9/2018,14.9486653,88.2,187,25.22233979,1,Salivary gland,IV,Metastatic,3,Partial response,9.232032854,0,Partial response,12.22176591,0,19.51540041,1,13,1,1,1,3,1,95,CYCLE 13 DAY 1,12/13/2019,13.141684,1,0.76985663
LOXO-TRK-15002-109-005,41,M,White,Y,Disease Progression,11/9/2018,14.9486653,88.2,187,25.22233979,1,Salivary gland,IV,Metastatic,3,Partial response,9.232032854,0,Partial response,12.22176591,0,19.51540041,1,15,1,1,1,3,1,95,CYCLE 15 DAY 1,2/7/2020,14.98152,1,0.76985663
LOXO-TRK-15002-113-002,38,M,White,Y,Protocol Deviation,9/20/2016,18.16837782,87.4,178,27.5849009,0,Salivary gland,III,Metastatic,0,Partial response,9.560574949,0,Partial response,9.560574949,0,22.30800821,1,0,2,1,3,3,2,75,CYCLE 1 DAY 1,9/20/2016,0,1,0.61780262
LOXO-TRK-15002-113-002,38,M,White,Y,Protocol Deviation,9/20/2016,18.16837782,87.4,178,27.5849009,0,Salivary gland,III,Metastatic,0,Partial response,9.560574949,0,Partial response,9.560574949,0,22.30800821,1,3,1,1,2,4,2,69,CYCLE 3 DAY 1,11/15/2016,1.87269,1,0.58990425
LOXO-TRK-15002-113-002,38,M,White,Y,Protocol Deviation,9/20/2016,18.16837782,87.4,178,27.5849009,0,Salivary gland,III,Metastatic,0,Partial response,9.560574949,0,Partial response,9.560574949,0,22.30800821,1,5,2,1,2,3,3,50,CYCLE 5 DAY 1,1/10/2017,3.7125256,1,0.61657459
LOXO-TRK-15002-113-002,38,M,White,Y,Protocol Deviation,9/20/2016,18.16837782,87.4,178,27.5849009,0,Salivary gland,III,Metastatic,0,Partial response,9.560574949,0,Partial response,9.560574949,0,22.30800821,1,7,2,1,3,3,2,60,CYCLE 7 DAY 1,3/7/2017,5.5523615,1,0.61780262
LOXO-TRK-15002-113-002,38,M,White,Y,Protocol Deviation,9/20/2016,18.16837782,87.4,178,27.5849009,0,Salivary gland,III,Metastatic,0,Partial response,9.560574949,0,Partial response,9.560574949,0,22.30800821,1,9,3,1,2,4,3,35,CYCLE 9 DAY 1,5/2/2017,7.3921971,1,0.45439219
LOXO-TRK-15002-113-002,38,M,White,Y,Protocol Deviation,9/20/2016,18.16837782,87.4,178,27.5849009,0,Salivary gland,III,Metastatic,0,Partial response,9.560574949,0,Partial response,9.560574949,0,22.30800821,1,11,2,1,2,3,2,89,CYCLE 11 DAY 1,7/7/2017,9.5605745,1,0.63314652
LOXO-TRK-15002-113-002,38,M,White,Y,Protocol Deviation,9/20/2016,18.16837782,87.4,178,27.5849009,0,Salivary gland,III,Metastatic,0,Partial response,9.560574949,0,Partial response,9.560574949,0,22.30800821,1,13,3,1,2,4,2,62,CYCLE 13 DAY 1,8/29/2017,11.301848,1,0.49470493
LOXO-TRK-15002-113-002,38,M,White,Y,Protocol Deviation,9/20/2016,18.16837782,87.4,178,27.5849009,0,Salivary gland,III,Metastatic,0,Partial response,9.560574949,0,Partial response,9.560574949,0,22.30800821,1,16,3,1,2,3,3,43,CYCLE 16 DAY 1,11/21/2017,14.061602,1,0.5778448
LOXO-TRK-15002-113-002,38,M,White,Y,Protocol Deviation,9/20/2016,18.16837782,87.4,178,27.5849009,0,Salivary gland,III,Metastatic,0,Partial response,9.560574949,0,Partial response,9.560574949,0,22.30800821,1,18,2,2,3,3,2,58,CYCLE 18 DAY 1,3/2/2018,17.379877,1,0.54123926
LOXO-TRK-15002-113-003,49,F,White,Y,Death,8/16/2018,2.332648871,52.6,150,23.37777778,1,Thyroid,IV,Metastatic,1,Stable disease,2.595482546,0,Stable disease,2.595482546,0,2.595482546,0,0,1,1,1,2,1,60,CYCLE 1 DAY 1,8/16/2018,0,0,0.8323648
LOXO-TRK-15002-113-003,49,F,White,Y,Death,8/16/2018,2.332648871,52.6,150,23.37777778,1,Thyroid,IV,Metastatic,1,Stable disease,2.595482546,0,Stable disease,2.595482546,0,2.595482546,0,3,1,1,1,2,1,65,CYCLE 3 DAY 1,10/9/2018,1.8069816,0,0.8323648
LOXO-TRK-15002-114-001,24,M,All others,Y,Disease Progression,5/10/2016,0.657084189,56.1,163,21.11483308,2,Soft tissue sarcoma,III,Locally advanced,1,Progressive disease,0.657084189,0,Progressive disease,0.657084189,0,1.18275154,0,0,1,1,1,2,1,50,CYCLE 1 DAY 1,5/10/2016,0,1,0.86498469
LOXO-TRK-15002-114-001,24,M,All others,Y,Disease Progression,5/10/2016,0.657084189,56.1,163,21.11483308,2,Soft tissue sarcoma,III,Locally advanced,1,Progressive disease,0.657084189,0,Progressive disease,0.657084189,0,1.18275154,0,96,1,4,5,2,4,30,END OF TREATMENT,5/31/2016,0.72279263,1,0.32314292
LOXO-TRK-15002-114-002,45,F,Asian,Y,Protocol Deviation,7/22/2016,14.91581109,55.3,.,.,2,Lung,IV,Metastatic,3,Partial response,14.6201232,1,Partial response,14.6201232,1,15.83572895,1,0,1,1,3,1,4,30,CYCLE 1 DAY 1,7/22/2016,0,0,0.66529781
LOXO-TRK-15002-114-002,45,F,Asian,Y,Protocol Deviation,7/22/2016,14.91581109,55.3,.,.,2,Lung,IV,Metastatic,3,Partial response,14.6201232,1,Partial response,14.6201232,1,15.83572895,1,3,1,1,1,1,1,80,CYCLE 3 DAY 1,9/16/2016,1.87269,0,0.97725827
LOXO-TRK-15002-114-002,45,F,Asian,Y,Protocol Deviation,7/22/2016,14.91581109,55.3,.,.,2,Lung,IV,Metastatic,3,Partial response,14.6201232,1,Partial response,14.6201232,1,15.83572895,1,5,1,1,1,1,1,80,CYCLE 5 DAY 1,11/8/2016,3.6139631,0,0.97725827
LOXO-TRK-15002-114-002,45,F,Asian,Y,Protocol Deviation,7/22/2016,14.91581109,55.3,.,.,2,Lung,IV,Metastatic,3,Partial response,14.6201232,1,Partial response,14.6201232,1,15.83572895,1,7,1,1,1,2,1,90,CYCLE 7 DAY 1,1/3/2017,5.4537988,0,0.83402151
LOXO-TRK-15002-114-002,45,F,Asian,Y,Protocol Deviation,7/22/2016,14.91581109,55.3,.,.,2,Lung,IV,Metastatic,3,Partial response,14.6201232,1,Partial response,14.6201232,1,15.83572895,1,9,1,1,1,1,1,80,CYCLE 9 DAY 1,2/28/2017,7.2936344,0,0.97725827
LOXO-TRK-15002-114-002,45,F,Asian,Y,Protocol Deviation,7/22/2016,14.91581109,55.3,.,.,2,Lung,IV,Metastatic,3,Partial response,14.6201232,1,Partial response,14.6201232,1,15.83572895,1,11,1,1,1,2,1,80,CYCLE 11 DAY 1,4/25/2017,9.1334705,0,0.83402151
LOXO-TRK-15002-114-002,45,F,Asian,Y,Protocol Deviation,7/22/2016,14.91581109,55.3,.,.,2,Lung,IV,Metastatic,3,Partial response,14.6201232,1,Partial response,14.6201232,1,15.83572895,1,13,1,1,1,2,1,80,CYCLE 13 DAY 1,6/20/2017,10.973306,0,0.83402151
LOXO-TRK-15002-114-002,45,F,Asian,Y,Protocol Deviation,7/22/2016,14.91581109,55.3,.,.,2,Lung,IV,Metastatic,3,Partial response,14.6201232,1,Partial response,14.6201232,1,15.83572895,1,16,1,1,2,2,3,50,CYCLE 16 DAY 1,9/12/2017,13.73306,0,0.70801651
LOXO-TRK-15002-114-002,45,F,Asian,Y,Protocol Deviation,7/22/2016,14.91581109,55.3,.,.,2,Lung,IV,Metastatic,3,Partial response,14.6201232,1,Partial response,14.6201232,1,15.83572895,1,17,1,1,2,3,3,50,CYCLE 17 DAY 1,10/10/2017,14.652977,0,0.66040629
LOXO-TRK-15002-114-003,25,M,All others,Y,Subject Decision,9/15/2016,43.00616016,79.7,168,28.23837869,0,Soft tissue sarcoma,IV,Metastatic,1,Partial response,40.93634497,1,Partial response,40.93634497,1,43.00616016,1,0,1,1,1,1,1,100,CYCLE 1 DAY 1,9/15/2016,0,1,0.98625875
LOXO-TRK-15002-114-003,25,M,All others,Y,Subject Decision,9/15/2016,43.00616016,79.7,168,28.23837869,0,Soft tissue sarcoma,IV,Metastatic,1,Partial response,40.93634497,1,Partial response,40.93634497,1,43.00616016,1,3,1,1,1,1,1,90,CYCLE 3 DAY 1,11/9/2016,1.8398358,1,0.98625875
LOXO-TRK-15002-114-003,25,M,All others,Y,Subject Decision,9/15/2016,43.00616016,79.7,168,28.23837869,0,Soft tissue sarcoma,IV,Metastatic,1,Partial response,40.93634497,1,Partial response,40.93634497,1,43.00616016,1,5,2,1,1,1,1,90,CYCLE 5 DAY 1,1/4/2017,3.6796715,1,0.88964415
LOXO-TRK-15002-114-003,25,M,All others,Y,Subject Decision,9/15/2016,43.00616016,79.7,168,28.23837869,0,Soft tissue sarcoma,IV,Metastatic,1,Partial response,40.93634497,1,Partial response,40.93634497,1,43.00616016,1,7,2,1,1,1,1,98,CYCLE 7 DAY 1,3/2/2017,5.5523615,1,0.88964415
LOXO-TRK-15002-114-003,25,M,All others,Y,Subject Decision,9/15/2016,43.00616016,79.7,168,28.23837869,0,Soft tissue sarcoma,IV,Metastatic,1,Partial response,40.93634497,1,Partial response,40.93634497,1,43.00616016,1,9,2,1,1,2,1,94,CYCLE 9 DAY 1,4/26/2017,7.3593431,1,0.79148608
LOXO-TRK-15002-114-003,25,M,All others,Y,Subject Decision,9/15/2016,43.00616016,79.7,168,28.23837869,0,Soft tissue sarcoma,IV,Metastatic,1,Partial response,40.93634497,1,Partial response,40.93634497,1,43.00616016,1,11,1,1,1,1,1,98,CYCLE 11 DAY 1,6/19/2017,9.1334705,1,0.98625875
LOXO-TRK-15002-114-003,25,M,All others,Y,Subject Decision,9/15/2016,43.00616016,79.7,168,28.23837869,0,Soft tissue sarcoma,IV,Metastatic,1,Partial response,40.93634497,1,Partial response,40.93634497,1,43.00616016,1,13,2,1,1,1,1,98,CYCLE 13 DAY 1,8/16/2017,11.039015,1,0.88964415
LOXO-TRK-15002-114-003,25,M,All others,Y,Subject Decision,9/15/2016,43.00616016,79.7,168,28.23837869,0,Soft tissue sarcoma,IV,Metastatic,1,Partial response,40.93634497,1,Partial response,40.93634497,1,43.00616016,1,16,2,1,1,1,1,98,CYCLE 16 DAY 1,11/15/2017,14.028748,1,0.88964415
LOXO-TRK-15002-114-003,25,M,All others,Y,Subject Decision,9/15/2016,43.00616016,79.7,168,28.23837869,0,Soft tissue sarcoma,IV,Metastatic,1,Partial response,40.93634497,1,Partial response,40.93634497,1,43.00616016,1,19,2,1,1,1,1,98,CYCLE 19 DAY 1,1/30/2018,16.525667,1,0.88964415
LOXO-TRK-15002-114-003,25,M,All others,Y,Subject Decision,9/15/2016,43.00616016,79.7,168,28.23837869,0,Soft tissue sarcoma,IV,Metastatic,1,Partial response,40.93634497,1,Partial response,40.93634497,1,43.00616016,1,22,2,1,1,1,1,98,CYCLE 22 DAY 1,4/24/2018,19.285421,1,0.88964415
LOXO-TRK-15002-114-003,25,M,All others,Y,Subject Decision,9/15/2016,43.00616016,79.7,168,28.23837869,0,Soft tissue sarcoma,IV,Metastatic,1,Partial response,40.93634497,1,Partial response,40.93634497,1,43.00616016,1,25,2,1,1,1,1,98,CYCLE 25 DAY 1,7/17/2018,22.045174,1,0.88964415
LOXO-TRK-15002-114-003,25,M,All others,Y,Subject Decision,9/15/2016,43.00616016,79.7,168,28.23837869,0,Soft tissue sarcoma,IV,Metastatic,1,Partial response,40.93634497,1,Partial response,40.93634497,1,43.00616016,1,28,2,1,1,2,1,96,CYCLE 28 DAY 1,10/9/2018,24.804928,1,0.79148608
LOXO-TRK-15002-114-003,25,M,All others,Y,Subject Decision,9/15/2016,43.00616016,79.7,168,28.23837869,0,Soft tissue sarcoma,IV,Metastatic,1,Partial response,40.93634497,1,Partial response,40.93634497,1,43.00616016,1,31,2,1,1,1,1,98,CYCLE 31 DAY 1,1/2/2019,27.597536,1,0.88964415
LOXO-TRK-15002-114-003,25,M,All others,Y,Subject Decision,9/15/2016,43.00616016,79.7,168,28.23837869,0,Soft tissue sarcoma,IV,Metastatic,1,Partial response,40.93634497,1,Partial response,40.93634497,1,43.00616016,1,34,2,1,1,1,1,98,CYCLE 34 DAY 1,3/26/2019,30.324436,1,0.88964415
LOXO-TRK-15002-114-003,25,M,All others,Y,Subject Decision,9/15/2016,43.00616016,79.7,168,28.23837869,0,Soft tissue sarcoma,IV,Metastatic,1,Partial response,40.93634497,1,Partial response,40.93634497,1,43.00616016,1,37,2,1,1,1,1,98,CYCLE 37 DAY 1,6/11/2019,32.85421,1,0.88964415
LOXO-TRK-15002-114-003,25,M,All others,Y,Subject Decision,9/15/2016,43.00616016,79.7,168,28.23837869,0,Soft tissue sarcoma,IV,Metastatic,1,Partial response,40.93634497,1,Partial response,40.93634497,1,43.00616016,1,40,2,1,1,1,1,98,CYCLE 40 DAY 1,9/3/2019,35.613964,1,0.88964415
LOXO-TRK-15002-114-003,25,M,All others,Y,Subject Decision,9/15/2016,43.00616016,79.7,168,28.23837869,0,Soft tissue sarcoma,IV,Metastatic,1,Partial response,40.93634497,1,Partial response,40.93634497,1,43.00616016,1,43,2,1,1,1,1,98,CYCLE 43 DAY 1,11/26/2019,38.373718,1,0.88964415
LOXO-TRK-15002-114-003,25,M,All others,Y,Subject Decision,9/15/2016,43.00616016,79.7,168,28.23837869,0,Soft tissue sarcoma,IV,Metastatic,1,Partial response,40.93634497,1,Partial response,40.93634497,1,43.00616016,1,46,2,1,1,1,1,98,CYCLE 46 DAY 1,2/12/2020,40.936344,1,0.88964415
LOXO-TRK-15002-114-004,76,M,White,Y,Disease Progression,10/18/2016,35.35112936,73.3,166,26.60037741,1,Lung,Not reported,Metastatic,3,Non-CR/Non-PD,33.01848049,0,Partial response,35.44969199,0,40.67351129,0,0,2,1,3,1,3,75,CYCLE 1 DAY 1,10/18/2016,0,1,0.72284663
LOXO-TRK-15002-114-004,76,M,White,Y,Disease Progression,10/18/2016,35.35112936,73.3,166,26.60037741,1,Lung,Not reported,Metastatic,3,Non-CR/Non-PD,33.01848049,0,Partial response,35.44969199,0,40.67351129,0,3,2,2,2,1,3,45,CYCLE 3 DAY 1,12/13/2016,1.87269,1,0.65341181
LOXO-TRK-15002-114-004,76,M,White,Y,Disease Progression,10/18/2016,35.35112936,73.3,166,26.60037741,1,Lung,Not reported,Metastatic,3,Non-CR/Non-PD,33.01848049,0,Partial response,35.44969199,0,40.67351129,0,5,2,2,2,1,1,50,CYCLE 5 DAY 1,2/7/2017,3.7125256,1,0.71942729
LOXO-TRK-15002-114-004,76,M,White,Y,Disease Progression,10/18/2016,35.35112936,73.3,166,26.60037741,1,Lung,Not reported,Metastatic,3,Non-CR/Non-PD,33.01848049,0,Partial response,35.44969199,0,40.67351129,0,7,1,2,2,1,2,75,CYCLE 7 DAY 1,4/7/2017,5.6509242,1,0.73704338
LOXO-TRK-15002-114-004,76,M,White,Y,Disease Progression,10/18/2016,35.35112936,73.3,166,26.60037741,1,Lung,Not reported,Metastatic,3,Non-CR/Non-PD,33.01848049,0,Partial response,35.44969199,0,40.67351129,0,9,2,2,2,1,3,70,CYCLE 9 DAY 1,5/30/2017,7.3921971,1,0.65341181
LOXO-TRK-15002-114-004,76,M,White,Y,Disease Progression,10/18/2016,35.35112936,73.3,166,26.60037741,1,Lung,Not reported,Metastatic,3,Non-CR/Non-PD,33.01848049,0,Partial response,35.44969199,0,40.67351129,0,11,2,1,2,1,3,75,CYCLE 11 DAY 1,7/25/2017,9.2320328,1,0.73935425
LOXO-TRK-15002-114-004,76,M,White,Y,Disease Progression,10/18/2016,35.35112936,73.3,166,26.60037741,1,Lung,Not reported,Metastatic,3,Non-CR/Non-PD,33.01848049,0,Partial response,35.44969199,0,40.67351129,0,13,2,1,2,1,1,70,CYCLE 13 DAY 1,9/19/2017,11.071869,1,0.81206411
LOXO-TRK-15002-114-004,76,M,White,Y,Disease Progression,10/18/2016,35.35112936,73.3,166,26.60037741,1,Lung,Not reported,Metastatic,3,Non-CR/Non-PD,33.01848049,0,Partial response,35.44969199,0,40.67351129,0,16,2,1,2,2,2,75,CYCLE 16 DAY 1,12/12/2017,13.831622,1,0.67823446
LOXO-TRK-15002-114-004,76,M,White,Y,Disease Progression,10/18/2016,35.35112936,73.3,166,26.60037741,1,Lung,Not reported,Metastatic,3,Non-CR/Non-PD,33.01848049,0,Partial response,35.44969199,0,40.67351129,0,19,2,2,2,1,2,70,CYCLE 19 DAY 1,3/7/2018,16.624229,1,0.68135858
LOXO-TRK-15002-114-004,76,M,White,Y,Disease Progression,10/18/2016,35.35112936,73.3,166,26.60037741,1,Lung,Not reported,Metastatic,3,Non-CR/Non-PD,33.01848049,0,Partial response,35.44969199,0,40.67351129,0,22,2,1,1,1,1,75,CYCLE 22 DAY 1,5/30/2018,19.383984,1,0.88739568
LOXO-TRK-15002-114-004,76,M,White,Y,Disease Progression,10/18/2016,35.35112936,73.3,166,26.60037741,1,Lung,Not reported,Metastatic,3,Non-CR/Non-PD,33.01848049,0,Partial response,35.44969199,0,40.67351129,0,25,2,2,2,2,3,50,CYCLE 25 DAY 1,8/22/2018,22.143738,1,0.58018762
LOXO-TRK-15002-114-004,76,M,White,Y,Disease Progression,10/18/2016,35.35112936,73.3,166,26.60037741,1,Lung,Not reported,Metastatic,3,Non-CR/Non-PD,33.01848049,0,Partial response,35.44969199,0,40.67351129,0,28,2,1,2,2,2,80,CYCLE 28 DAY 1,11/14/2018,24.90349,1,0.67823446
LOXO-TRK-15002-114-004,76,M,White,Y,Disease Progression,10/18/2016,35.35112936,73.3,166,26.60037741,1,Lung,Not reported,Metastatic,3,Non-CR/Non-PD,33.01848049,0,Partial response,35.44969199,0,40.67351129,0,31,2,1,2,2,2,45,CYCLE 31 DAY 1,2/6/2019,27.663244,1,0.67823446
LOXO-TRK-15002-114-004,76,M,White,Y,Disease Progression,10/18/2016,35.35112936,73.3,166,26.60037741,1,Lung,Not reported,Metastatic,3,Non-CR/Non-PD,33.01848049,0,Partial response,35.44969199,0,40.67351129,0,34,2,1,2,2,2,70,CYCLE 34 DAY 1,5/1/2019,30.422998,1,0.67823446
LOXO-TRK-15002-114-004,76,M,White,Y,Disease Progression,10/18/2016,35.35112936,73.3,166,26.60037741,1,Lung,Not reported,Metastatic,3,Non-CR/Non-PD,33.01848049,0,Partial response,35.44969199,0,40.67351129,0,37,2,1,2,1,2,75,CYCLE 37 DAY 1,7/24/2019,33.182751,1,0.76669103
LOXO-TRK-15002-114-004,76,M,White,Y,Disease Progression,10/18/2016,35.35112936,73.3,166,26.60037741,1,Lung,Not reported,Metastatic,3,Non-CR/Non-PD,33.01848049,0,Partial response,35.44969199,0,40.67351129,0,96,3,3,4,2,4,46,END OF TREATMENT,11/5/2019,36.59959,1,0.38246775
LOXO-TRK-15002-114-005,26,F,White,Y,Physician Decision,6/1/2017,21.15811088,68.1,171,23.2892172,1,Soft tissue sarcoma,I,Metastatic,2,Complete response,20.66529774,1,Complete response,20.66529774,1,36.33675565,1,-1,1,1,1,4,1,45,SCREENING,6/1/2017,0,0,0.75907582
LOXO-TRK-15002-114-005,26,F,White,Y,Physician Decision,6/1/2017,21.15811088,68.1,171,23.2892172,1,Soft tissue sarcoma,I,Metastatic,2,Complete response,20.66529774,1,Complete response,20.66529774,1,36.33675565,1,0,1,1,1,4,1,45,CYCLE 1 DAY 1,6/1/2017,0,0,0.75907582
LOXO-TRK-15002-114-005,26,F,White,Y,Physician Decision,6/1/2017,21.15811088,68.1,171,23.2892172,1,Soft tissue sarcoma,I,Metastatic,2,Complete response,20.66529774,1,Complete response,20.66529774,1,36.33675565,1,3,1,1,1,2,1,85,CYCLE 3 DAY 1,7/24/2017,1.7741274,0,0.84945232
LOXO-TRK-15002-114-005,26,F,White,Y,Physician Decision,6/1/2017,21.15811088,68.1,171,23.2892172,1,Soft tissue sarcoma,I,Metastatic,2,Complete response,20.66529774,1,Complete response,20.66529774,1,36.33675565,1,5,2,1,1,3,1,90,CYCLE 5 DAY 1,9/19/2017,3.6468172,0,0.71624696
LOXO-TRK-15002-114-005,26,F,White,Y,Physician Decision,6/1/2017,21.15811088,68.1,171,23.2892172,1,Soft tissue sarcoma,I,Metastatic,2,Complete response,20.66529774,1,Complete response,20.66529774,1,36.33675565,1,6,4,1,1,2,1,70,CYCLE 6 DAY 1,10/25/2017,4.8295689,0,0.60126871
LOXO-TRK-15002-114-005,26,F,White,Y,Physician Decision,6/1/2017,21.15811088,68.1,171,23.2892172,1,Soft tissue sarcoma,I,Metastatic,2,Complete response,20.66529774,1,Complete response,20.66529774,1,36.33675565,1,7,3,1,1,2,1,90,CYCLE 7 DAY 1,11/20/2017,5.6837783,0,0.72170162
LOXO-TRK-15002-114-005,26,F,White,Y,Physician Decision,6/1/2017,21.15811088,68.1,171,23.2892172,1,Soft tissue sarcoma,I,Metastatic,2,Complete response,20.66529774,1,Complete response,20.66529774,1,36.33675565,1,8,1,1,1,1,1,100,CYCLE 8 DAY 1,12/14/2017,6.4722791,0,0.98298526
LOXO-TRK-15002-114-005,26,F,White,Y,Physician Decision,6/1/2017,21.15811088,68.1,171,23.2892172,1,Soft tissue sarcoma,I,Metastatic,2,Complete response,20.66529774,1,Complete response,20.66529774,1,36.33675565,1,9,2,1,1,3,2,60,CYCLE 9 DAY 1,1/18/2018,7.6221766,0,0.68922442
LOXO-TRK-15002-114-005,26,F,White,Y,Physician Decision,6/1/2017,21.15811088,68.1,171,23.2892172,1,Soft tissue sarcoma,I,Metastatic,2,Complete response,20.66529774,1,Complete response,20.66529774,1,36.33675565,1,10,3,1,1,2,1,90,CYCLE 10 DAY 1,2/22/2018,8.7720737,0,0.72170162
LOXO-TRK-15002-114-005,26,F,White,Y,Physician Decision,6/1/2017,21.15811088,68.1,171,23.2892172,1,Soft tissue sarcoma,I,Metastatic,2,Complete response,20.66529774,1,Complete response,20.66529774,1,36.33675565,1,12,3,1,1,3,1,75,CYCLE 12 DAY 1,4/19/2018,10.61191,0,0.66852856
LOXO-TRK-15002-114-005,26,F,White,Y,Physician Decision,6/1/2017,21.15811088,68.1,171,23.2892172,1,Soft tissue sarcoma,I,Metastatic,2,Complete response,20.66529774,1,Complete response,20.66529774,1,36.33675565,1,14,2,1,1,2,1,95,CYCLE 14 DAY 1,6/14/2018,12.451745,0,0.77921736
LOXO-TRK-15002-114-005,26,F,White,Y,Physician Decision,6/1/2017,21.15811088,68.1,171,23.2892172,1,Soft tissue sarcoma,I,Metastatic,2,Complete response,20.66529774,1,Complete response,20.66529774,1,36.33675565,1,17,3,1,1,3,2,95,CYCLE 17 DAY 1,9/6/2018,15.211499,0,0.64929658
LOXO-TRK-15002-114-005,26,F,White,Y,Physician Decision,6/1/2017,21.15811088,68.1,171,23.2892172,1,Soft tissue sarcoma,I,Metastatic,2,Complete response,20.66529774,1,Complete response,20.66529774,1,36.33675565,1,20,3,1,1,3,1,90,CYCLE 20 DAY 1,12/3/2018,18.102669,0,0.66852856
LOXO-TRK-15002-114-005,26,F,White,Y,Physician Decision,6/1/2017,21.15811088,68.1,171,23.2892172,1,Soft tissue sarcoma,I,Metastatic,2,Complete response,20.66529774,1,Complete response,20.66529774,1,36.33675565,1,96,3,1,1,2,2,95,END OF TREATMENT,3/7/2019,21.190966,0,0.69962025
LOXO-TRK-15002-114-006,60,M,White,Y,Subject Decision,4/9/2018,23.95071869,105.2,177,33.57911201,1,Thyroid,III,Metastatic,0,Partial response,22.11088296,1,Partial response,22.11088296,1,25.13347023,1,-1,2,1,2,3,2,45,SCREENING,3/27/2018,0,1,0.62433475
LOXO-TRK-15002-114-006,60,M,White,Y,Subject Decision,4/9/2018,23.95071869,105.2,177,33.57911201,1,Thyroid,III,Metastatic,0,Partial response,22.11088296,1,Partial response,22.11088296,1,25.13347023,1,0,2,1,2,3,2,45,CYCLE 1 DAY 1,4/9/2018,0,1,0.62433475
LOXO-TRK-15002-114-006,60,M,White,Y,Subject Decision,4/9/2018,23.95071869,105.2,177,33.57911201,1,Thyroid,III,Metastatic,0,Partial response,22.11088296,1,Partial response,22.11088296,1,25.13347023,1,3,1,1,3,2,2,80,CYCLE 3 DAY 1,6/5/2018,1.9055442,1,0.71072054
LOXO-TRK-15002-114-006,60,M,White,Y,Subject Decision,4/9/2018,23.95071869,105.2,177,33.57911201,1,Thyroid,III,Metastatic,0,Partial response,22.11088296,1,Partial response,22.11088296,1,25.13347023,1,5,2,1,2,3,2,65,CYCLE 5 DAY 1,7/31/2018,3.7453799,1,0.62433475
LOXO-TRK-15002-114-006,60,M,White,Y,Subject Decision,4/9/2018,23.95071869,105.2,177,33.57911201,1,Thyroid,III,Metastatic,0,Partial response,22.11088296,1,Partial response,22.11088296,1,25.13347023,1,7,2,1,3,3,2,75,CYCLE 7 DAY 1,9/25/2018,5.5852156,1,0.61334109
LOXO-TRK-15002-114-006,60,M,White,Y,Subject Decision,4/9/2018,23.95071869,105.2,177,33.57911201,1,Thyroid,III,Metastatic,0,Partial response,22.11088296,1,Partial response,22.11088296,1,25.13347023,1,9,1,1,2,2,2,70,CYCLE 9 DAY 1,11/20/2018,7.4250512,1,0.73000634
LOXO-TRK-15002-114-006,60,M,White,Y,Subject Decision,4/9/2018,23.95071869,105.2,177,33.57911201,1,Thyroid,III,Metastatic,0,Partial response,22.11088296,1,Partial response,22.11088296,1,25.13347023,1,11,1,1,2,2,2,70,CYCLE 11 DAY 1,1/15/2019,9.2648869,1,0.73000634
LOXO-TRK-15002-114-006,60,M,White,Y,Subject Decision,4/9/2018,23.95071869,105.2,177,33.57911201,1,Thyroid,III,Metastatic,0,Partial response,22.11088296,1,Partial response,22.11088296,1,25.13347023,1,13,2,2,2,3,2,60,CYCLE 13 DAY 1,3/12/2019,11.104723,1,0.54909569
LOXO-TRK-15002-114-006,60,M,White,Y,Subject Decision,4/9/2018,23.95071869,105.2,177,33.57911201,1,Thyroid,III,Metastatic,0,Partial response,22.11088296,1,Partial response,22.11088296,1,25.13347023,1,16,1,1,2,2,2,75,CYCLE 16 DAY 1,6/4/2019,13.864476,1,0.73000634
LOXO-TRK-15002-114-006,60,M,White,Y,Subject Decision,4/9/2018,23.95071869,105.2,177,33.57911201,1,Thyroid,III,Metastatic,0,Partial response,22.11088296,1,Partial response,22.11088296,1,25.13347023,1,19,1,2,2,2,2,70,CYCLE 19 DAY 1,8/27/2019,16.624229,1,0.64861232
LOXO-TRK-15002-114-006,60,M,White,Y,Subject Decision,4/9/2018,23.95071869,105.2,177,33.57911201,1,Thyroid,III,Metastatic,0,Partial response,22.11088296,1,Partial response,22.11088296,1,25.13347023,1,22,1,1,2,2,2,70,CYCLE 22 DAY 1,11/19/2019,19.383984,1,0.73000634
LOXO-TRK-15002-114-006,60,M,White,Y,Subject Decision,4/9/2018,23.95071869,105.2,177,33.57911201,1,Thyroid,III,Metastatic,0,Partial response,22.11088296,1,Partial response,22.11088296,1,25.13347023,1,25,1,1,1,2,1,85,CYCLE 25 DAY 1,2/11/2020,22.143738,1,0.83908522
LOXO-TRK-15002-116-001,66,M,White,Y,,7/26/2018,23.03080082,83.6,182,25.23849777,1,Lung,IV,Metastatic,1,Complete response,22.93223819,1,Stable disease,22.93223819,1,23.03080082,1,0,1,1,1,1,1,80,CYCLE 1 DAY 1,7/26/2018,0,1,0.97841382
LOXO-TRK-15002-116-001,66,M,White,Y,,7/26/2018,23.03080082,83.6,182,25.23849777,1,Lung,IV,Metastatic,1,Complete response,22.93223819,1,Stable disease,22.93223819,1,23.03080082,1,3,1,1,1,1,1,75,CYCLE 3 DAY 1,9/20/2018,1.87269,1,0.97841382
LOXO-TRK-15002-116-001,66,M,White,Y,,7/26/2018,23.03080082,83.6,182,25.23849777,1,Lung,IV,Metastatic,1,Complete response,22.93223819,1,Stable disease,22.93223819,1,23.03080082,1,5,1,1,2,2,2,75,CYCLE 5 DAY 1,11/15/2018,3.7125256,1,0.73062217
LOXO-TRK-15002-116-001,66,M,White,Y,,7/26/2018,23.03080082,83.6,182,25.23849777,1,Lung,IV,Metastatic,1,Complete response,22.93223819,1,Stable disease,22.93223819,1,23.03080082,1,7,1,1,2,1,2,75,CYCLE 7 DAY 1,1/10/2019,5.5523615,1,0.82231855
LOXO-TRK-15002-116-001,66,M,White,Y,,7/26/2018,23.03080082,83.6,182,25.23849777,1,Lung,IV,Metastatic,1,Complete response,22.93223819,1,Stable disease,22.93223819,1,23.03080082,1,9,2,1,1,2,1,80,CYCLE 9 DAY 1,3/7/2019,7.3921971,1,0.77039218
LOXO-TRK-15002-116-001,66,M,White,Y,,7/26/2018,23.03080082,83.6,182,25.23849777,1,Lung,IV,Metastatic,1,Complete response,22.93223819,1,Stable disease,22.93223819,1,23.03080082,1,13,2,1,1,1,1,88,CYCLE 13 DAY 1,6/27/2019,11.071869,1,0.8816269
LOXO-TRK-15002-116-001,66,M,White,Y,,7/26/2018,23.03080082,83.6,182,25.23849777,1,Lung,IV,Metastatic,1,Complete response,22.93223819,1,Stable disease,22.93223819,1,23.03080082,1,16,1,1,1,1,1,85,CYCLE 16 DAY 1,9/19/2019,13.831622,1,0.97841382
LOXO-TRK-15002-116-001,66,M,White,Y,,7/26/2018,23.03080082,83.6,182,25.23849777,1,Lung,IV,Metastatic,1,Complete response,22.93223819,1,Stable disease,22.93223819,1,23.03080082,1,19,1,1,1,1,1,90,CYCLE 19 DAY 1,12/12/2019,16.591375,1,0.97841382
LOXO-TRK-15002-116-001,66,M,White,Y,,7/26/2018,23.03080082,83.6,182,25.23849777,1,Lung,IV,Metastatic,1,Complete response,22.93223819,1,Stable disease,22.93223819,1,23.03080082,1,22,1,1,1,1,1,95,CYCLE 22 DAY 1,3/5/2020,19.35113,1,0.97841382
LOXO-TRK-15002-116-001,66,M,White,Y,,7/26/2018,23.03080082,83.6,182,25.23849777,1,Lung,IV,Metastatic,1,Complete response,22.93223819,1,Stable disease,22.93223819,1,23.03080082,1,26,1,1,2,1,1,95,CYCLE 26 DAY 1,6/25/2020,23.030802,1,0.88827306
LOXO-TRK-15002-117-001,75,M,White,Y,,11/22/2016,43.33470226,121.4,183,36.25070919,0,Thyroid,IV,Metastatic,3,Partial response,42.41478439,1,Partial response,42.41478439,1,43.33470226,1,0,1,1,1,1,1,85,CYCLE 1 DAY 1,11/22/2016,0,1,0.97842181
LOXO-TRK-15002-117-001,75,M,White,Y,,11/22/2016,43.33470226,121.4,183,36.25070919,0,Thyroid,IV,Metastatic,3,Partial response,42.41478439,1,Partial response,42.41478439,1,43.33470226,1,3,1,1,2,1,1,80,CYCLE 3 DAY 1,1/17/2017,1.87269,1,0.8858375
LOXO-TRK-15002-117-001,75,M,White,Y,,11/22/2016,43.33470226,121.4,183,36.25070919,0,Thyroid,IV,Metastatic,3,Partial response,42.41478439,1,Partial response,42.41478439,1,43.33470226,1,5,1,1,1,1,1,88,CYCLE 5 DAY 1,3/14/2017,3.7125256,1,0.97842181
LOXO-TRK-15002-117-001,75,M,White,Y,,11/22/2016,43.33470226,121.4,183,36.25070919,0,Thyroid,IV,Metastatic,3,Partial response,42.41478439,1,Partial response,42.41478439,1,43.33470226,1,6,1,2,4,1,4,80,CYCLE 6 DAY 1,4/11/2017,4.6324434,1,0.55565423
LOXO-TRK-15002-117-001,75,M,White,Y,,11/22/2016,43.33470226,121.4,183,36.25070919,0,Thyroid,IV,Metastatic,3,Partial response,42.41478439,1,Partial response,42.41478439,1,43.33470226,1,9,2,5,5,3,5,65,CYCLE 9 DAY 1,7/5/2017,7.4250512,1,-0.12652934
LOXO-TRK-15002-117-001,75,M,White,Y,,11/22/2016,43.33470226,121.4,183,36.25070919,0,Thyroid,IV,Metastatic,3,Partial response,42.41478439,1,Partial response,42.41478439,1,43.33470226,1,11,2,4,5,1,5,50,CYCLE 11 DAY 1,8/29/2017,9.2320328,1,0.005470551
LOXO-TRK-15002-117-001,75,M,White,Y,,11/22/2016,43.33470226,121.4,183,36.25070919,0,Thyroid,IV,Metastatic,3,Partial response,42.41478439,1,Partial response,42.41478439,1,43.33470226,1,13,3,4,5,1,5,80,CYCLE 13 DAY 1,10/24/2017,11.071869,1,-0.025428312
LOXO-TRK-15002-117-001,75,M,White,Y,,11/22/2016,43.33470226,121.4,183,36.25070919,0,Thyroid,IV,Metastatic,3,Partial response,42.41478439,1,Partial response,42.41478439,1,43.33470226,1,16,2,4,5,2,5,80,CYCLE 16 DAY 1,1/16/2018,13.831622,1,-0.00545596
LOXO-TRK-15002-117-001,75,M,White,Y,,11/22/2016,43.33470226,121.4,183,36.25070919,0,Thyroid,IV,Metastatic,3,Partial response,42.41478439,1,Partial response,42.41478439,1,43.33470226,1,19,3,4,5,,5,40,CYCLE 19 DAY 1,4/10/2018,16.591375,1,
LOXO-TRK-15002-117-001,75,M,White,Y,,11/22/2016,43.33470226,121.4,183,36.25070919,0,Thyroid,IV,Metastatic,3,Partial response,42.41478439,1,Partial response,42.41478439,1,43.33470226,1,22,3,4,5,,4,70,CYCLE 22 DAY 1,7/3/2018,19.35113,1,
LOXO-TRK-15002-117-001,75,M,White,Y,,11/22/2016,43.33470226,121.4,183,36.25070919,0,Thyroid,IV,Metastatic,3,Partial response,42.41478439,1,Partial response,42.41478439,1,43.33470226,1,25,2,5,5,2,5,75,CYCLE 25 DAY 1,9/25/2018,22.110884,1,-0.1005785
LOXO-TRK-15002-117-001,75,M,White,Y,,11/22/2016,43.33470226,121.4,183,36.25070919,0,Thyroid,IV,Metastatic,3,Partial response,42.41478439,1,Partial response,42.41478439,1,43.33470226,1,28,2,5,5,1,2,65,CYCLE 28 DAY 1,12/18/2018,24.870636,1,-0.007743431
LOXO-TRK-15002-117-001,75,M,White,Y,,11/22/2016,43.33470226,121.4,183,36.25070919,0,Thyroid,IV,Metastatic,3,Partial response,42.41478439,1,Partial response,42.41478439,1,43.33470226,1,31,2,5,5,1,5,80,CYCLE 31 DAY 1,3/12/2019,27.63039,1,-0.0907351
LOXO-TRK-15002-117-001,75,M,White,Y,,11/22/2016,43.33470226,121.4,183,36.25070919,0,Thyroid,IV,Metastatic,3,Partial response,42.41478439,1,Partial response,42.41478439,1,43.33470226,1,34,2,5,5,,5,70,CYCLE 34 DAY 1,6/5/2019,30.422998,1,
LOXO-TRK-15002-117-001,75,M,White,Y,,11/22/2016,43.33470226,121.4,183,36.25070919,0,Thyroid,IV,Metastatic,3,Partial response,42.41478439,1,Partial response,42.41478439,1,43.33470226,1,37,2,5,5,2,5,50,CYCLE 37 DAY 1,8/28/2019,33.182751,1,-0.1005785
LOXO-TRK-15002-117-001,75,M,White,Y,,11/22/2016,43.33470226,121.4,183,36.25070919,0,Thyroid,IV,Metastatic,3,Partial response,42.41478439,1,Partial response,42.41478439,1,43.33470226,1,40,2,5,5,2,5,80,CYCLE 40 DAY 1,12/19/2019,36.895279,1,-0.1005785
LOXO-TRK-15002-117-001,75,M,White,Y,,11/22/2016,43.33470226,121.4,183,36.25070919,0,Thyroid,IV,Metastatic,3,Partial response,42.41478439,1,Partial response,42.41478439,1,43.33470226,1,43,3,5,5,2,4,45,CYCLE 43 DAY 1,3/12/2020,39.655029,1,-0.078606784
LOXO-TRK-15002-117-001,75,M,White,Y,,11/22/2016,43.33470226,121.4,183,36.25070919,0,Thyroid,IV,Metastatic,3,Partial response,42.41478439,1,Partial response,42.41478439,1,43.33470226,1,46,3,5,5,3,5,45,CYCLE 46 DAY 1,6/4/2020,42.414783,1,-0.15231258
LOXO-TRK-15002-122-001,65,F,White,Y,Disease Progression,9/21/2016,2.234086242,86.2,170,29.82698962,1,Salivary gland,Not reported,Metastatic,0,Progressive disease,2.069815195,0,Progressive disease,2.069815195,0,4.073921971,0,0,3,4,4,3,4,50,CYCLE 1 DAY 1,9/21/2016,0,0,0.26567495
LOXO-TRK-15002-123-001,56,M,White,Y,Disease Progression,5/22/2017,5.749486653,110,178,34.71783866,1,Bone sarcoma,Not reported,Locally advanced,0,Stable disease,3.712525667,0,Stable disease,5.650924025,0,35.97535934,1,0,1,3,3,3,3,60,CYCLE 1 DAY 1,5/22/2017,0,1,0.55179381
LOXO-TRK-15002-123-001,56,M,White,Y,Disease Progression,5/22/2017,5.749486653,110,178,34.71783866,1,Bone sarcoma,Not reported,Locally advanced,0,Stable disease,3.712525667,0,Stable disease,5.650924025,0,35.97535934,1,3,1,2,3,4,3,40,CYCLE 3 DAY 1,7/24/2017,2.1026695,1,0.41451475
LOXO-TRK-15002-123-001,56,M,White,Y,Disease Progression,5/22/2017,5.749486653,110,178,34.71783866,1,Bone sarcoma,Not reported,Locally advanced,0,Stable disease,3.712525667,0,Stable disease,5.650924025,0,35.97535934,1,5,2,2,3,4,3,25,CYCLE 5 DAY 1,9/18/2017,3.9425051,1,0.36715814
LOXO-TRK-15002-123-001,56,M,White,Y,Disease Progression,5/22/2017,5.749486653,110,178,34.71783866,1,Bone sarcoma,Not reported,Locally advanced,0,Stable disease,3.712525667,0,Stable disease,5.650924025,0,35.97535934,1,96,2,3,3,4,3,20,END OF TREATMENT,11/13/2017,5.782341,1,0.32649481
LOXO-TRK-15002-123-002,59,M,Black,Y,,11/21/2017,31.3100616,85.3,172,28.83315306,1,Salivary gland,Not reported,Metastatic,1,Partial response,30.2587269,1,Partial response,30.2587269,1,31.3100616,1,0,1,1,1,3,2,80,CYCLE 1 DAY 1,11/21/2017,0,1,0.73023117
LOXO-TRK-15002-123-002,59,M,Black,Y,,11/21/2017,31.3100616,85.3,172,28.83315306,1,Salivary gland,Not reported,Metastatic,1,Partial response,30.2587269,1,Partial response,30.2587269,1,31.3100616,1,3,1,1,1,3,1,75,CYCLE 3 DAY 1,1/16/2018,1.87269,1,0.7651031
LOXO-TRK-15002-123-002,59,M,Black,Y,,11/21/2017,31.3100616,85.3,172,28.83315306,1,Salivary gland,Not reported,Metastatic,1,Partial response,30.2587269,1,Partial response,30.2587269,1,31.3100616,1,5,1,1,2,3,1,80,CYCLE 5 DAY 1,3/13/2018,3.7125256,1,0.70822656
LOXO-TRK-15002-123-002,59,M,Black,Y,,11/21/2017,31.3100616,85.3,172,28.83315306,1,Salivary gland,Not reported,Metastatic,1,Partial response,30.2587269,1,Partial response,30.2587269,1,31.3100616,1,7,1,1,1,1,2,90,CYCLE 7 DAY 1,5/8/2018,5.5523615,1,0.90280938
LOXO-TRK-15002-123-002,59,M,Black,Y,,11/21/2017,31.3100616,85.3,172,28.83315306,1,Salivary gland,Not reported,Metastatic,1,Partial response,30.2587269,1,Partial response,30.2587269,1,31.3100616,1,8,1,1,1,1,2,85,CYCLE 8 DAY 1,6/1/2018,6.3408623,1,0.90280938
LOXO-TRK-15002-123-002,59,M,Black,Y,,11/21/2017,31.3100616,85.3,172,28.83315306,1,Salivary gland,Not reported,Metastatic,1,Partial response,30.2587269,1,Partial response,30.2587269,1,31.3100616,1,9,1,1,1,1,2,85,CYCLE 9 DAY 1,7/3/2018,7.3921971,1,0.90280938
LOXO-TRK-15002-123-002,59,M,Black,Y,,11/21/2017,31.3100616,85.3,172,28.83315306,1,Salivary gland,Not reported,Metastatic,1,Partial response,30.2587269,1,Partial response,30.2587269,1,31.3100616,1,11,1,1,1,2,2,80,CYCLE 11 DAY 1,8/28/2018,9.2320328,1,0.79138309
LOXO-TRK-15002-123-002,59,M,Black,Y,,11/21/2017,31.3100616,85.3,172,28.83315306,1,Salivary gland,Not reported,Metastatic,1,Partial response,30.2587269,1,Partial response,30.2587269,1,31.3100616,1,13,1,1,1,2,2,80,CYCLE 13 DAY 1,10/26/2018,11.170431,1,0.79138309
LOXO-TRK-15002-123-002,59,M,Black,Y,,11/21/2017,31.3100616,85.3,172,28.83315306,1,Salivary gland,Not reported,Metastatic,1,Partial response,30.2587269,1,Partial response,30.2587269,1,31.3100616,1,16,1,1,1,1,2,88,CYCLE 16 DAY 1,1/15/2019,13.831622,1,0.90280938
LOXO-TRK-15002-123-002,59,M,Black,Y,,11/21/2017,31.3100616,85.3,172,28.83315306,1,Salivary gland,Not reported,Metastatic,1,Partial response,30.2587269,1,Partial response,30.2587269,1,31.3100616,1,19,1,1,2,2,2,80,CYCLE 19 DAY 1,4/11/2019,16.657084,1,0.72996378
LOXO-TRK-15002-123-002,59,M,Black,Y,,11/21/2017,31.3100616,85.3,172,28.83315306,1,Salivary gland,Not reported,Metastatic,1,Partial response,30.2587269,1,Partial response,30.2587269,1,31.3100616,1,20,1,1,1,2,2,85,CYCLE 20 DAY 1,5/7/2019,17.511293,1,0.79138309
LOXO-TRK-15002-123-002,59,M,Black,Y,,11/21/2017,31.3100616,85.3,172,28.83315306,1,Salivary gland,Not reported,Metastatic,1,Partial response,30.2587269,1,Partial response,30.2587269,1,31.3100616,1,22,1,1,1,1,2,90,CYCLE 22 DAY 1,7/2/2019,19.35113,1,0.90280938
LOXO-TRK-15002-123-002,59,M,Black,Y,,11/21/2017,31.3100616,85.3,172,28.83315306,1,Salivary gland,Not reported,Metastatic,1,Partial response,30.2587269,1,Partial response,30.2587269,1,31.3100616,1,25,1,1,1,1,2,90,CYCLE 25 DAY 1,9/24/2019,22.110884,1,0.90280938
LOXO-TRK-15002-123-002,59,M,Black,Y,,11/21/2017,31.3100616,85.3,172,28.83315306,1,Salivary gland,Not reported,Metastatic,1,Partial response,30.2587269,1,Partial response,30.2587269,1,31.3100616,1,28,1,1,1,1,1,90,CYCLE 28 DAY 1,12/17/2019,24.870636,1,0.97899485
LOXO-TRK-15002-123-002,59,M,Black,Y,,11/21/2017,31.3100616,85.3,172,28.83315306,1,Salivary gland,Not reported,Metastatic,1,Partial response,30.2587269,1,Partial response,30.2587269,1,31.3100616,1,31,1,1,1,1,2,90,CYCLE 31 DAY 1,3/10/2020,27.63039,1,0.90280938
LOXO-TRK-15002-123-002,59,M,Black,Y,,11/21/2017,31.3100616,85.3,172,28.83315306,1,Salivary gland,Not reported,Metastatic,1,Partial response,30.2587269,1,Partial response,30.2587269,1,31.3100616,1,34,1,1,1,1,2,90,CYCLE 34 DAY 1,6/2/2020,30.390144,1,0.90280938
LOXO-TRK-15002-124-002,63,F,White,Y,Disease Progression,1/12/2017,25.00205339,57.2,.,.,1,Thyroid,Not reported,Metastatic,3,Partial response,16.55852156,0,Partial response,16.55852156,0,27.79466119,0,0,2,1,2,1,2,85,CYCLE 1 DAY 1,1/12/2017,0,0,0.75904346
LOXO-TRK-15002-124-002,63,F,White,Y,Disease Progression,1/12/2017,25.00205339,57.2,.,.,1,Thyroid,Not reported,Metastatic,3,Partial response,16.55852156,0,Partial response,16.55852156,0,27.79466119,0,2,2,1,1,2,2,90,CYCLE 2 DAY 1,2/9/2017,0.95277208,0,0.72869778
LOXO-TRK-15002-124-002,63,F,White,Y,Disease Progression,1/12/2017,25.00205339,57.2,.,.,1,Thyroid,Not reported,Metastatic,3,Partial response,16.55852156,0,Partial response,16.55852156,0,27.79466119,0,3,2,1,2,2,1,95,CYCLE 3 DAY 1,3/8/2017,1.8398358,0,0.71085954
LOXO-TRK-15002-124-002,63,F,White,Y,Disease Progression,1/12/2017,25.00205339,57.2,.,.,1,Thyroid,Not reported,Metastatic,3,Partial response,16.55852156,0,Partial response,16.55852156,0,27.79466119,0,5,1,1,1,1,1,97,CYCLE 5 DAY 1,5/4/2017,3.7125256,0,0.97467208
LOXO-TRK-15002-124-002,63,F,White,Y,Disease Progression,1/12/2017,25.00205339,57.2,.,.,1,Thyroid,Not reported,Metastatic,3,Partial response,16.55852156,0,Partial response,16.55852156,0,27.79466119,0,7,1,1,1,1,2,98,CYCLE 7 DAY 1,6/29/2017,5.5523615,0,0.89573061
LOXO-TRK-15002-124-002,63,F,White,Y,Disease Progression,1/12/2017,25.00205339,57.2,.,.,1,Thyroid,Not reported,Metastatic,3,Partial response,16.55852156,0,Partial response,16.55852156,0,27.79466119,0,9,1,1,1,2,1,97,CYCLE 9 DAY 1,8/24/2017,7.3921971,0,0.82914978
LOXO-TRK-15002-124-002,63,F,White,Y,Disease Progression,1/12/2017,25.00205339,57.2,.,.,1,Thyroid,Not reported,Metastatic,3,Partial response,16.55852156,0,Partial response,16.55852156,0,27.79466119,0,11,1,1,1,1,1,98,CYCLE 11 DAY 1,10/23/2017,9.3634501,0,0.97467208
LOXO-TRK-15002-124-002,63,F,White,Y,Disease Progression,1/12/2017,25.00205339,57.2,.,.,1,Thyroid,Not reported,Metastatic,3,Partial response,16.55852156,0,Partial response,16.55852156,0,27.79466119,0,13,1,1,1,1,1,98,CYCLE 13 DAY 1,12/14/2017,11.071869,0,0.97467208
LOXO-TRK-15002-124-002,63,F,White,Y,Disease Progression,1/12/2017,25.00205339,57.2,.,.,1,Thyroid,Not reported,Metastatic,3,Partial response,16.55852156,0,Partial response,16.55852156,0,27.79466119,0,16,1,1,1,1,1,100,CYCLE 16 DAY 1,3/13/2018,13.995893,0,0.97467208
LOXO-TRK-15002-124-002,63,F,White,Y,Disease Progression,1/12/2017,25.00205339,57.2,.,.,1,Thyroid,Not reported,Metastatic,3,Partial response,16.55852156,0,Partial response,16.55852156,0,27.79466119,0,19,1,1,1,2,1,100,CYCLE 19 DAY 1,5/31/2018,16.591375,0,0.82914978
LOXO-TRK-15002-124-002,63,F,White,Y,Disease Progression,1/12/2017,25.00205339,57.2,.,.,1,Thyroid,Not reported,Metastatic,3,Partial response,16.55852156,0,Partial response,16.55852156,0,27.79466119,0,22,1,1,1,1,1,100,CYCLE 22 DAY 1,8/23/2018,19.35113,0,0.97467208
LOXO-TRK-15002-124-002,63,F,White,Y,Disease Progression,1/12/2017,25.00205339,57.2,.,.,1,Thyroid,Not reported,Metastatic,3,Partial response,16.55852156,0,Partial response,16.55852156,0,27.79466119,0,25,1,1,1,2,1,98,CYCLE 25 DAY 1,11/15/2018,22.110884,0,0.82914978
LOXO-TRK-15002-124-002,63,F,White,Y,Disease Progression,1/12/2017,25.00205339,57.2,.,.,1,Thyroid,Not reported,Metastatic,3,Partial response,16.55852156,0,Partial response,16.55852156,0,27.79466119,0,96,1,1,1,2,1,98,END OF TREATMENT,2/12/2019,25.034908,0,0.82914978
LOXO-TRK-15002-125-002,37,M,Black,Y,Physician Decision,3/21/2018,18.72689938,58.5,168,20.72704082,1,Salivary gland,Not reported,Locally advanced,1,Non-CR/Non-PD,18.36550308,1,Partial response,18.36550308,1,24.57494867,1,2,1,1,1,3,3,75,CYCLE 2 DAY 1,4/17/2018,0.91991788,1,0.71424007
LOXO-TRK-15002-125-002,37,M,Black,Y,Physician Decision,3/21/2018,18.72689938,58.5,168,20.72704082,1,Salivary gland,Not reported,Locally advanced,1,Non-CR/Non-PD,18.36550308,1,Partial response,18.36550308,1,24.57494867,1,3,1,1,1,3,2,75,CYCLE 3 DAY 1,5/15/2018,1.8398358,1,0.73472571
LOXO-TRK-15002-125-002,37,M,Black,Y,Physician Decision,3/21/2018,18.72689938,58.5,168,20.72704082,1,Salivary gland,Not reported,Locally advanced,1,Non-CR/Non-PD,18.36550308,1,Partial response,18.36550308,1,24.57494867,1,4,1,2,1,3,2,75,CYCLE 4 DAY 1,6/12/2018,2.7597537,1,0.66372246
LOXO-TRK-15002-125-002,37,M,Black,Y,Physician Decision,3/21/2018,18.72689938,58.5,168,20.72704082,1,Salivary gland,Not reported,Locally advanced,1,Non-CR/Non-PD,18.36550308,1,Partial response,18.36550308,1,24.57494867,1,5,1,1,1,2,3,87,CYCLE 5 DAY 1,7/10/2018,3.6796715,1,0.76919103
LOXO-TRK-15002-125-002,37,M,Black,Y,Physician Decision,3/21/2018,18.72689938,58.5,168,20.72704082,1,Salivary gland,Not reported,Locally advanced,1,Non-CR/Non-PD,18.36550308,1,Partial response,18.36550308,1,24.57494867,1,7,1,1,2,2,2,88,CYCLE 7 DAY 1,9/4/2018,5.5195074,1,0.73809445
LOXO-TRK-15002-125-002,37,M,Black,Y,Physician Decision,3/21/2018,18.72689938,58.5,168,20.72704082,1,Salivary gland,Not reported,Locally advanced,1,Non-CR/Non-PD,18.36550308,1,Partial response,18.36550308,1,24.57494867,1,9,1,1,2,2,3,93,CYCLE 9 DAY 1,10/30/2018,7.3593431,1,0.7103675
LOXO-TRK-15002-125-002,37,M,Black,Y,Physician Decision,3/21/2018,18.72689938,58.5,168,20.72704082,1,Salivary gland,Not reported,Locally advanced,1,Non-CR/Non-PD,18.36550308,1,Partial response,18.36550308,1,24.57494867,1,11,1,1,1,3,3,86,CYCLE 11 DAY 1,12/28/2018,9.2977409,1,0.71424007
LOXO-TRK-15002-125-002,37,M,Black,Y,Physician Decision,3/21/2018,18.72689938,58.5,168,20.72704082,1,Salivary gland,Not reported,Locally advanced,1,Non-CR/Non-PD,18.36550308,1,Partial response,18.36550308,1,24.57494867,1,13,1,1,2,1,3,97,CYCLE 13 DAY 1,2/19/2019,11.039015,1,0.78690004
LOXO-TRK-15002-125-002,37,M,Black,Y,Physician Decision,3/21/2018,18.72689938,58.5,168,20.72704082,1,Salivary gland,Not reported,Locally advanced,1,Non-CR/Non-PD,18.36550308,1,Partial response,18.36550308,1,24.57494867,1,16,1,1,1,1,2,97,CYCLE 16 DAY 1,5/14/2019,13.798768,1,0.91008353
LOXO-TRK-15002-125-002,37,M,Black,Y,Physician Decision,3/21/2018,18.72689938,58.5,168,20.72704082,1,Salivary gland,Not reported,Locally advanced,1,Non-CR/Non-PD,18.36550308,1,Partial response,18.36550308,1,24.57494867,1,19,1,1,1,3,2,75,CYCLE 19 DAY 1,8/6/2019,16.558521,1,0.73472571
LOXO-TRK-15002-125-002,37,M,Black,Y,Physician Decision,3/21/2018,18.72689938,58.5,168,20.72704082,1,Salivary gland,Not reported,Locally advanced,1,Non-CR/Non-PD,18.36550308,1,Partial response,18.36550308,1,24.57494867,1,21,1,1,1,3,2,70,CYCLE 21 DAY 1,10/1/2019,18.398357,1,0.73472571
LOXO-TRK-15002-130-001,62,F,All others,Y,Disease Progression,1/27/2017,37.02669405,67.5,162,25.72016461,0,Salivary gland,II,Metastatic,1,Partial response,34.26694045,0,Partial response,25.65913758,0,41.36344969,1,0,1,1,1,1,1,80,CYCLE 1 DAY 1,1/27/2017,0,0,0.97471046
LOXO-TRK-15002-130-001,62,F,All others,Y,Disease Progression,1/27/2017,37.02669405,67.5,162,25.72016461,0,Salivary gland,II,Metastatic,1,Partial response,34.26694045,0,Partial response,25.65913758,0,41.36344969,1,2,1,1,1,1,1,95,CYCLE 2 DAY 1,2/24/2017,0.95277208,0,0.97471046
LOXO-TRK-15002-130-001,62,F,All others,Y,Disease Progression,1/27/2017,37.02669405,67.5,162,25.72016461,0,Salivary gland,II,Metastatic,1,Partial response,34.26694045,0,Partial response,25.65913758,0,41.36344969,1,3,1,1,1,1,1,90,CYCLE 3 DAY 1,4/11/2017,2.4640658,0,0.97471046
LOXO-TRK-15002-130-001,62,F,All others,Y,Disease Progression,1/27/2017,37.02669405,67.5,162,25.72016461,0,Salivary gland,II,Metastatic,1,Partial response,34.26694045,0,Partial response,25.65913758,0,41.36344969,1,5,1,1,1,1,1,95,CYCLE 5 DAY 1,6/8/2017,4.3696098,0,0.97471046
LOXO-TRK-15002-130-001,62,F,All others,Y,Disease Progression,1/27/2017,37.02669405,67.5,162,25.72016461,0,Salivary gland,II,Metastatic,1,Partial response,34.26694045,0,Partial response,25.65913758,0,41.36344969,1,7,1,1,1,1,1,95,CYCLE 7 DAY 1,8/4/2017,6.2422996,0,0.97471046
LOXO-TRK-15002-130-001,62,F,All others,Y,Disease Progression,1/27/2017,37.02669405,67.5,162,25.72016461,0,Salivary gland,II,Metastatic,1,Partial response,34.26694045,0,Partial response,25.65913758,0,41.36344969,1,9,1,1,1,1,1,95,CYCLE 9 DAY 1,9/29/2017,8.0821352,0,0.97471046
LOXO-TRK-15002-130-001,62,F,All others,Y,Disease Progression,1/27/2017,37.02669405,67.5,162,25.72016461,0,Salivary gland,II,Metastatic,1,Partial response,34.26694045,0,Partial response,25.65913758,0,41.36344969,1,16,1,1,1,1,1,70,CYCLE 16 DAY 1,4/20/2018,14.75154,0,0.97471046
LOXO-TRK-15002-130-001,62,F,All others,Y,Disease Progression,1/27/2017,37.02669405,67.5,162,25.72016461,0,Salivary gland,II,Metastatic,1,Partial response,34.26694045,0,Partial response,25.65913758,0,41.36344969,1,19,1,1,1,1,1,95,CYCLE 19 DAY 1,7/13/2018,17.511293,0,0.97471046
LOXO-TRK-15002-130-001,62,F,All others,Y,Disease Progression,1/27/2017,37.02669405,67.5,162,25.72016461,0,Salivary gland,II,Metastatic,1,Partial response,34.26694045,0,Partial response,25.65913758,0,41.36344969,1,25,1,1,1,1,1,80,CYCLE 25 DAY 1,12/28/2018,23.030802,0,0.97471046
LOXO-TRK-15002-130-001,62,F,All others,Y,Disease Progression,1/27/2017,37.02669405,67.5,162,25.72016461,0,Salivary gland,II,Metastatic,1,Partial response,34.26694045,0,Partial response,25.65913758,0,41.36344969,1,28,1,1,1,1,1,97,CYCLE 28 DAY 1,3/22/2019,25.790554,0,0.97471046
LOXO-TRK-15002-130-001,62,F,All others,Y,Disease Progression,1/27/2017,37.02669405,67.5,162,25.72016461,0,Salivary gland,II,Metastatic,1,Partial response,34.26694045,0,Partial response,25.65913758,0,41.36344969,1,34,1,1,1,1,1,99,CYCLE 34 DAY 1,9/10/2019,31.441479,0,0.97471046
LOXO-TRK-15002-130-001,62,F,All others,Y,Disease Progression,1/27/2017,37.02669405,67.5,162,25.72016461,0,Salivary gland,II,Metastatic,1,Partial response,34.26694045,0,Partial response,25.65913758,0,41.36344969,1,37,1,1,1,1,1,100,CYCLE 37 DAY 1,12/6/2019,34.299793,0,0.97471046
LOXO-TRK-15002-133-001,45,M,White,Y,Disease Progression,12/4/2018,8.049281314,95.6,175,31.21632653,3,Lung,IV,Metastatic,3,Partial response,5.32238193,0,Partial response,7.227926078,0,8.509240246,0,0,3,2,3,2,3,40,CYCLE 1 DAY 1,12/4/2018,0,1,0.53401101
LOXO-TRK-15002-133-001,45,M,White,Y,Disease Progression,12/4/2018,8.049281314,95.6,175,31.21632653,3,Lung,IV,Metastatic,3,Partial response,5.32238193,0,Partial response,7.227926078,0,8.509240246,0,1,1,1,1,1,2,88,CYCLE 1 DAY 8,12/11/2018,0.26283368,1,0.90673959
LOXO-TRK-15002-133-001,45,M,White,Y,Disease Progression,12/4/2018,8.049281314,95.6,175,31.21632653,3,Lung,IV,Metastatic,3,Partial response,5.32238193,0,Partial response,7.227926078,0,8.509240246,0,2,2,2,1,1,1,85,CYCLE 2 DAY 1,12/31/2018,0.91991788,1,0.82832694
LOXO-TRK-15002-133-001,45,M,White,Y,Disease Progression,12/4/2018,8.049281314,95.6,175,31.21632653,3,Lung,IV,Metastatic,3,Partial response,5.32238193,0,Partial response,7.227926078,0,8.509240246,0,3,1,1,1,1,1,93,CYCLE 3 DAY 1,1/28/2019,1.8398358,1,0.98102748
LOXO-TRK-15002-133-001,45,M,White,Y,Disease Progression,12/4/2018,8.049281314,95.6,175,31.21632653,3,Lung,IV,Metastatic,3,Partial response,5.32238193,0,Partial response,7.227926078,0,8.509240246,0,4,1,1,1,1,1,95,CYCLE 4 DAY 1,2/25/2019,2.7597537,1,0.98102748
LOXO-TRK-15002-133-001,45,M,White,Y,Disease Progression,12/4/2018,8.049281314,95.6,175,31.21632653,3,Lung,IV,Metastatic,3,Partial response,5.32238193,0,Partial response,7.227926078,0,8.509240246,0,5,1,1,1,1,1,99,CYCLE 5 DAY 1,3/26/2019,3.7125256,1,0.98102748
LOXO-TRK-15002-133-001,45,M,White,Y,Disease Progression,12/4/2018,8.049281314,95.6,175,31.21632653,3,Lung,IV,Metastatic,3,Partial response,5.32238193,0,Partial response,7.227926078,0,8.509240246,0,6,1,1,1,1,1,100,CYCLE 6 DAY 1,4/22/2019,4.5995893,1,0.98102748
LOXO-TRK-15002-133-001,45,M,White,Y,Disease Progression,12/4/2018,8.049281314,95.6,175,31.21632653,3,Lung,IV,Metastatic,3,Partial response,5.32238193,0,Partial response,7.227926078,0,8.509240246,0,7,1,1,1,1,1,99,CYCLE 7 DAY 1,5/20/2019,5.5195074,1,0.98102748
LOXO-TRK-15002-133-001,45,M,White,Y,Disease Progression,12/4/2018,8.049281314,95.6,175,31.21632653,3,Lung,IV,Metastatic,3,Partial response,5.32238193,0,Partial response,7.227926078,0,8.509240246,0,8,1,1,1,1,1,99,CYCLE 8 DAY 1,6/17/2019,6.439425,1,0.98102748
LOXO-TRK-15002-133-001,45,M,White,Y,Disease Progression,12/4/2018,8.049281314,95.6,175,31.21632653,3,Lung,IV,Metastatic,3,Partial response,5.32238193,0,Partial response,7.227926078,0,8.509240246,0,9,1,1,1,1,1,99,CYCLE 9 DAY 1,7/15/2019,7.3593431,1,0.98102748
LOXO-TRK-15002-133-001,45,M,White,Y,Disease Progression,12/4/2018,8.049281314,95.6,175,31.21632653,3,Lung,IV,Metastatic,3,Partial response,5.32238193,0,Partial response,7.227926078,0,8.509240246,0,96,2,2,3,3,3,60,END OF TREATMENT,8/8/2019,8.1478443,1,0.5319643
LOXO-TRK-15002-133-002,54,M,White,Y,Disease Progression,12/28/2018,7.523613963,134.7,180,41.57407407,2,Prostate,Not reported,Metastatic,6,Progressive disease,1.80698152,0,Stable disease,5.289527721,0,10.31622177,0,0,1,3,3,2,3,35,CYCLE 1 DAY 1,12/28/2018,0,1,0.58859932
LOXO-TRK-15002-133-002,54,M,White,Y,Disease Progression,12/28/2018,7.523613963,134.7,180,41.57407407,2,Prostate,Not reported,Metastatic,6,Progressive disease,1.80698152,0,Stable disease,5.289527721,0,10.31622177,0,2,2,2,2,2,2,82,CYCLE 2 DAY 1,1/24/2019,0.91991788,1,0.59855253
LOXO-TRK-15002-133-002,54,M,White,Y,Disease Progression,12/28/2018,7.523613963,134.7,180,41.57407407,2,Prostate,Not reported,Metastatic,6,Progressive disease,1.80698152,0,Stable disease,5.289527721,0,10.31622177,0,3,2,2,3,2,4,67,CYCLE 3 DAY 1,2/21/2019,1.8398358,1,0.48751637
LOXO-TRK-15002-133-002,54,M,White,Y,Disease Progression,12/28/2018,7.523613963,134.7,180,41.57407407,2,Prostate,Not reported,Metastatic,6,Progressive disease,1.80698152,0,Stable disease,5.289527721,0,10.31622177,0,4,2,3,4,3,4,90,CYCLE 4 DAY 1,3/21/2019,2.7597537,1,0.38341662
LOXO-TRK-15002-133-002,54,M,White,Y,Disease Progression,12/28/2018,7.523613963,134.7,180,41.57407407,2,Prostate,Not reported,Metastatic,6,Progressive disease,1.80698152,0,Stable disease,5.289527721,0,10.31622177,0,5,2,3,3,3,4,58,CYCLE 5 DAY 1,4/15/2019,3.5811088,1,0.40712568
LOXO-TRK-15002-133-002,54,M,White,Y,Disease Progression,12/28/2018,7.523613963,134.7,180,41.57407407,2,Prostate,Not reported,Metastatic,6,Progressive disease,1.80698152,0,Stable disease,5.289527721,0,10.31622177,0,6,2,2,3,4,5,50,CYCLE 6 DAY 1,5/16/2019,4.5995893,1,0.16382113
LOXO-TRK-15002-133-002,54,M,White,Y,Disease Progression,12/28/2018,7.523613963,134.7,180,41.57407407,2,Prostate,Not reported,Metastatic,6,Progressive disease,1.80698152,0,Stable disease,5.289527721,0,10.31622177,0,7,3,1,3,3,4,60,CYCLE 7 DAY 1,6/13/2019,5.5195074,1,0.48507988
LOXO-TRK-15002-133-002,54,M,White,Y,Disease Progression,12/28/2018,7.523613963,134.7,180,41.57407407,2,Prostate,Not reported,Metastatic,6,Progressive disease,1.80698152,0,Stable disease,5.289527721,0,10.31622177,0,8,1,2,3,3,3,60,CYCLE 8 DAY 1,7/11/2019,6.439425,1,0.57038856
LOXO-TRK-15002-133-002,54,M,White,Y,Disease Progression,12/28/2018,7.523613963,134.7,180,41.57407407,2,Prostate,Not reported,Metastatic,6,Progressive disease,1.80698152,0,Stable disease,5.289527721,0,10.31622177,0,9,3,2,4,4,3,55,CYCLE 9 DAY 1,8/8/2019,7.3593431,1,0.29819506
LOXO-TRK-15002-133-002,54,M,White,Y,Disease Progression,12/28/2018,7.523613963,134.7,180,41.57407407,2,Prostate,Not reported,Metastatic,6,Progressive disease,1.80698152,0,Stable disease,5.289527721,0,10.31622177,0,96,3,4,4,4,4,19,END OF TREATMENT,8/14/2019,7.556468,1,0.08925911
LOXO-TRK-15002-134-001,61,F,White,Y,Physician Decision,6/29/2017,20.23819302,.,.,.,2,GIST,IV,Metastatic,3,Partial response,19.25256674,1,Partial response,19.25256674,1,21.42094456,1,0,2,1,2,3,4,30,CYCLE 1 DAY 1,6/29/2017,0,0,0.5580942
LOXO-TRK-15002-134-001,61,F,White,Y,Physician Decision,6/29/2017,20.23819302,.,.,.,2,GIST,IV,Metastatic,3,Partial response,19.25256674,1,Partial response,19.25256674,1,21.42094456,1,3,1,1,1,1,2,80,CYCLE 3 DAY 1,8/23/2017,1.8398358,0,0.89578164
LOXO-TRK-15002-134-001,61,F,White,Y,Physician Decision,6/29/2017,20.23819302,.,.,.,2,GIST,IV,Metastatic,3,Partial response,19.25256674,1,Partial response,19.25256674,1,21.42094456,1,4,2,1,1,2,2,90,CYCLE 4 DAY 1,9/20/2017,2.7597537,0,0.72896194
LOXO-TRK-15002-134-001,61,F,White,Y,Physician Decision,6/29/2017,20.23819302,.,.,.,2,GIST,IV,Metastatic,3,Partial response,19.25256674,1,Partial response,19.25256674,1,21.42094456,1,5,1,1,1,1,1,93,CYCLE 5 DAY 1,10/18/2017,3.6796715,0,0.97476453
LOXO-TRK-15002-134-001,61,F,White,Y,Physician Decision,6/29/2017,20.23819302,.,.,.,2,GIST,IV,Metastatic,3,Partial response,19.25256674,1,Partial response,19.25256674,1,21.42094456,1,7,2,1,1,1,1,90,CYCLE 7 DAY 1,12/13/2017,5.5195074,0,0.87032318
LOXO-TRK-15002-134-001,61,F,White,Y,Physician Decision,6/29/2017,20.23819302,.,.,.,2,GIST,IV,Metastatic,3,Partial response,19.25256674,1,Partial response,19.25256674,1,21.42094456,1,8,1,1,1,2,2,83,CYCLE 8 DAY 1,1/17/2018,6.6694045,0,0.78662622
LOXO-TRK-15002-134-001,61,F,White,Y,Physician Decision,6/29/2017,20.23819302,.,.,.,2,GIST,IV,Metastatic,3,Partial response,19.25256674,1,Partial response,19.25256674,1,21.42094456,1,10,1,1,1,2,1,80,CYCLE 10 DAY 1,3/7/2018,8.2792606,0,0.82937807
LOXO-TRK-15002-134-001,61,F,White,Y,Physician Decision,6/29/2017,20.23819302,.,.,.,2,GIST,IV,Metastatic,3,Partial response,19.25256674,1,Partial response,19.25256674,1,21.42094456,1,11,1,1,1,1,1,100,CYCLE 11 DAY 1,4/4/2018,9.1991787,0,0.97476453
LOXO-TRK-15002-134-001,61,F,White,Y,Physician Decision,6/29/2017,20.23819302,.,.,.,2,GIST,IV,Metastatic,3,Partial response,19.25256674,1,Partial response,19.25256674,1,21.42094456,1,12,1,1,2,3,1,90,CYCLE 12 DAY 1,5/2/2018,10.119097,0,0.71058619
LOXO-TRK-15002-134-001,61,F,White,Y,Physician Decision,6/29/2017,20.23819302,.,.,.,2,GIST,IV,Metastatic,3,Partial response,19.25256674,1,Partial response,19.25256674,1,21.42094456,1,13,2,1,2,1,1,89,CYCLE 13 DAY 1,5/30/2018,11.039015,0,0.80853075
LOXO-TRK-15002-134-001,61,F,White,Y,Physician Decision,6/29/2017,20.23819302,.,.,.,2,GIST,IV,Metastatic,3,Partial response,19.25256674,1,Partial response,19.25256674,1,21.42094456,1,14,1,1,1,1,1,95,CYCLE 14 DAY 1,6/27/2018,11.958932,0,0.97476453
LOXO-TRK-15002-134-001,61,F,White,Y,Physician Decision,6/29/2017,20.23819302,.,.,.,2,GIST,IV,Metastatic,3,Partial response,19.25256674,1,Partial response,19.25256674,1,21.42094456,1,15,1,1,1,1,1,88,CYCLE 15 DAY 1,7/25/2018,12.87885,0,0.97476453
LOXO-TRK-15002-134-001,61,F,White,Y,Physician Decision,6/29/2017,20.23819302,.,.,.,2,GIST,IV,Metastatic,3,Partial response,19.25256674,1,Partial response,19.25256674,1,21.42094456,1,16,3,1,1,2,1,75,CYCLE 16 DAY 1,8/29/2018,14.028748,0,0.70192051
LOXO-TRK-15002-134-001,61,F,White,Y,Physician Decision,6/29/2017,20.23819302,.,.,.,2,GIST,IV,Metastatic,3,Partial response,19.25256674,1,Partial response,19.25256674,1,21.42094456,1,17,1,1,1,1,1,88,CYCLE 17 DAY 1,9/19/2018,14.718686,0,0.97476453
LOXO-TRK-15002-134-001,61,F,White,Y,Physician Decision,6/29/2017,20.23819302,.,.,.,2,GIST,IV,Metastatic,3,Partial response,19.25256674,1,Partial response,19.25256674,1,21.42094456,1,18,3,1,1,1,2,58,CYCLE 18 DAY 1,10/17/2018,15.638604,0,0.75709182
LOXO-TRK-15002-134-001,61,F,White,Y,Physician Decision,6/29/2017,20.23819302,.,.,.,2,GIST,IV,Metastatic,3,Partial response,19.25256674,1,Partial response,19.25256674,1,21.42094456,1,19,1,1,1,1,1,89,CYCLE 19 DAY 1,11/14/2018,16.558521,0,0.97476453
LOXO-TRK-15002-134-001,61,F,White,Y,Physician Decision,6/29/2017,20.23819302,.,.,.,2,GIST,IV,Metastatic,3,Partial response,19.25256674,1,Partial response,19.25256674,1,21.42094456,1,20,1,1,1,1,1,93,CYCLE 20 DAY 1,12/12/2018,17.478439,0,0.97476453
LOXO-TRK-15002-134-001,61,F,White,Y,Physician Decision,6/29/2017,20.23819302,.,.,.,2,GIST,IV,Metastatic,3,Partial response,19.25256674,1,Partial response,19.25256674,1,21.42094456,1,21,1,1,1,1,1,91,CYCLE 21 DAY 1,1/9/2019,18.398357,0,0.97476453
LOXO-TRK-15002-134-001,61,F,White,Y,Physician Decision,6/29/2017,20.23819302,.,.,.,2,GIST,IV,Metastatic,3,Partial response,19.25256674,1,Partial response,19.25256674,1,21.42094456,1,22,1,1,1,1,1,95,CYCLE 22 DAY 1,2/6/2019,19.318275,0,0.97476453
LOXO-TRK-15002-134-001,61,F,White,Y,Physician Decision,6/29/2017,20.23819302,.,.,.,2,GIST,IV,Metastatic,3,Partial response,19.25256674,1,Partial response,19.25256674,1,21.42094456,1,96,1,1,1,1,1,90,END OF TREATMENT,3/6/2019,20.238194,0,0.97476453
LOXO-TRK-15002-134-002,58,F,White,Y,Physician Decision,6/13/2018,7.852156058,66,152,28.56648199,1,Lung,IV,Metastatic,2,Partial response,6.932238193,1,Partial response,6.932238193,1,9.954825462,1,2,1,4,4,5,4,50,CYCLE 2 DAY 1,7/11/2018,0.95277208,0,-0.025959233
LOXO-TRK-15002-134-002,58,F,White,Y,Physician Decision,6/13/2018,7.852156058,66,152,28.56648199,1,Lung,IV,Metastatic,2,Partial response,6.932238193,1,Partial response,6.932238193,1,9.954825462,1,5,5,5,5,5,5,90,CYCLE 5 DAY 1,10/3/2018,3.7125256,0,-0.57645696
LOXO-TRK-15002-134-002,58,F,White,Y,Physician Decision,6/13/2018,7.852156058,66,152,28.56648199,1,Lung,IV,Metastatic,2,Partial response,6.932238193,1,Partial response,6.932238193,1,9.954825462,1,6,1,1,1,3,1,80,CYCLE 6 DAY 1,10/24/2018,4.4024639,0,0.76068366
LOXO-TRK-15002-134-002,58,F,White,Y,Physician Decision,6/13/2018,7.852156058,66,152,28.56648199,1,Lung,IV,Metastatic,2,Partial response,6.932238193,1,Partial response,6.932238193,1,9.954825462,1,7,1,1,3,3,3,90,CYCLE 7 DAY 1,11/20/2018,5.2895279,0,0.6476717
LOXO-TRK-15002-134-002,58,F,White,Y,Physician Decision,6/13/2018,7.852156058,66,152,28.56648199,1,Lung,IV,Metastatic,2,Partial response,6.932238193,1,Partial response,6.932238193,1,9.954825462,1,9,1,1,1,3,3,70,CYCLE 9 DAY 1,1/10/2019,6.9650922,0,0.70872527
LOXO-TRK-15002-134-002,58,F,White,Y,Physician Decision,6/13/2018,7.852156058,66,152,28.56648199,1,Lung,IV,Metastatic,2,Partial response,6.932238193,1,Partial response,6.932238193,1,9.954825462,1,96,1,1,3,3,4,80,END OF TREATMENT,2/6/2019,7.8521562,0,0.57007217
LOXO-TRK-15002-134-003,62,F,White,Y,Physician Decision,11/20/2018,2.825462012,73,158,29.24210864,2,Colon,IV,Metastatic,0,Stable disease,1.905544148,1,Stable disease,1.905544148,1,4.698151951,1,0,2,2,3,4,3,50,CYCLE 1 DAY 1,11/20/2018,0,0,0.33246857
LOXO-TRK-15002-134-003,62,F,White,Y,Physician Decision,11/20/2018,2.825462012,73,158,29.24210864,2,Colon,IV,Metastatic,0,Stable disease,1.905544148,1,Stable disease,1.905544148,1,4.698151951,1,2,1,1,2,3,1,70,CYCLE 2 DAY 1,12/19/2018,0.98562628,0,0.71022832
LOXO-TRK-15002-134-003,62,F,White,Y,Physician Decision,11/20/2018,2.825462012,73,158,29.24210864,2,Colon,IV,Metastatic,0,Stable disease,1.905544148,1,Stable disease,1.905544148,1,4.698151951,1,3,1,1,1,3,1,75,CYCLE 3 DAY 1,1/16/2019,1.9055442,0,0.76031494
LOXO-TRK-15002-134-003,62,F,White,Y,Physician Decision,11/20/2018,2.825462012,73,158,29.24210864,2,Colon,IV,Metastatic,0,Stable disease,1.905544148,1,Stable disease,1.905544148,1,4.698151951,1,96,1,5,3,3,1,70,END OF TREATMENT,2/28/2019,3.3182752,0,0.47080681
LOXO-TRK-15002-155-001,45,F,White,Y,Disease Progression,9/14/2016,9.396303901,48,165,17.63085399,1,Soft tissue sarcoma,IV,Metastatic,0,Partial response,5.519507187,0,Partial response,5.519507187,0,44.45174538,1,0,1,1,1,1,2,75,CYCLE 1 DAY 1,9/14/2016,0,0,0.89814591
LOXO-TRK-15002-155-001,45,F,White,Y,Disease Progression,9/14/2016,9.396303901,48,165,17.63085399,1,Soft tissue sarcoma,IV,Metastatic,0,Partial response,5.519507187,0,Partial response,5.519507187,0,44.45174538,1,3,1,1,1,2,1,85,CYCLE 3 DAY 1,11/8/2016,1.8398358,0,0.83402151
LOXO-TRK-15002-155-001,45,F,White,Y,Disease Progression,9/14/2016,9.396303901,48,165,17.63085399,1,Soft tissue sarcoma,IV,Metastatic,0,Partial response,5.519507187,0,Partial response,5.519507187,0,44.45174538,1,5,1,1,1,1,1,85,CYCLE 5 DAY 1,1/5/2017,3.7453799,0,0.97725827
LOXO-TRK-15002-155-001,45,F,White,Y,Disease Progression,9/14/2016,9.396303901,48,165,17.63085399,1,Soft tissue sarcoma,IV,Metastatic,0,Partial response,5.519507187,0,Partial response,5.519507187,0,44.45174538,1,7,2,1,1,1,1,85,CYCLE 7 DAY 1,2/28/2017,5.5195074,0,0.87095642
LOXO-TRK-15002-155-001,45,F,White,Y,Disease Progression,9/14/2016,9.396303901,48,165,17.63085399,1,Soft tissue sarcoma,IV,Metastatic,0,Partial response,5.519507187,0,Partial response,5.519507187,0,44.45174538,1,9,1,1,1,1,1,95,CYCLE 9 DAY 1,4/25/2017,7.3593431,0,0.97725827
LOXO-TRK-15002-201-001,55,F,Asian,Y,,2/8/2019,16.78850103,43.7,145,20.78478002,1,Thyroid,IV,Metastatic,2,Partial response,16.6899384,1,Partial response,16.6899384,1,16.78850103,1,0,1,1,2,2,1,60,CYCLE 1 DAY 1,2/8/2019,0,0,0.77606714
LOXO-TRK-15002-201-001,55,F,Asian,Y,,2/8/2019,16.78850103,43.7,145,20.78478002,1,Thyroid,IV,Metastatic,2,Partial response,16.6899384,1,Partial response,16.6899384,1,16.78850103,1,3,1,1,1,2,1,85,CYCLE 3 DAY 1,4/8/2019,1.9712526,0,0.83057237
LOXO-TRK-15002-201-001,55,F,Asian,Y,,2/8/2019,16.78850103,43.7,145,20.78478002,1,Thyroid,IV,Metastatic,2,Partial response,16.6899384,1,Partial response,16.6899384,1,16.78850103,1,4,1,1,1,2,1,85,CYCLE 4 DAY 1,5/3/2019,2.7926078,0,0.83057237
LOXO-TRK-15002-201-001,55,F,Asian,Y,,2/8/2019,16.78850103,43.7,145,20.78478002,1,Thyroid,IV,Metastatic,2,Partial response,16.6899384,1,Partial response,16.6899384,1,16.78850103,1,5,1,1,1,2,1,80,CYCLE 5 DAY 1,5/30/2019,3.6796715,0,0.83057237
LOXO-TRK-15002-201-001,55,F,Asian,Y,,2/8/2019,16.78850103,43.7,145,20.78478002,1,Thyroid,IV,Metastatic,2,Partial response,16.6899384,1,Partial response,16.6899384,1,16.78850103,1,7,2,1,1,2,1,80,CYCLE 7 DAY 1,7/29/2019,5.6509242,0,0.76205832
LOXO-TRK-15002-201-001,55,F,Asian,Y,,2/8/2019,16.78850103,43.7,145,20.78478002,1,Thyroid,IV,Metastatic,2,Partial response,16.6899384,1,Partial response,16.6899384,1,16.78850103,1,9,1,1,1,2,1,80,CYCLE 9 DAY 1,9/23/2019,7.4907598,0,0.83057237
LOXO-TRK-15002-201-001,55,F,Asian,Y,,2/8/2019,16.78850103,43.7,145,20.78478002,1,Thyroid,IV,Metastatic,2,Partial response,16.6899384,1,Partial response,16.6899384,1,16.78850103,1,11,1,1,1,1,1,80,CYCLE 11 DAY 1,11/20/2019,9.3963041,0,0.97540599
LOXO-TRK-15002-201-001,55,F,Asian,Y,,2/8/2019,16.78850103,43.7,145,20.78478002,1,Thyroid,IV,Metastatic,2,Partial response,16.6899384,1,Partial response,16.6899384,1,16.78850103,1,12,1,1,1,1,1,80,CYCLE 12 DAY 1,12/16/2019,10.250513,0,0.97540599
LOXO-TRK-15002-201-001,55,F,Asian,Y,,2/8/2019,16.78850103,43.7,145,20.78478002,1,Thyroid,IV,Metastatic,2,Partial response,16.6899384,1,Partial response,16.6899384,1,16.78850103,1,13,1,1,1,2,1,85,CYCLE 13 DAY 1,1/15/2020,11.236139,0,0.83057237
LOXO-TRK-15002-201-001,55,F,Asian,Y,,2/8/2019,16.78850103,43.7,145,20.78478002,1,Thyroid,IV,Metastatic,2,Partial response,16.6899384,1,Partial response,16.6899384,1,16.78850103,1,14,1,1,1,3,1,80,CYCLE 14 DAY 1,2/14/2020,12.221766,0,0.76099342
LOXO-TRK-15002-201-001,55,F,Asian,Y,,2/8/2019,16.78850103,43.7,145,20.78478002,1,Thyroid,IV,Metastatic,2,Partial response,16.6899384,1,Partial response,16.6899384,1,16.78850103,1,15,1,1,1,2,1,85,CYCLE 15 DAY 1,3/11/2020,13.075975,0,0.83057237
LOXO-TRK-15002-201-001,55,F,Asian,Y,,2/8/2019,16.78850103,43.7,145,20.78478002,1,Thyroid,IV,Metastatic,2,Partial response,16.6899384,1,Partial response,16.6899384,1,16.78850103,1,16,1,1,1,1,1,85,CYCLE 16 DAY 1,4/8/2020,13.995893,0,0.97540599
LOXO-TRK-15002-201-001,55,F,Asian,Y,,2/8/2019,16.78850103,43.7,145,20.78478002,1,Thyroid,IV,Metastatic,2,Partial response,16.6899384,1,Partial response,16.6899384,1,16.78850103,1,19,1,1,2,3,2,85,CYCLE 19 DAY 1,7/2/2020,16.788502,0,0.67794591
LOXO-TRK-15002-202-001,6,F,Asian,Y,,9/4/2017,34.0698152,23,120,15.97222222,0,Thyroid,IV,Metastatic,0,Non-CR/Non-PD,32.98562628,1,Complete response,32.98562628,1,34.0698152,1,,,,,,,,,,,0,
LOXO-TRK-15002-202-002,69,M,Asian,Y,Disease Progression,11/15/2018,10.4476386,71,171,24.28097534,1,Pancreas,IV,Metastatic,1,Stable disease,6.373716632,0,Stable disease,11.59753593,0,12.02464066,0,-1,1,1,1,1,1,90,SCREENING,11/9/2018,0,1,0.97831547
LOXO-TRK-15002-202-002,69,M,Asian,Y,Disease Progression,11/15/2018,10.4476386,71,171,24.28097534,1,Pancreas,IV,Metastatic,1,Stable disease,6.373716632,0,Stable disease,11.59753593,0,12.02464066,0,0,1,1,1,1,1,90,CYCLE 1 DAY 1,11/15/2018,0,1,0.97831547
LOXO-TRK-15002-202-002,69,M,Asian,Y,Disease Progression,11/15/2018,10.4476386,71,171,24.28097534,1,Pancreas,IV,Metastatic,1,Stable disease,6.373716632,0,Stable disease,11.59753593,0,12.02464066,0,2,1,1,1,1,1,85,CYCLE 2 DAY 1,12/20/2018,1.1827515,1,0.97831547
LOXO-TRK-15002-202-002,69,M,Asian,Y,Disease Progression,11/15/2018,10.4476386,71,171,24.28097534,1,Pancreas,IV,Metastatic,1,Stable disease,6.373716632,0,Stable disease,11.59753593,0,12.02464066,0,3,1,1,1,1,2,60,CYCLE 3 DAY 1,1/24/2019,2.3326488,1,0.902628
LOXO-TRK-15002-202-002,69,M,Asian,Y,Disease Progression,11/15/2018,10.4476386,71,171,24.28097534,1,Pancreas,IV,Metastatic,1,Stable disease,6.373716632,0,Stable disease,11.59753593,0,12.02464066,0,4,1,1,1,1,1,70,CYCLE 4 DAY 1,2/21/2019,3.2525668,1,0.97831547
LOXO-TRK-15002-202-002,69,M,Asian,Y,Disease Progression,11/15/2018,10.4476386,71,171,24.28097534,1,Pancreas,IV,Metastatic,1,Stable disease,6.373716632,0,Stable disease,11.59753593,0,12.02464066,0,5,1,1,1,1,1,70,CYCLE 5 DAY 1,3/20/2019,4.1396303,1,0.97831547
LOXO-TRK-15002-202-002,69,M,Asian,Y,Disease Progression,11/15/2018,10.4476386,71,171,24.28097534,1,Pancreas,IV,Metastatic,1,Stable disease,6.373716632,0,Stable disease,11.59753593,0,12.02464066,0,6,1,1,1,1,1,40,CYCLE 6 DAY 1,4/18/2019,5.0924025,1,0.97831547
LOXO-TRK-15002-202-002,69,M,Asian,Y,Disease Progression,11/15/2018,10.4476386,71,171,24.28097534,1,Pancreas,IV,Metastatic,1,Stable disease,6.373716632,0,Stable disease,11.59753593,0,12.02464066,0,7,1,1,1,2,2,50,CYCLE 7 DAY 1,6/10/2019,6.8336754,1,0.79038835
LOXO-TRK-15002-202-002,69,M,Asian,Y,Disease Progression,11/15/2018,10.4476386,71,171,24.28097534,1,Pancreas,IV,Metastatic,1,Stable disease,6.373716632,0,Stable disease,11.59753593,0,12.02464066,0,8,1,1,2,2,2,60,CYCLE 8 DAY 1,7/11/2019,7.8521562,1,0.73053145
LOXO-TRK-15002-202-002,69,M,Asian,Y,Disease Progression,11/15/2018,10.4476386,71,171,24.28097534,1,Pancreas,IV,Metastatic,1,Stable disease,6.373716632,0,Stable disease,11.59753593,0,12.02464066,0,9,2,2,2,1,2,75,CYCLE 9 DAY 1,9/25/2019,10.349076,1,0.6722073
LOXO-TRK-15002-221-005,48,F,White,Y,,8/13/2019,11.17043121,66.2,164,24.6133254,0,Soft tissue sarcoma,IV,Metastatic,2,Stable disease,11.10472279,0,Stable disease,11.17043121,1,11.17043121,1,0,1,1,1,1,1,100,CYCLE 1 DAY 1,8/13/2019,0,0,0.97661072
LOXO-TRK-15002-221-005,48,F,White,Y,,8/13/2019,11.17043121,66.2,164,24.6133254,0,Soft tissue sarcoma,IV,Metastatic,2,Stable disease,11.10472279,0,Stable disease,11.17043121,1,11.17043121,1,2,1,1,1,2,1,80,CYCLE 2 DAY 1,9/13/2019,1.0513347,0,0.83273542
LOXO-TRK-15002-221-005,48,F,White,Y,,8/13/2019,11.17043121,66.2,164,24.6133254,0,Soft tissue sarcoma,IV,Metastatic,2,Stable disease,11.10472279,0,Stable disease,11.17043121,1,11.17043121,1,3,1,1,1,2,1,80,CYCLE 3 DAY 1,10/8/2019,1.87269,0,0.83273542
LOXO-TRK-15002-221-005,48,F,White,Y,,8/13/2019,11.17043121,66.2,164,24.6133254,0,Soft tissue sarcoma,IV,Metastatic,2,Stable disease,11.10472279,0,Stable disease,11.17043121,1,11.17043121,1,4,1,1,1,2,1,80,CYCLE 4 DAY 1,11/8/2019,2.8911705,0,0.83273542
LOXO-TRK-15002-221-005,48,F,White,Y,,8/13/2019,11.17043121,66.2,164,24.6133254,0,Soft tissue sarcoma,IV,Metastatic,2,Stable disease,11.10472279,0,Stable disease,11.17043121,1,11.17043121,1,5,1,1,1,2,2,90,CYCLE 5 DAY 1,12/3/2019,3.7125256,0,0.78844637
LOXO-TRK-15002-221-005,48,F,White,Y,,8/13/2019,11.17043121,66.2,164,24.6133254,0,Soft tissue sarcoma,IV,Metastatic,2,Stable disease,11.10472279,0,Stable disease,11.17043121,1,11.17043121,1,6,1,1,1,2,2,80,CYCLE 6 DAY 1,1/3/2020,4.7310061,0,0.78844637
LOXO-TRK-15002-221-005,48,F,White,Y,,8/13/2019,11.17043121,66.2,164,24.6133254,0,Soft tissue sarcoma,IV,Metastatic,2,Stable disease,11.10472279,0,Stable disease,11.17043121,1,11.17043121,1,7,1,1,1,2,1,90,CYCLE 7 DAY 1,1/29/2020,5.5852156,0,0.83273542
LOXO-TRK-15002-221-005,48,F,White,Y,,8/13/2019,11.17043121,66.2,164,24.6133254,0,Soft tissue sarcoma,IV,Metastatic,2,Stable disease,11.10472279,0,Stable disease,11.17043121,1,11.17043121,1,8,1,1,1,2,2,80,CYCLE 8 DAY 1,2/26/2020,6.5051336,0,0.78844637
LOXO-TRK-15002-221-005,48,F,White,Y,,8/13/2019,11.17043121,66.2,164,24.6133254,0,Soft tissue sarcoma,IV,Metastatic,2,Stable disease,11.10472279,0,Stable disease,11.17043121,1,11.17043121,1,11,1,1,1,2,2,90,CYCLE 11 DAY 1,5/22/2020,9.330595,0,0.78844637
LOXO-TRK-15002-221-005,48,F,White,Y,,8/13/2019,11.17043121,66.2,164,24.6133254,0,Soft tissue sarcoma,IV,Metastatic,2,Stable disease,11.10472279,0,Stable disease,11.17043121,1,11.17043121,1,12,1,1,1,2,2,90,CYCLE 12 DAY 1,6/17/2020,10.184805,0,0.78844637
LOXO-TRK-15002-221-005,48,F,White,Y,,8/13/2019,11.17043121,66.2,164,24.6133254,0,Soft tissue sarcoma,IV,Metastatic,2,Stable disease,11.10472279,0,Stable disease,11.17043121,1,11.17043121,1,13,1,1,1,3,2,60,CYCLE 13 DAY 1,7/17/2020,11.170431,0,0.73130053
LOXO-TRK-15002-240-002,31,M,Asian,Y,,4/10/2019,14.75154004,77.8,174,25.69692165,0,Salivary gland,Not reported,Metastatic,0,Partial response,14.06160164,1,Partial response,14.06160164,1,15.27720739,1,0,2,1,1,2,2,70,CYCLE 1 DAY 1,4/10/2019,0,1,0.7482059
LOXO-TRK-15002-240-002,31,M,Asian,Y,,4/10/2019,14.75154004,77.8,174,25.69692165,0,Salivary gland,Not reported,Metastatic,0,Partial response,14.06160164,1,Partial response,14.06160164,1,15.27720739,1,2,3,1,2,2,2,70,CYCLE 2 DAY 1,5/7/2019,0.91991788,1,0.65258127
LOXO-TRK-15002-240-002,31,M,Asian,Y,,4/10/2019,14.75154004,77.8,174,25.69692165,0,Salivary gland,Not reported,Metastatic,0,Partial response,14.06160164,1,Partial response,14.06160164,1,15.27720739,1,3,2,1,2,3,2,70,CYCLE 3 DAY 1,6/5/2019,1.87269,1,0.64069289
LOXO-TRK-15002-240-002,31,M,Asian,Y,,4/10/2019,14.75154004,77.8,174,25.69692165,0,Salivary gland,Not reported,Metastatic,0,Partial response,14.06160164,1,Partial response,14.06160164,1,15.27720739,1,4,2,1,1,2,2,65,CYCLE 4 DAY 1,7/1/2019,2.7268994,1,0.7482059
LOXO-TRK-15002-240-002,31,M,Asian,Y,,4/10/2019,14.75154004,77.8,174,25.69692165,0,Salivary gland,Not reported,Metastatic,0,Partial response,14.06160164,1,Partial response,14.06160164,1,15.27720739,1,5,2,1,1,2,2,65,CYCLE 5 DAY 1,7/30/2019,3.6796715,1,0.7482059
LOXO-TRK-15002-240-002,31,M,Asian,Y,,4/10/2019,14.75154004,77.8,174,25.69692165,0,Salivary gland,Not reported,Metastatic,0,Partial response,14.06160164,1,Partial response,14.06160164,1,15.27720739,1,6,2,1,2,3,2,50,CYCLE 6 DAY 1,8/28/2019,4.6324434,1,0.64069289
LOXO-TRK-15002-240-002,31,M,Asian,Y,,4/10/2019,14.75154004,77.8,174,25.69692165,0,Salivary gland,Not reported,Metastatic,0,Partial response,14.06160164,1,Partial response,14.06160164,1,15.27720739,1,7,2,1,2,3,2,50,CYCLE 7 DAY 1,9/24/2019,5.5195074,1,0.64069289
LOXO-TRK-15002-240-002,31,M,Asian,Y,,4/10/2019,14.75154004,77.8,174,25.69692165,0,Salivary gland,Not reported,Metastatic,0,Partial response,14.06160164,1,Partial response,14.06160164,1,15.27720739,1,8,2,1,1,3,2,50,CYCLE 8 DAY 1,10/23/2019,6.4722791,1,0.68953454
LOXO-TRK-15002-240-002,31,M,Asian,Y,,4/10/2019,14.75154004,77.8,174,25.69692165,0,Salivary gland,Not reported,Metastatic,0,Partial response,14.06160164,1,Partial response,14.06160164,1,15.27720739,1,9,3,1,2,4,3,40,CYCLE 9 DAY 1,11/19/2019,7.3593431,1,0.46933416
LOXO-TRK-15002-240-002,31,M,Asian,Y,,4/10/2019,14.75154004,77.8,174,25.69692165,0,Salivary gland,Not reported,Metastatic,0,Partial response,14.06160164,1,Partial response,14.06160164,1,15.27720739,1,10,1,1,1,3,1,50,CYCLE 10 DAY 1,12/18/2019,8.3121147,1,0.77718174
LOXO-TRK-15002-240-002,31,M,Asian,Y,,4/10/2019,14.75154004,77.8,174,25.69692165,0,Salivary gland,Not reported,Metastatic,0,Partial response,14.06160164,1,Partial response,14.06160164,1,15.27720739,1,11,1,1,1,1,1,50,CYCLE 11 DAY 1,1/14/2020,9.1991787,1,0.98455524
LOXO-TRK-15002-240-002,31,M,Asian,Y,,4/10/2019,14.75154004,77.8,174,25.69692165,0,Salivary gland,Not reported,Metastatic,0,Partial response,14.06160164,1,Partial response,14.06160164,1,15.27720739,1,12,2,1,2,3,1,50,CYCLE 12 DAY 1,2/12/2020,10.151951,1,0.66708285
LOXO-TRK-15002-240-002,31,M,Asian,Y,,4/10/2019,14.75154004,77.8,174,25.69692165,0,Salivary gland,Not reported,Metastatic,0,Partial response,14.06160164,1,Partial response,14.06160164,1,15.27720739,1,13,2,1,1,3,1,50,CYCLE 13 DAY 1,3/10/2020,11.039015,1,0.71874887
LOXO-TRK-15002-240-002,31,M,Asian,Y,,4/10/2019,14.75154004,77.8,174,25.69692165,0,Salivary gland,Not reported,Metastatic,0,Partial response,14.06160164,1,Partial response,14.06160164,1,15.27720739,1,14,2,1,1,3,1,50,CYCLE 14 DAY 1,4/15/2020,12.221766,1,0.71874887
LOXO-TRK-15002-240-002,31,M,Asian,Y,,4/10/2019,14.75154004,77.8,174,25.69692165,0,Salivary gland,Not reported,Metastatic,0,Partial response,14.06160164,1,Partial response,14.06160164,1,15.27720739,1,15,1,1,1,2,1,50,CYCLE 15 DAY 1,5/13/2020,13.141684,1,0.85602355
LOXO-TRK-15002-240-002,31,M,Asian,Y,,4/10/2019,14.75154004,77.8,174,25.69692165,0,Salivary gland,Not reported,Metastatic,0,Partial response,14.06160164,1,Partial response,14.06160164,1,15.27720739,1,16,2,1,1,3,1,50,CYCLE 16 DAY 1,6/10/2020,14.061602,1,0.71874887
LOXO-TRK-15002-240-003,72,F,Asian,Y,Disease Progression,5/16/2019,5.9137577,71.6,157,29.04783156,0,Cervix,Not reported,Metastatic,0,Stable disease,5.059548255,0,Stable disease,5.9137577,0,11.99178645,1,0,1,1,1,1,1,80,CYCLE 1 DAY 1,5/16/2019,0,0,0.97490144
LOXO-TRK-15002-240-003,72,F,Asian,Y,Disease Progression,5/16/2019,5.9137577,71.6,157,29.04783156,0,Cervix,Not reported,Metastatic,0,Stable disease,5.059548255,0,Stable disease,5.9137577,0,11.99178645,1,2,1,1,1,2,1,95,CYCLE 2 DAY 1,6/13/2019,0.95277208,0,0.82927835
LOXO-TRK-15002-240-003,72,F,Asian,Y,Disease Progression,5/16/2019,5.9137577,71.6,157,29.04783156,0,Cervix,Not reported,Metastatic,0,Stable disease,5.059548255,0,Stable disease,5.9137577,0,11.99178645,1,3,1,1,2,2,1,70,CYCLE 3 DAY 1,7/9/2019,1.8069816,0,0.77035767
LOXO-TRK-15002-240-003,72,F,Asian,Y,Disease Progression,5/16/2019,5.9137577,71.6,157,29.04783156,0,Cervix,Not reported,Metastatic,0,Stable disease,5.059548255,0,Stable disease,5.9137577,0,11.99178645,1,4,2,1,2,2,1,70,CYCLE 4 DAY 1,8/5/2019,2.6940451,0,0.70919555
LOXO-TRK-15002-240-003,72,F,Asian,Y,Disease Progression,5/16/2019,5.9137577,71.6,157,29.04783156,0,Cervix,Not reported,Metastatic,0,Stable disease,5.059548255,0,Stable disease,5.9137577,0,11.99178645,1,5,2,1,3,1,2,50,CYCLE 5 DAY 1,9/3/2019,3.6468172,0,0.73362732
LOXO-TRK-15002-240-003,72,F,Asian,Y,Disease Progression,5/16/2019,5.9137577,71.6,157,29.04783156,0,Cervix,Not reported,Metastatic,0,Stable disease,5.059548255,0,Stable disease,5.9137577,0,11.99178645,1,6,1,1,3,2,2,70,CYCLE 6 DAY 1,10/16/2019,5.0595484,0,0.7093876
LOXO-TRK-15002-240-003,72,F,Asian,Y,Disease Progression,5/16/2019,5.9137577,71.6,157,29.04783156,0,Cervix,Not reported,Metastatic,0,Stable disease,5.059548255,0,Stable disease,5.9137577,0,11.99178645,1,96,1,1,2,2,2,75,END OF TREATMENT,11/11/2019,5.9137578,0,0.7287432
LOXO-TRK-15002-240-004,38,M,Asian,Y,,9/30/2019,9.330595483,57.9,174,19.12405866,0,Soft tissue sarcoma,Not reported,Locally advanced,3,Stable disease,9.232032854,1,Stable disease,9.232032854,1,9.330595483,1,0,2,1,1,2,1,70,CYCLE 1 DAY 1,9/30/2019,0,1,0.77852994
LOXO-TRK-15002-240-004,38,M,Asian,Y,,9/30/2019,9.330595483,57.9,174,19.12405866,0,Soft tissue sarcoma,Not reported,Locally advanced,3,Stable disease,9.232032854,1,Stable disease,9.232032854,1,9.330595483,1,2,2,1,1,2,1,80,CYCLE 2 DAY 1,10/28/2019,0.95277208,1,0.77852994
LOXO-TRK-15002-240-004,38,M,Asian,Y,,9/30/2019,9.330595483,57.9,174,19.12405866,0,Soft tissue sarcoma,Not reported,Locally advanced,3,Stable disease,9.232032854,1,Stable disease,9.232032854,1,9.330595483,1,3,2,1,1,2,2,80,CYCLE 3 DAY 1,11/25/2019,1.87269,1,0.74316484
LOXO-TRK-15002-240-004,38,M,Asian,Y,,9/30/2019,9.330595483,57.9,174,19.12405866,0,Soft tissue sarcoma,Not reported,Locally advanced,3,Stable disease,9.232032854,1,Stable disease,9.232032854,1,9.330595483,1,4,2,1,1,2,1,75,CYCLE 4 DAY 1,12/23/2019,2.7926078,1,0.77852994
LOXO-TRK-15002-240-004,38,M,Asian,Y,,9/30/2019,9.330595483,57.9,174,19.12405866,0,Soft tissue sarcoma,Not reported,Locally advanced,3,Stable disease,9.232032854,1,Stable disease,9.232032854,1,9.330595483,1,5,2,1,1,2,1,80,CYCLE 5 DAY 1,1/20/2020,3.7125256,1,0.77852994
LOXO-TRK-15002-240-004,38,M,Asian,Y,,9/30/2019,9.330595483,57.9,174,19.12405866,0,Soft tissue sarcoma,Not reported,Locally advanced,3,Stable disease,9.232032854,1,Stable disease,9.232032854,1,9.330595483,1,6,2,1,1,2,1,80,CYCLE 6 DAY 1,2/17/2020,4.6324434,1,0.77852994
LOXO-TRK-15002-240-004,38,M,Asian,Y,,9/30/2019,9.330595483,57.9,174,19.12405866,0,Soft tissue sarcoma,Not reported,Locally advanced,3,Stable disease,9.232032854,1,Stable disease,9.232032854,1,9.330595483,1,7,2,1,1,2,1,80,CYCLE 7 DAY 1,3/16/2020,5.5523615,1,0.77852994
LOXO-TRK-15002-240-004,38,M,Asian,Y,,9/30/2019,9.330595483,57.9,174,19.12405866,0,Soft tissue sarcoma,Not reported,Locally advanced,3,Stable disease,9.232032854,1,Stable disease,9.232032854,1,9.330595483,1,8,1,1,1,1,1,80,CYCLE 8 DAY 1,4/16/2020,6.5708418,1,0.9826628
LOXO-TRK-15002-240-004,38,M,Asian,Y,,9/30/2019,9.330595483,57.9,174,19.12405866,0,Soft tissue sarcoma,Not reported,Locally advanced,3,Stable disease,9.232032854,1,Stable disease,9.232032854,1,9.330595483,1,9,1,1,1,1,1,80,CYCLE 9 DAY 1,5/11/2020,7.3921971,1,0.9826628
LOXO-TRK-15002-240-004,38,M,Asian,Y,,9/30/2019,9.330595483,57.9,174,19.12405866,0,Soft tissue sarcoma,Not reported,Locally advanced,3,Stable disease,9.232032854,1,Stable disease,9.232032854,1,9.330595483,1,10,1,1,1,1,1,85,CYCLE 10 DAY 1,6/8/2020,8.3121147,1,0.9826628
LOXO-TRK-15002-240-004,38,M,Asian,Y,,9/30/2019,9.330595483,57.9,174,19.12405866,0,Soft tissue sarcoma,Not reported,Locally advanced,3,Stable disease,9.232032854,1,Stable disease,9.232032854,1,9.330595483,1,11,1,1,1,1,1,80,CYCLE 11 DAY 1,7/6/2020,9.2320328,1,0.9826628
LOXO-TRK-15002-260-001,44,F,White,Y,,12/12/2018,19.05544148,45.1,155,18.77211238,0,Soft tissue sarcoma,I,Metastatic,0,Complete response,16.98562628,1,Complete response,16.98562628,1,19.05544148,1,0,1,1,1,1,2,85,CYCLE 1 DAY 1,12/12/2018,0,0,0.8985756
LOXO-TRK-15002-260-001,44,F,White,Y,,12/12/2018,19.05544148,45.1,155,18.77211238,0,Soft tissue sarcoma,I,Metastatic,0,Complete response,16.98562628,1,Complete response,16.98562628,1,19.05544148,1,2,2,1,1,1,1,70,CYCLE 2 DAY 1,1/7/2019,0.88706368,0,0.87125528
LOXO-TRK-15002-260-001,44,F,White,Y,,12/12/2018,19.05544148,45.1,155,18.77211238,0,Soft tissue sarcoma,I,Metastatic,0,Complete response,16.98562628,1,Complete response,16.98562628,1,19.05544148,1,3,3,1,1,1,1,79,CYCLE 3 DAY 1,2/12/2019,2.0698152,0,0.79772902
LOXO-TRK-15002-260-001,44,F,White,Y,,12/12/2018,19.05544148,45.1,155,18.77211238,0,Soft tissue sarcoma,I,Metastatic,0,Complete response,16.98562628,1,Complete response,16.98562628,1,19.05544148,1,5,2,1,1,1,1,88,CYCLE 5 DAY 1,4/12/2019,4.0082135,0,0.87125528
LOXO-TRK-15002-260-001,44,F,White,Y,,12/12/2018,19.05544148,45.1,155,18.77211238,0,Soft tissue sarcoma,I,Metastatic,0,Complete response,16.98562628,1,Complete response,16.98562628,1,19.05544148,1,6,1,1,1,1,1,85,CYCLE 6 DAY 1,5/10/2019,4.9281316,0,0.97749591
LOXO-TRK-15002-260-001,44,F,White,Y,,12/12/2018,19.05544148,45.1,155,18.77211238,0,Soft tissue sarcoma,I,Metastatic,0,Complete response,16.98562628,1,Complete response,16.98562628,1,19.05544148,1,7,3,1,1,1,1,64,CYCLE 7 DAY 1,6/3/2019,5.7166324,0,0.79772902
LOXO-TRK-15002-260-001,44,F,White,Y,,12/12/2018,19.05544148,45.1,155,18.77211238,0,Soft tissue sarcoma,I,Metastatic,0,Complete response,16.98562628,1,Complete response,16.98562628,1,19.05544148,1,8,3,1,1,1,1,72,CYCLE 8 DAY 1,7/1/2019,6.6365504,0,0.79772902
LOXO-TRK-15002-260-001,44,F,White,Y,,12/12/2018,19.05544148,45.1,155,18.77211238,0,Soft tissue sarcoma,I,Metastatic,0,Complete response,16.98562628,1,Complete response,16.98562628,1,19.05544148,1,9,3,1,1,1,1,70,CYCLE 9 DAY 1,8/2/2019,7.6878848,0,0.79772902
LOXO-TRK-15002-260-001,44,F,White,Y,,12/12/2018,19.05544148,45.1,155,18.77211238,0,Soft tissue sarcoma,I,Metastatic,0,Complete response,16.98562628,1,Complete response,16.98562628,1,19.05544148,1,10,1,1,1,1,1,80,CYCLE 10 DAY 1,9/2/2019,8.7063656,0,0.97749591
LOXO-TRK-15002-260-001,44,F,White,Y,,12/12/2018,19.05544148,45.1,155,18.77211238,0,Soft tissue sarcoma,I,Metastatic,0,Complete response,16.98562628,1,Complete response,16.98562628,1,19.05544148,1,11,2,1,1,1,1,80,CYCLE 11 DAY 1,10/2/2019,9.6919918,0,0.87125528
LOXO-TRK-15002-260-001,44,F,White,Y,,12/12/2018,19.05544148,45.1,155,18.77211238,0,Soft tissue sarcoma,I,Metastatic,0,Complete response,16.98562628,1,Complete response,16.98562628,1,19.05544148,1,12,3,1,1,2,1,80,CYCLE 12 DAY 1,11/1/2019,10.677618,0,0.70604342
LOXO-TRK-15002-260-001,44,F,White,Y,,12/12/2018,19.05544148,45.1,155,18.77211238,0,Soft tissue sarcoma,I,Metastatic,0,Complete response,16.98562628,1,Complete response,16.98562628,1,19.05544148,1,13,3,1,1,1,1,70,CYCLE 13 DAY 1,12/2/2019,11.696098,0,0.79772902
LOXO-TRK-15002-260-001,44,F,White,Y,,12/12/2018,19.05544148,45.1,155,18.77211238,0,Soft tissue sarcoma,I,Metastatic,0,Complete response,16.98562628,1,Complete response,16.98562628,1,19.05544148,1,15,3,1,1,1,1,75,CYCLE 15 DAY 1,2/10/2020,13.995893,0,0.79772902
LOXO-TRK-15002-260-001,44,F,White,Y,,12/12/2018,19.05544148,45.1,155,18.77211238,0,Soft tissue sarcoma,I,Metastatic,0,Complete response,16.98562628,1,Complete response,16.98562628,1,19.05544148,1,16,1,1,1,1,1,87,CYCLE 16 DAY 1,3/9/2020,14.915812,0,0.97749591
LOXO-TRK-15002-260-001,44,F,White,Y,,12/12/2018,19.05544148,45.1,155,18.77211238,0,Soft tissue sarcoma,I,Metastatic,0,Complete response,16.98562628,1,Complete response,16.98562628,1,19.05544148,1,17,3,1,1,1,1,80,CYCLE 17 DAY 1,4/3/2020,15.737166,0,0.79772902
LOXO-TRK-15002-260-001,44,F,White,Y,,12/12/2018,19.05544148,45.1,155,18.77211238,0,Soft tissue sarcoma,I,Metastatic,0,Complete response,16.98562628,1,Complete response,16.98562628,1,19.05544148,1,18,3,1,1,2,1,82,CYCLE 18 DAY 1,5/11/2020,16.985626,0,0.70604342
LOXO-TRK-15002-260-001,44,F,White,Y,,12/12/2018,19.05544148,45.1,155,18.77211238,0,Soft tissue sarcoma,I,Metastatic,0,Complete response,16.98562628,1,Complete response,16.98562628,1,19.05544148,1,19,1,1,1,1,1,83,CYCLE 19 DAY 1,6/8/2020,17.905544,0,0.97749591
LOXO-TRK-15002-260-001,44,F,White,Y,,12/12/2018,19.05544148,45.1,155,18.77211238,0,Soft tissue sarcoma,I,Metastatic,0,Complete response,16.98562628,1,Complete response,16.98562628,1,19.05544148,1,20,2,1,1,1,1,87,CYCLE 20 DAY 1,7/13/2020,19.055441,0,0.87125528
LOXO-TRK-15002-260-003,56,F,White,Y,,1/16/2019,17.57700205,52,172,17.57706869,2,Thyroid,IV,Metastatic,7,Partial response,17.57700205,1,Partial response,17.57700205,1,17.57700205,1,0,2,2,3,3,5,15,CYCLE 1 DAY 1,1/16/2019,0,0,0.31844959
LOXO-TRK-15002-260-003,56,F,White,Y,,1/16/2019,17.57700205,52,172,17.57706869,2,Thyroid,IV,Metastatic,7,Partial response,17.57700205,1,Partial response,17.57700205,1,17.57700205,1,3,2,1,1,2,3,60,CYCLE 3 DAY 1,3/15/2019,1.9383984,0,0.70773357
LOXO-TRK-15002-260-003,56,F,White,Y,,1/16/2019,17.57700205,52,172,17.57706869,2,Thyroid,IV,Metastatic,7,Partial response,17.57700205,1,Partial response,17.57700205,1,17.57700205,1,5,1,1,1,2,2,65,CYCLE 5 DAY 1,5/10/2019,3.778234,0,0.78723419
LOXO-TRK-15002-260-003,56,F,White,Y,,1/16/2019,17.57700205,52,172,17.57706869,2,Thyroid,IV,Metastatic,7,Partial response,17.57700205,1,Partial response,17.57700205,1,17.57700205,1,6,1,1,1,2,2,67,CYCLE 6 DAY 1,6/7/2019,4.6981521,0,0.78723419
LOXO-TRK-15002-260-003,56,F,White,Y,,1/16/2019,17.57700205,52,172,17.57706869,2,Thyroid,IV,Metastatic,7,Partial response,17.57700205,1,Partial response,17.57700205,1,17.57700205,1,7,1,1,1,3,2,60,CYCLE 7 DAY 1,7/3/2019,5.5523615,0,0.73022169
LOXO-TRK-15002-260-003,56,F,White,Y,,1/16/2019,17.57700205,52,172,17.57706869,2,Thyroid,IV,Metastatic,7,Partial response,17.57700205,1,Partial response,17.57700205,1,17.57700205,1,8,1,1,1,1,2,65,CYCLE 8 DAY 1,8/2/2019,6.5379877,0,0.89605379
LOXO-TRK-15002-260-003,56,F,White,Y,,1/16/2019,17.57700205,52,172,17.57706869,2,Thyroid,IV,Metastatic,7,Partial response,17.57700205,1,Partial response,17.57700205,1,17.57700205,1,9,1,1,1,2,2,60,CYCLE 9 DAY 1,9/2/2019,7.556468,0,0.78723419
LOXO-TRK-15002-260-003,56,F,White,Y,,1/16/2019,17.57700205,52,172,17.57706869,2,Thyroid,IV,Metastatic,7,Partial response,17.57700205,1,Partial response,17.57700205,1,17.57700205,1,10,1,1,1,2,2,60,CYCLE 10 DAY 1,10/2/2019,8.5420942,0,0.78723419
LOXO-TRK-15002-260-003,56,F,White,Y,,1/16/2019,17.57700205,52,172,17.57706869,2,Thyroid,IV,Metastatic,7,Partial response,17.57700205,1,Partial response,17.57700205,1,17.57700205,1,11,1,1,1,2,2,55,CYCLE 11 DAY 1,11/6/2019,9.6919918,0,0.78723419
LOXO-TRK-15002-260-003,56,F,White,Y,,1/16/2019,17.57700205,52,172,17.57706869,2,Thyroid,IV,Metastatic,7,Partial response,17.57700205,1,Partial response,17.57700205,1,17.57700205,1,12,1,1,1,1,2,65,CYCLE 12 DAY 1,12/9/2019,10.77618,0,0.89605379
LOXO-TRK-15002-260-003,56,F,White,Y,,1/16/2019,17.57700205,52,172,17.57706869,2,Thyroid,IV,Metastatic,7,Partial response,17.57700205,1,Partial response,17.57700205,1,17.57700205,1,13,1,1,1,2,2,65,CYCLE 13 DAY 1,1/8/2020,11.761807,0,0.78723419
LOXO-TRK-15002-260-003,56,F,White,Y,,1/16/2019,17.57700205,52,172,17.57706869,2,Thyroid,IV,Metastatic,7,Partial response,17.57700205,1,Partial response,17.57700205,1,17.57700205,1,14,1,1,1,2,2,65,CYCLE 14 DAY 1,2/3/2020,12.616016,0,0.78723419
LOXO-TRK-15002-260-003,56,F,White,Y,,1/16/2019,17.57700205,52,172,17.57706869,2,Thyroid,IV,Metastatic,7,Partial response,17.57700205,1,Partial response,17.57700205,1,17.57700205,1,15,1,1,1,2,2,63,CYCLE 15 DAY 1,3/9/2020,13.765914,0,0.78723419
LOXO-TRK-15002-260-003,56,F,White,Y,,1/16/2019,17.57700205,52,172,17.57706869,2,Thyroid,IV,Metastatic,7,Partial response,17.57700205,1,Partial response,17.57700205,1,17.57700205,1,16,1,1,1,2,2,50,CYCLE 16 DAY 1,4/6/2020,14.685832,0,0.78723419
LOXO-TRK-15002-260-003,56,F,White,Y,,1/16/2019,17.57700205,52,172,17.57706869,2,Thyroid,IV,Metastatic,7,Partial response,17.57700205,1,Partial response,17.57700205,1,17.57700205,1,17,1,1,1,1,2,70,CYCLE 17 DAY 1,5/4/2020,15.605749,0,0.89605379
LOXO-TRK-15002-260-003,56,F,White,Y,,1/16/2019,17.57700205,52,172,17.57706869,2,Thyroid,IV,Metastatic,7,Partial response,17.57700205,1,Partial response,17.57700205,1,17.57700205,1,18,1,1,1,1,2,70,CYCLE 18 DAY 1,6/3/2020,16.591375,0,0.89605379
LOXO-TRK-15002-260-003,56,F,White,Y,,1/16/2019,17.57700205,52,172,17.57706869,2,Thyroid,IV,Metastatic,7,Partial response,17.57700205,1,Partial response,17.57700205,1,17.57700205,1,19,1,1,1,1,2,65,CYCLE 19 DAY 1,7/3/2020,17.577002,0,0.89605379
LOXO-TRK-15002-260-004,51,M,White,Y,Disease Progression,2/18/2019,5.650924025,65,174,21.46915048,1,Lung,IV,Metastatic,1,Partial response,5.683778234,1,Progressive disease,1.872689938,0,6.50513347,1,0,4,3,4,4,3,30,CYCLE 1 DAY 1,2/18/2019,0,1,0.12360831
LOXO-TRK-15002-260-004,51,M,White,Y,Disease Progression,2/18/2019,5.650924025,65,174,21.46915048,1,Lung,IV,Metastatic,1,Partial response,5.683778234,1,Progressive disease,1.872689938,0,6.50513347,1,3,2,4,3,3,3,40,CYCLE 3 DAY 1,4/15/2019,1.87269,1,0.45645955
LOXO-TRK-15002-260-004,51,M,White,Y,Disease Progression,2/18/2019,5.650924025,65,174,21.46915048,1,Lung,IV,Metastatic,1,Partial response,5.683778234,1,Progressive disease,1.872689938,0,6.50513347,1,5,4,3,2,3,3,30,CYCLE 5 DAY 1,6/14/2019,3.8439424,1,0.3106387
LOXO-TRK-15002-260-004,51,M,White,Y,Disease Progression,2/18/2019,5.650924025,65,174,21.46915048,1,Lung,IV,Metastatic,1,Partial response,5.683778234,1,Progressive disease,1.872689938,0,6.50513347,1,6,4,4,4,5,5,30,CYCLE 6 DAY 1,7/12/2019,4.7638602,1,-0.23209447
LOXO-TRK-15002-260-004,51,M,White,Y,Disease Progression,2/18/2019,5.650924025,65,174,21.46915048,1,Lung,IV,Metastatic,1,Partial response,5.683778234,1,Progressive disease,1.872689938,0,6.50513347,1,7,4,4,4,5,4,35,CYCLE 7 DAY 1,8/9/2019,5.6837783,1,-0.1743241
LOXO-TRK-15002-301-001,77,M,White,Y,Disease Progression,10/10/2017,2.102669405,76.6,182,23.12522642,1,Thyroid,IV,Metastatic,0,Progressive disease,1.872689938,0,Progressive disease,1.872689938,0,14.09445585,0,0,2,1,1,1,1,75,CYCLE 1 DAY 1,10/10/2017,0,1,0.88815212
LOXO-TRK-15002-301-001,77,M,White,Y,Disease Progression,10/10/2017,2.102669405,76.6,182,23.12522642,1,Thyroid,IV,Metastatic,0,Progressive disease,1.872689938,0,Progressive disease,1.872689938,0,14.09445585,0,3,1,1,1,1,1,70,CYCLE 3 DAY 1,12/5/2017,1.87269,1,0.97852576
LOXO-TRK-15002-301-001,77,M,White,Y,Disease Progression,10/10/2017,2.102669405,76.6,182,23.12522642,1,Thyroid,IV,Metastatic,0,Progressive disease,1.872689938,0,Progressive disease,1.872689938,0,14.09445585,0,96,2,1,1,1,1,70,END OF TREATMENT,12/12/2017,2.1026695,1,0.88815212
LOXO-TRK-15002-301-002,31,F,White,Y,Disease Progression,4/26/2018,20.13963039,61.6,163,23.18491475,2,Soft tissue sarcoma,IV,Metastatic,0,Partial response,5.486652977,0,Partial response,9.002053388,0,24.11498973,1,0,3,1,2,3,4,55,CYCLE 1 DAY 1,4/26/2018,0,0,0.52073783
LOXO-TRK-15002-301-002,31,F,White,Y,Disease Progression,4/26/2018,20.13963039,61.6,163,23.18491475,2,Soft tissue sarcoma,IV,Metastatic,0,Partial response,5.486652977,0,Partial response,9.002053388,0,24.11498973,1,2,1,1,1,3,1,80,CYCLE 2 DAY 1,5/22/2018,0.88706368,0,0.76815128
LOXO-TRK-15002-301-002,31,F,White,Y,Disease Progression,4/26/2018,20.13963039,61.6,163,23.18491475,2,Soft tissue sarcoma,IV,Metastatic,0,Partial response,5.486652977,0,Partial response,9.002053388,0,24.11498973,1,3,2,1,1,2,1,80,CYCLE 3 DAY 1,6/19/2018,1.8069816,0,0.77420628
LOXO-TRK-15002-301-002,31,F,White,Y,Disease Progression,4/26/2018,20.13963039,61.6,163,23.18491475,2,Soft tissue sarcoma,IV,Metastatic,0,Partial response,5.486652977,0,Partial response,9.002053388,0,24.11498973,1,4,1,1,1,2,1,80,CYCLE 4 DAY 1,7/17/2018,2.7268994,0,0.8439613
LOXO-TRK-15002-301-002,31,F,White,Y,Disease Progression,4/26/2018,20.13963039,61.6,163,23.18491475,2,Soft tissue sarcoma,IV,Metastatic,0,Partial response,5.486652977,0,Partial response,9.002053388,0,24.11498973,1,5,2,1,1,2,2,75,CYCLE 5 DAY 1,8/14/2018,3.6468172,0,0.7412675
LOXO-TRK-15002-301-002,31,F,White,Y,Disease Progression,4/26/2018,20.13963039,61.6,163,23.18491475,2,Soft tissue sarcoma,IV,Metastatic,0,Partial response,5.486652977,0,Partial response,9.002053388,0,24.11498973,1,6,2,1,1,3,2,70,CYCLE 6 DAY 1,9/11/2018,4.5667353,0,0.68684429
LOXO-TRK-15002-301-002,31,F,White,Y,Disease Progression,4/26/2018,20.13963039,61.6,163,23.18491475,2,Soft tissue sarcoma,IV,Metastatic,0,Partial response,5.486652977,0,Partial response,9.002053388,0,24.11498973,1,7,2,1,1,2,1,60,CYCLE 7 DAY 1,10/9/2018,5.4866529,0,0.77420628
LOXO-TRK-15002-301-002,31,F,White,Y,Disease Progression,4/26/2018,20.13963039,61.6,163,23.18491475,2,Soft tissue sarcoma,IV,Metastatic,0,Partial response,5.486652977,0,Partial response,9.002053388,0,24.11498973,1,8,2,1,1,1,1,80,CYCLE 8 DAY 1,11/6/2018,6.4065709,0,0.87756276
LOXO-TRK-15002-301-002,31,F,White,Y,Disease Progression,4/26/2018,20.13963039,61.6,163,23.18491475,2,Soft tissue sarcoma,IV,Metastatic,0,Partial response,5.486652977,0,Partial response,9.002053388,0,24.11498973,1,9,1,1,1,1,1,80,CYCLE 9 DAY 1,12/4/2018,7.3264885,0,0.9812879
LOXO-TRK-15002-301-002,31,F,White,Y,Disease Progression,4/26/2018,20.13963039,61.6,163,23.18491475,2,Soft tissue sarcoma,IV,Metastatic,0,Partial response,5.486652977,0,Partial response,9.002053388,0,24.11498973,1,10,1,1,1,1,1,70,CYCLE 10 DAY 1,1/2/2019,8.2792606,0,0.9812879
LOXO-TRK-15002-301-002,31,F,White,Y,Disease Progression,4/26/2018,20.13963039,61.6,163,23.18491475,2,Soft tissue sarcoma,IV,Metastatic,0,Partial response,5.486652977,0,Partial response,9.002053388,0,24.11498973,1,11,1,1,1,1,1,80,CYCLE 11 DAY 1,1/29/2019,9.1663246,0,0.9812879
LOXO-TRK-15002-301-002,31,F,White,Y,Disease Progression,4/26/2018,20.13963039,61.6,163,23.18491475,2,Soft tissue sarcoma,IV,Metastatic,0,Partial response,5.486652977,0,Partial response,9.002053388,0,24.11498973,1,13,2,1,1,2,1,75,CYCLE 13 DAY 1,3/26/2019,11.00616,0,0.77420628
LOXO-TRK-15002-301-002,31,F,White,Y,Disease Progression,4/26/2018,20.13963039,61.6,163,23.18491475,2,Soft tissue sarcoma,IV,Metastatic,0,Partial response,5.486652977,0,Partial response,9.002053388,0,24.11498973,1,15,1,1,1,1,1,90,CYCLE 15 DAY 1,5/21/2019,12.845996,0,0.9812879
LOXO-TRK-15002-301-002,31,F,White,Y,Disease Progression,4/26/2018,20.13963039,61.6,163,23.18491475,2,Soft tissue sarcoma,IV,Metastatic,0,Partial response,5.486652977,0,Partial response,9.002053388,0,24.11498973,1,18,1,1,1,2,1,80,CYCLE 18 DAY 1,8/13/2019,15.605749,0,0.8439613
LOXO-TRK-15002-301-002,31,F,White,Y,Disease Progression,4/26/2018,20.13963039,61.6,163,23.18491475,2,Soft tissue sarcoma,IV,Metastatic,0,Partial response,5.486652977,0,Partial response,9.002053388,0,24.11498973,1,21,2,1,1,2,1,70,CYCLE 21 DAY 1,11/6/2019,18.398357,0,0.77420628
LOXO-TRK-15002-301-002,31,F,White,Y,Disease Progression,4/26/2018,20.13963039,61.6,163,23.18491475,2,Soft tissue sarcoma,IV,Metastatic,0,Partial response,5.486652977,0,Partial response,9.002053388,0,24.11498973,1,96,3,1,1,2,2,70,END OF TREATMENT,1/2/2020,20.271048,0,0.69357258
LOXO-TRK-15002-301-003,19,F,White,Y,Disease Progression,8/28/2018,2.792607803,43.6,163,16.410102,1,Soft tissue sarcoma,Not reported,Metastatic,3,Stable disease,2.891170431,0,Stable disease,2.759753593,0,2.891170431,0,0,1,1,2,3,1,70,CYCLE 1 DAY 1,8/28/2018,0,0,0.71890956
LOXO-TRK-15002-301-003,19,F,White,Y,Disease Progression,8/28/2018,2.792607803,43.6,163,16.410102,1,Soft tissue sarcoma,Not reported,Metastatic,3,Stable disease,2.891170431,0,Stable disease,2.759753593,0,2.891170431,0,2,1,1,1,2,1,70,CYCLE 2 DAY 1,9/25/2018,0.95277208,0,0.85920721
LOXO-TRK-15002-301-003,19,F,White,Y,Disease Progression,8/28/2018,2.792607803,43.6,163,16.410102,1,Soft tissue sarcoma,Not reported,Metastatic,3,Stable disease,2.891170431,0,Stable disease,2.759753593,0,2.891170431,0,3,1,1,1,1,1,80,CYCLE 3 DAY 1,10/23/2018,1.87269,0,0.98539162
LOXO-TRK-15002-301-004,61,F,White,Y,,2/19/2019,16.88706366,55.9,159,22.11146711,1,Salivary gland,Not reported,Metastatic,0,Partial response,16.82135524,1,Partial response,16.82135524,1,16.88706366,1,0,1,1,1,3,2,70,CYCLE 1 DAY 1,2/19/2019,0,0,0.7295115
LOXO-TRK-15002-301-004,61,F,White,Y,,2/19/2019,16.88706366,55.9,159,22.11146711,1,Salivary gland,Not reported,Metastatic,0,Partial response,16.82135524,1,Partial response,16.82135524,1,16.88706366,1,3,1,1,1,1,1,80,CYCLE 3 DAY 1,4/16/2019,1.87269,0,0.97476453
LOXO-TRK-15002-301-004,61,F,White,Y,,2/19/2019,16.88706366,55.9,159,22.11146711,1,Salivary gland,Not reported,Metastatic,0,Partial response,16.82135524,1,Partial response,16.82135524,1,16.88706366,1,5,1,1,1,2,1,80,CYCLE 5 DAY 1,6/13/2019,3.778234,0,0.82937807
LOXO-TRK-15002-301-004,61,F,White,Y,,2/19/2019,16.88706366,55.9,159,22.11146711,1,Salivary gland,Not reported,Metastatic,0,Partial response,16.82135524,1,Partial response,16.82135524,1,16.88706366,1,7,1,1,1,2,,90,CYCLE 7 DAY 1,8/8/2019,5.6180696,0,
LOXO-TRK-15002-301-004,61,F,White,Y,,2/19/2019,16.88706366,55.9,159,22.11146711,1,Salivary gland,Not reported,Metastatic,0,Partial response,16.82135524,1,Partial response,16.82135524,1,16.88706366,1,9,1,1,1,1,1,84,CYCLE 9 DAY 1,10/8/2019,7.6221766,0,0.97476453
LOXO-TRK-15002-301-004,61,F,White,Y,,2/19/2019,16.88706366,55.9,159,22.11146711,1,Salivary gland,Not reported,Metastatic,0,Partial response,16.82135524,1,Partial response,16.82135524,1,16.88706366,1,11,1,1,1,2,1,80,CYCLE 11 DAY 1,12/3/2019,9.4620123,0,0.82937807
LOXO-TRK-15002-301-004,61,F,White,Y,,2/19/2019,16.88706366,55.9,159,22.11146711,1,Salivary gland,Not reported,Metastatic,0,Partial response,16.82135524,1,Partial response,16.82135524,1,16.88706366,1,13,1,1,1,2,1,80,CYCLE 13 DAY 1,1/28/2020,11.301848,0,0.82937807
LOXO-TRK-15002-301-004,61,F,White,Y,,2/19/2019,16.88706366,55.9,159,22.11146711,1,Salivary gland,Not reported,Metastatic,0,Partial response,16.82135524,1,Partial response,16.82135524,1,16.88706366,1,16,5,1,1,3,2,80,CYCLE 16 DAY 1,4/23/2020,14.12731,0,0.48872483
LOXO-TRK-15002-301-004,61,F,White,Y,,2/19/2019,16.88706366,55.9,159,22.11146711,1,Salivary gland,Not reported,Metastatic,0,Partial response,16.82135524,1,Partial response,16.82135524,1,16.88706366,1,19,2,1,1,1,1,90,CYCLE 19 DAY 1,7/14/2020,16.821356,0,0.87032318
LOXO-TRK-15002-301-005,52,F,White,Y,Disease Progression,4/23/2019,2.266940452,68.2,170,23.59861592,1,Thyroid,IV,Metastatic,0,Progressive disease,1.642710472,0,Progressive disease,1.642710472,0,3.449691992,0,0,3,1,1,2,2,70,CYCLE 1 DAY 1,4/23/2019,0,0,0.67569512
LOXO-TRK-15002-301-005,52,F,White,Y,Disease Progression,4/23/2019,2.266940452,68.2,170,23.59861592,1,Thyroid,IV,Metastatic,0,Progressive disease,1.642710472,0,Progressive disease,1.642710472,0,3.449691992,0,3,2,2,2,3,3,55,CYCLE 3 DAY 1,6/18/2019,1.87269,0,0.53635317
LOXO-TRK-15002-401-001,47,M,Asian,Y,,5/31/2017,37.25667351,57.7,167,20.6891606,0,Soft tissue sarcoma,II,Metastatic,2,Complete response,35.97535934,1,Partial response,35.97535934,1,37.25667351,1,0,2,1,1,1,1,70,CYCLE 1 DAY 1,5/31/2017,0,1,0.87928718
LOXO-TRK-15002-401-001,47,M,Asian,Y,,5/31/2017,37.25667351,57.7,167,20.6891606,0,Soft tissue sarcoma,II,Metastatic,2,Complete response,35.97535934,1,Partial response,35.97535934,1,37.25667351,1,3,2,1,1,2,1,85,CYCLE 3 DAY 1,7/24/2017,1.8069816,1,0.77330106
LOXO-TRK-15002-401-001,47,M,Asian,Y,,5/31/2017,37.25667351,57.7,167,20.6891606,0,Soft tissue sarcoma,II,Metastatic,2,Complete response,35.97535934,1,Partial response,35.97535934,1,37.25667351,1,5,1,1,1,1,1,90,CYCLE 5 DAY 1,9/18/2017,3.6468172,1,0.98062319
LOXO-TRK-15002-401-001,47,M,Asian,Y,,5/31/2017,37.25667351,57.7,167,20.6891606,0,Soft tissue sarcoma,II,Metastatic,2,Complete response,35.97535934,1,Partial response,35.97535934,1,37.25667351,1,7,1,1,1,1,1,78,CYCLE 7 DAY 1,11/13/2017,5.4866529,1,0.98062319
LOXO-TRK-15002-401-001,47,M,Asian,Y,,5/31/2017,37.25667351,57.7,167,20.6891606,0,Soft tissue sarcoma,II,Metastatic,2,Complete response,35.97535934,1,Partial response,35.97535934,1,37.25667351,1,9,1,1,1,2,1,70,CYCLE 9 DAY 1,1/8/2018,7.3264885,1,0.84327555
LOXO-TRK-15002-401-001,47,M,Asian,Y,,5/31/2017,37.25667351,57.7,167,20.6891606,0,Soft tissue sarcoma,II,Metastatic,2,Complete response,35.97535934,1,Partial response,35.97535934,1,37.25667351,1,11,1,1,2,1,1,80,CYCLE 11 DAY 1,3/5/2018,9.1663246,1,0.90360999
LOXO-TRK-15002-401-001,47,M,Asian,Y,,5/31/2017,37.25667351,57.7,167,20.6891606,0,Soft tissue sarcoma,II,Metastatic,2,Complete response,35.97535934,1,Partial response,35.97535934,1,37.25667351,1,13,1,1,1,1,1,80,CYCLE 13 DAY 1,4/30/2018,11.00616,1,0.98062319
LOXO-TRK-15002-401-001,47,M,Asian,Y,,5/31/2017,37.25667351,57.7,167,20.6891606,0,Soft tissue sarcoma,II,Metastatic,2,Complete response,35.97535934,1,Partial response,35.97535934,1,37.25667351,1,16,1,1,1,1,1,80,CYCLE 16 DAY 1,7/23/2018,13.765914,1,0.98062319
LOXO-TRK-15002-401-001,47,M,Asian,Y,,5/31/2017,37.25667351,57.7,167,20.6891606,0,Soft tissue sarcoma,II,Metastatic,2,Complete response,35.97535934,1,Partial response,35.97535934,1,37.25667351,1,19,1,1,1,1,1,78,CYCLE 19 DAY 1,10/11/2018,16.394251,1,0.98062319
LOXO-TRK-15002-401-001,47,M,Asian,Y,,5/31/2017,37.25667351,57.7,167,20.6891606,0,Soft tissue sarcoma,II,Metastatic,2,Complete response,35.97535934,1,Partial response,35.97535934,1,37.25667351,1,22,1,1,1,1,1,70,CYCLE 22 DAY 1,1/7/2019,19.285421,1,0.98062319
LOXO-TRK-15002-401-001,47,M,Asian,Y,,5/31/2017,37.25667351,57.7,167,20.6891606,0,Soft tissue sarcoma,II,Metastatic,2,Complete response,35.97535934,1,Partial response,35.97535934,1,37.25667351,1,25,1,1,1,1,1,80,CYCLE 25 DAY 1,4/1/2019,22.045174,1,0.98062319
LOXO-TRK-15002-401-001,47,M,Asian,Y,,5/31/2017,37.25667351,57.7,167,20.6891606,0,Soft tissue sarcoma,II,Metastatic,2,Complete response,35.97535934,1,Partial response,35.97535934,1,37.25667351,1,28,2,1,1,1,2,65,CYCLE 28 DAY 1,6/24/2019,24.804928,1,0.83162433
LOXO-TRK-15002-401-001,47,M,Asian,Y,,5/31/2017,37.25667351,57.7,167,20.6891606,0,Soft tissue sarcoma,II,Metastatic,2,Complete response,35.97535934,1,Partial response,35.97535934,1,37.25667351,1,31,1,1,1,1,1,85,CYCLE 31 DAY 1,9/17/2019,27.597536,1,0.98062319
LOXO-TRK-15002-401-001,47,M,Asian,Y,,5/31/2017,37.25667351,57.7,167,20.6891606,0,Soft tissue sarcoma,II,Metastatic,2,Complete response,35.97535934,1,Partial response,35.97535934,1,37.25667351,1,34,2,1,1,1,1,81,CYCLE 34 DAY 1,12/6/2019,30.225872,1,0.87928718
LOXO-TRK-15002-401-001,47,M,Asian,Y,,5/31/2017,37.25667351,57.7,167,20.6891606,0,Soft tissue sarcoma,II,Metastatic,2,Complete response,35.97535934,1,Partial response,35.97535934,1,37.25667351,1,37,1,1,1,1,1,78,CYCLE 37 DAY 1,3/3/2020,33.117043,1,0.98062319
LOXO-TRK-15002-401-001,47,M,Asian,Y,,5/31/2017,37.25667351,57.7,167,20.6891606,0,Soft tissue sarcoma,II,Metastatic,2,Complete response,35.97535934,1,Partial response,35.97535934,1,37.25667351,1,40,1,1,1,1,1,78,CYCLE 40 DAY 1,6/2/2020,36.106777,1,0.98062319
LOXO-TRK-15002-401-002,47,F,Asian,Y,Disease Progression,6/13/2018,6.833675565,46.5,161,17.93912272,1,Soft tissue sarcoma,IV,Metastatic,5,Progressive disease,1.80698152,0,Stable disease,6.833675565,0,20.82956879,0,0,1,1,2,2,2,75,CYCLE 1 DAY 1,6/13/2018,0,0,0.73413754
LOXO-TRK-15002-401-002,47,F,Asian,Y,Disease Progression,6/13/2018,6.833675565,46.5,161,17.93912272,1,Soft tissue sarcoma,IV,Metastatic,5,Progressive disease,1.80698152,0,Stable disease,6.833675565,0,20.82956879,0,3,1,1,1,2,2,80,CYCLE 3 DAY 1,8/8/2018,1.87269,0,0.78866786
LOXO-TRK-15002-401-002,47,F,Asian,Y,Disease Progression,6/13/2018,6.833675565,46.5,161,17.93912272,1,Soft tissue sarcoma,IV,Metastatic,5,Progressive disease,1.80698152,0,Stable disease,6.833675565,0,20.82956879,0,5,1,1,1,2,1,80,CYCLE 5 DAY 1,10/3/2018,3.7125256,0,0.83313304
LOXO-TRK-15002-401-002,47,F,Asian,Y,Disease Progression,6/13/2018,6.833675565,46.5,161,17.93912272,1,Soft tissue sarcoma,IV,Metastatic,5,Progressive disease,1.80698152,0,Stable disease,6.833675565,0,20.82956879,0,7,1,1,2,2,2,75,CYCLE 7 DAY 1,11/28/2018,5.5523615,0,0.73413754
LOXO-TRK-15002-401-003,33,M,Asian,Y,Disease Progression,1/7/2019,0.919917865,46.7,164,17.36317668,2,Soft tissue sarcoma,IV,Metastatic,1,Progressive disease,1.084188912,0,Progressive disease,1.149897331,0,2.036960986,1,0,1,2,3,3,2,50,CYCLE 1 DAY 1,1/7/2019,0,1,0.5777424
LOXO-TRK-15002-401-003,33,M,Asian,Y,Disease Progression,1/7/2019,0.919917865,46.7,164,17.36317668,2,Soft tissue sarcoma,IV,Metastatic,1,Progressive disease,1.084188912,0,Progressive disease,1.149897331,0,2.036960986,1,96,3,4,5,3,5,30,END OF TREATMENT,2/8/2019,1.0841889,1,0.016080933
LOXO-TRK-15002-401-008,64,M,Asian,Y,,3/4/2019,16.22997947,74.2,169,25.97948251,1,Lung,IV,Metastatic,3,Partial response,14.12731006,1,Partial response,14.12731006,1,16.22997947,1,0,1,1,1,1,1,60,CYCLE 1 DAY 1,3/4/2019,0,1,0.9785378
LOXO-TRK-15002-401-008,64,M,Asian,Y,,3/4/2019,16.22997947,74.2,169,25.97948251,1,Lung,IV,Metastatic,3,Partial response,14.12731006,1,Partial response,14.12731006,1,16.22997947,1,3,1,1,1,2,2,60,CYCLE 3 DAY 1,5/2/2019,1.9712526,1,0.79072016
LOXO-TRK-15002-401-008,64,M,Asian,Y,,3/4/2019,16.22997947,74.2,169,25.97948251,1,Lung,IV,Metastatic,3,Partial response,14.12731006,1,Partial response,14.12731006,1,16.22997947,1,5,1,1,1,3,2,50,CYCLE 5 DAY 1,6/26/2019,3.778234,1,0.72907674
LOXO-TRK-15002-401-008,64,M,Asian,Y,,3/4/2019,16.22997947,74.2,169,25.97948251,1,Lung,IV,Metastatic,3,Partial response,14.12731006,1,Partial response,14.12731006,1,16.22997947,1,7,1,1,1,2,1,80,CYCLE 7 DAY 1,8/28/2019,5.8480492,1,0.83854216
LOXO-TRK-15002-401-008,64,M,Asian,Y,,3/4/2019,16.22997947,74.2,169,25.97948251,1,Lung,IV,Metastatic,3,Partial response,14.12731006,1,Partial response,14.12731006,1,16.22997947,1,9,1,1,1,2,1,50,CYCLE 9 DAY 1,10/23/2019,7.6878848,1,0.83854216
LOXO-TRK-15002-401-008,64,M,Asian,Y,,3/4/2019,16.22997947,74.2,169,25.97948251,1,Lung,IV,Metastatic,3,Partial response,14.12731006,1,Partial response,14.12731006,1,16.22997947,1,11,1,1,1,1,1,90,CYCLE 11 DAY 1,12/11/2019,9.2977409,1,0.9785378
LOXO-TRK-15002-401-008,64,M,Asian,Y,,3/4/2019,16.22997947,74.2,169,25.97948251,1,Lung,IV,Metastatic,3,Partial response,14.12731006,1,Partial response,14.12731006,1,16.22997947,1,13,1,1,1,1,1,80,CYCLE 13 DAY 1,2/12/2020,11.367557,1,0.9785378
LOXO-TRK-15002-401-008,64,M,Asian,Y,,3/4/2019,16.22997947,74.2,169,25.97948251,1,Lung,IV,Metastatic,3,Partial response,14.12731006,1,Partial response,14.12731006,1,16.22997947,1,16,1,1,1,2,1,60,CYCLE 16 DAY 1,5/15/2020,14.422997,1,0.83854216
LOXO-TRK-15002-401-009,60,F,Asian,Y,Disease Progression,2/28/2019,5.716632444,43.9,152,19.00103878,2,Soft tissue sarcoma,III,Locally advanced,1,Stable disease,3.613963039,0,Complete response,3.613963039,0,9.757700205,0,0,2,1,2,3,2,70,CYCLE 1 DAY 1,2/28/2019,0,0,0.62595493
LOXO-TRK-15002-401-009,60,F,Asian,Y,Disease Progression,2/28/2019,5.716632444,43.9,152,19.00103878,2,Soft tissue sarcoma,III,Locally advanced,1,Stable disease,3.613963039,0,Complete response,3.613963039,0,9.757700205,0,3,1,1,1,1,1,100,CYCLE 3 DAY 1,4/24/2019,1.8398358,0,0.97483528
LOXO-TRK-15002-401-009,60,F,Asian,Y,Disease Progression,2/28/2019,5.716632444,43.9,152,19.00103878,2,Soft tissue sarcoma,III,Locally advanced,1,Stable disease,3.613963039,0,Complete response,3.613963039,0,9.757700205,0,5,1,1,2,2,1,100,CYCLE 5 DAY 1,6/19/2019,3.6796715,0,0.77340704
LOXO-TRK-15002-401-009,60,F,Asian,Y,Disease Progression,2/28/2019,5.716632444,43.9,152,19.00103878,2,Soft tissue sarcoma,III,Locally advanced,1,Stable disease,3.613963039,0,Complete response,3.613963039,0,9.757700205,0,7,1,1,2,3,1,70,CYCLE 7 DAY 1,8/14/2019,5.5195074,0,0.71092391
LOXO-TRK-15002-401-010,46,M,Asian,Y,Disease Progression,3/6/2019,14.55441478,77.9,172,26.33180097,1,Soft tissue sarcoma,Not reported,Metastatic,2,Stable disease,13.73305955,1,Stable disease,13.73305955,0,15.14579055,1,0,2,1,1,2,1,80,CYCLE 1 DAY 1,3/6/2019,0,1,0.77377021
LOXO-TRK-15002-401-010,46,M,Asian,Y,Disease Progression,3/6/2019,14.55441478,77.9,172,26.33180097,1,Soft tissue sarcoma,Not reported,Metastatic,2,Stable disease,13.73305955,1,Stable disease,13.73305955,0,15.14579055,1,3,1,1,1,1,1,90,CYCLE 3 DAY 1,4/30/2019,1.8398358,1,0.98082018
LOXO-TRK-15002-401-010,46,M,Asian,Y,Disease Progression,3/6/2019,14.55441478,77.9,172,26.33180097,1,Soft tissue sarcoma,Not reported,Metastatic,2,Stable disease,13.73305955,1,Stable disease,13.73305955,0,15.14579055,1,5,1,1,1,1,1,90,CYCLE 5 DAY 1,6/26/2019,3.7125256,1,0.98082018
LOXO-TRK-15002-401-010,46,M,Asian,Y,Disease Progression,3/6/2019,14.55441478,77.9,172,26.33180097,1,Soft tissue sarcoma,Not reported,Metastatic,2,Stable disease,13.73305955,1,Stable disease,13.73305955,0,15.14579055,1,7,1,1,1,1,1,95,CYCLE 7 DAY 1,8/21/2019,5.5523615,1,0.98082018
LOXO-TRK-15002-401-010,46,M,Asian,Y,Disease Progression,3/6/2019,14.55441478,77.9,172,26.33180097,1,Soft tissue sarcoma,Not reported,Metastatic,2,Stable disease,13.73305955,1,Stable disease,13.73305955,0,15.14579055,1,9,1,1,1,1,1,95,CYCLE 9 DAY 1,10/16/2019,7.3921971,1,0.98082018
LOXO-TRK-15002-401-010,46,M,Asian,Y,Disease Progression,3/6/2019,14.55441478,77.9,172,26.33180097,1,Soft tissue sarcoma,Not reported,Metastatic,2,Stable disease,13.73305955,1,Stable disease,13.73305955,0,15.14579055,1,11,1,1,1,1,1,95,CYCLE 11 DAY 1,12/11/2019,9.2320328,1,0.98082018
LOXO-TRK-15002-401-010,46,M,Asian,Y,Disease Progression,3/6/2019,14.55441478,77.9,172,26.33180097,1,Soft tissue sarcoma,Not reported,Metastatic,2,Stable disease,13.73305955,1,Stable disease,13.73305955,0,15.14579055,1,13,1,1,1,1,1,95,CYCLE 13 DAY 1,2/6/2020,11.104723,1,0.98082018
LOXO-TRK-15002-401-010,46,M,Asian,Y,Disease Progression,3/6/2019,14.55441478,77.9,172,26.33180097,1,Soft tissue sarcoma,Not reported,Metastatic,2,Stable disease,13.73305955,1,Stable disease,13.73305955,0,15.14579055,1,16,1,1,1,1,1,85,CYCLE 16 DAY 1,4/30/2020,13.864476,1,0.98082018
LOXO-TRK-15002-401-010,46,M,Asian,Y,Disease Progression,3/6/2019,14.55441478,77.9,172,26.33180097,1,Soft tissue sarcoma,Not reported,Metastatic,2,Stable disease,13.73305955,1,Stable disease,13.73305955,0,15.14579055,1,96,1,1,1,3,1,75,END OF TREATMENT,6/3/2020,14.98152,1,0.76779431
LOXO-TRK-15002-401-011,38,F,Asian,Y,,10/2/2019,9.264887064,71.1,165,26.11570248,1,Lung,IV,Metastatic,2,Partial response,7.227926078,0,Partial response,5.32238193,0,9.264887064,1,0,2,1,2,2,1,85,CYCLE 1 DAY 1,10/2/2019,0,0,0.72632891
LOXO-TRK-15002-401-011,38,F,Asian,Y,,10/2/2019,9.264887064,71.1,165,26.11570248,1,Lung,IV,Metastatic,2,Partial response,7.227926078,0,Partial response,5.32238193,0,9.264887064,1,3,2,1,1,2,1,90,CYCLE 3 DAY 1,11/27/2019,1.87269,0,0.76886815
LOXO-TRK-15002-401-011,38,F,Asian,Y,,10/2/2019,9.264887064,71.1,165,26.11570248,1,Lung,IV,Metastatic,2,Partial response,7.227926078,0,Partial response,5.32238193,0,9.264887064,1,5,1,1,1,2,1,85,CYCLE 5 DAY 1,1/15/2020,3.4825461,0,0.83814108
LOXO-TRK-15002-401-011,38,F,Asian,Y,,10/2/2019,9.264887064,71.1,165,26.11570248,1,Lung,IV,Metastatic,2,Partial response,7.227926078,0,Partial response,5.32238193,0,9.264887064,1,7,1,1,1,1,1,90,CYCLE 7 DAY 1,3/19/2020,5.5852156,0,0.97910893
LOXO-TRK-15002-401-011,38,F,Asian,Y,,10/2/2019,9.264887064,71.1,165,26.11570248,1,Lung,IV,Metastatic,2,Partial response,7.227926078,0,Partial response,5.32238193,0,9.264887064,1,9,1,1,1,2,1,95,CYCLE 9 DAY 1,5/14/2020,7.4250512,0,0.83814108
LOXO-TRK-15002-401-011,38,F,Asian,Y,,10/2/2019,9.264887064,71.1,165,26.11570248,1,Lung,IV,Metastatic,2,Partial response,7.227926078,0,Partial response,5.32238193,0,9.264887064,1,11,2,1,1,2,1,85,CYCLE 11 DAY 1,7/9/2020,9.2648869,0,0.76886815
LOXO-TRK-15002-501-001,56,F,White,Y,,12/31/2018,18.52977413,71,166,25.76571346,0,Breast,II,Locally advanced,0,Complete response,16.59137577,1,Complete response,16.59137577,1,18.52977413,1,0,3,1,1,2,1,50,CYCLE 1 DAY 1,12/31/2018,0,0,0.70220548
LOXO-TRK-15002-501-001,56,F,White,Y,,12/31/2018,18.52977413,71,166,25.76571346,0,Breast,II,Locally advanced,0,Complete response,16.59137577,1,Complete response,16.59137577,1,18.52977413,1,3,2,1,1,2,1,70,CYCLE 3 DAY 1,2/26/2019,1.9055442,0,0.76187265
LOXO-TRK-15002-501-001,56,F,White,Y,,12/31/2018,18.52977413,71,166,25.76571346,0,Breast,II,Locally advanced,0,Complete response,16.59137577,1,Complete response,16.59137577,1,18.52977413,1,4,4,1,1,2,1,65,CYCLE 4 DAY 1,3/25/2019,2.7926078,0,0.63933921
LOXO-TRK-15002-501-001,56,F,White,Y,,12/31/2018,18.52977413,71,166,25.76571346,0,Breast,II,Locally advanced,0,Complete response,16.59137577,1,Complete response,16.59137577,1,18.52977413,1,5,3,1,1,2,1,75,CYCLE 5 DAY 1,4/23/2019,3.7453799,0,0.70220548
LOXO-TRK-15002-501-001,56,F,White,Y,,12/31/2018,18.52977413,71,166,25.76571346,0,Breast,II,Locally advanced,0,Complete response,16.59137577,1,Complete response,16.59137577,1,18.52977413,1,7,3,1,1,1,1,75,CYCLE 7 DAY 1,6/18/2019,5.5852156,0,0.79733402
LOXO-TRK-15002-501-001,56,F,White,Y,,12/31/2018,18.52977413,71,166,25.76571346,0,Breast,II,Locally advanced,0,Complete response,16.59137577,1,Complete response,16.59137577,1,18.52977413,1,8,3,1,1,2,1,75,CYCLE 8 DAY 1,7/15/2019,6.4722791,0,0.70220548
LOXO-TRK-15002-501-001,56,F,White,Y,,12/31/2018,18.52977413,71,166,25.76571346,0,Breast,II,Locally advanced,0,Complete response,16.59137577,1,Complete response,16.59137577,1,18.52977413,1,9,2,1,1,1,1,80,CYCLE 9 DAY 1,8/13/2019,7.4250512,0,0.86967099
LOXO-TRK-15002-501-001,56,F,White,Y,,12/31/2018,18.52977413,71,166,25.76571346,0,Breast,II,Locally advanced,0,Complete response,16.59137577,1,Complete response,16.59137577,1,18.52977413,1,10,2,1,1,2,1,75,CYCLE 10 DAY 1,9/9/2019,8.3121147,0,0.76187265
LOXO-TRK-15002-501-001,56,F,White,Y,,12/31/2018,18.52977413,71,166,25.76571346,0,Breast,II,Locally advanced,0,Complete response,16.59137577,1,Complete response,16.59137577,1,18.52977413,1,11,3,1,1,2,1,75,CYCLE 11 DAY 1,10/8/2019,9.2648869,0,0.70220548
LOXO-TRK-15002-501-001,56,F,White,Y,,12/31/2018,18.52977413,71,166,25.76571346,0,Breast,II,Locally advanced,0,Complete response,16.59137577,1,Complete response,16.59137577,1,18.52977413,1,12,2,1,1,1,1,70,CYCLE 12 DAY 1,11/4/2019,10.151951,0,0.86967099
LOXO-TRK-15002-501-001,56,F,White,Y,,12/31/2018,18.52977413,71,166,25.76571346,0,Breast,II,Locally advanced,0,Complete response,16.59137577,1,Complete response,16.59137577,1,18.52977413,1,14,2,1,1,2,1,65,CYCLE 14 DAY 1,12/31/2019,12.024641,0,0.76187265
LOXO-TRK-15002-501-001,56,F,White,Y,,12/31/2018,18.52977413,71,166,25.76571346,0,Breast,II,Locally advanced,0,Complete response,16.59137577,1,Complete response,16.59137577,1,18.52977413,1,16,2,1,1,2,1,75,CYCLE 16 DAY 1,2/25/2020,13.864476,0,0.76187265
LOXO-TRK-15002-501-001,56,F,White,Y,,12/31/2018,18.52977413,71,166,25.76571346,0,Breast,II,Locally advanced,0,Complete response,16.59137577,1,Complete response,16.59137577,1,18.52977413,1,19,2,1,2,2,2,60,CYCLE 19 DAY 1,5/19/2020,16.624229,0,0.67720455
LOXO-TRK-15002-501-003,65,F,White,Y,Disease Progression,4/16/2019,7.392197125,55,159,21.75546853,1,Breast,Not reported,Metastatic,0,Stable disease,3.679671458,0,Stable disease,3.679671458,0,12.97741273,1,0,4,1,3,4,4,45,CYCLE 1 DAY 1,4/16/2019,0,0,0.17228697
LOXO-TRK-15002-501-003,65,F,White,Y,Disease Progression,4/16/2019,7.392197125,55,159,21.75546853,1,Breast,Not reported,Metastatic,0,Stable disease,3.679671458,0,Stable disease,3.679671458,0,12.97741273,1,3,1,1,1,1,1,80,CYCLE 3 DAY 1,6/13/2019,1.9383984,0,0.97464341
LOXO-TRK-15002-501-003,65,F,White,Y,Disease Progression,4/16/2019,7.392197125,55,159,21.75546853,1,Breast,Not reported,Metastatic,0,Stable disease,3.679671458,0,Stable disease,3.679671458,0,12.97741273,1,4,1,1,1,2,1,80,CYCLE 4 DAY 1,7/10/2019,2.8254621,0,0.82901812
LOXO-TRK-15002-501-003,65,F,White,Y,Disease Progression,4/16/2019,7.392197125,55,159,21.75546853,1,Breast,Not reported,Metastatic,0,Stable disease,3.679671458,0,Stable disease,3.679671458,0,12.97741273,1,6,1,1,1,1,1,85,CYCLE 6 DAY 1,9/3/2019,4.6324434,0,0.97464341
LOXO-TRK-15002-501-003,65,F,White,Y,Disease Progression,4/16/2019,7.392197125,55,159,21.75546853,1,Breast,Not reported,Metastatic,0,Stable disease,3.679671458,0,Stable disease,3.679671458,0,12.97741273,1,7,1,1,1,1,1,90,CYCLE 7 DAY 1,10/2/2019,5.5852156,0,0.97464341
LOXO-TRK-15002-501-003,65,F,White,Y,Disease Progression,4/16/2019,7.392197125,55,159,21.75546853,1,Breast,Not reported,Metastatic,0,Stable disease,3.679671458,0,Stable disease,3.679671458,0,12.97741273,1,8,2,1,1,1,1,90,CYCLE 8 DAY 1,10/29/2019,6.4722791,0,0.87153327
LOXO-TRK-15002-501-003,65,F,White,Y,Disease Progression,4/16/2019,7.392197125,55,159,21.75546853,1,Breast,Not reported,Metastatic,0,Stable disease,3.679671458,0,Stable disease,3.679671458,0,12.97741273,1,96,1,1,1,1,1,90,END OF TREATMENT,11/27/2019,7.4250512,0,0.97464341
LOXO-TRK-15002-702-001,32,F,White,Y,Disease Progression,12/29/2016,0.919917865,89.6,168,31.74603175,0,Cholangiocarcinoma,IV,Metastatic,3,Not evaluable,1.839835729,0,Progressive disease,0.985626283,0,1.839835729,0,-1,2,1,1,1,2,72,SCREENING,12/21/2016,0,0,0.83268559
LOXO-TRK-15002-702-001,32,F,White,Y,Disease Progression,12/29/2016,0.919917865,89.6,168,31.74603175,0,Cholangiocarcinoma,IV,Metastatic,3,Not evaluable,1.839835729,0,Progressive disease,0.985626283,0,1.839835729,0,2,2,1,1,1,2,75,CYCLE 2 DAY 1,1/26/2017,0.95277208,0,0.83268559
LOXO-TRK-15002-702-003,49,F,White,Y,,8/14/2019,11.10472279,67.2,165,24.68319559,0,Breast,II,Metastatic,6,Complete response,11.00616016,1,Partial response,6.406570842,0,11.10472279,1,0,3,1,1,2,2,60,CYCLE 1 DAY 1,8/14/2019,0,0,0.67749929
LOXO-TRK-15002-702-003,49,F,White,Y,,8/14/2019,11.10472279,67.2,165,24.68319559,0,Breast,II,Metastatic,6,Complete response,11.00616016,1,Partial response,6.406570842,0,11.10472279,1,1,1,1,2,3,1,60,CYCLE 1 DAY 8,8/21/2019,0.26283368,0,0.71298563
LOXO-TRK-15002-702-003,49,F,White,Y,,8/14/2019,11.10472279,67.2,165,24.68319559,0,Breast,II,Metastatic,6,Complete response,11.00616016,1,Partial response,6.406570842,0,11.10472279,1,2,1,1,1,3,3,70,CYCLE 2 DAY 1,9/11/2019,0.95277208,0,0.71049345
LOXO-TRK-15002-702-003,49,F,White,Y,,8/14/2019,11.10472279,67.2,165,24.68319559,0,Breast,II,Metastatic,6,Complete response,11.00616016,1,Partial response,6.406570842,0,11.10472279,1,3,2,1,2,2,2,55,CYCLE 3 DAY 1,10/14/2019,2.0369611,0,0.6801542
LOXO-TRK-15002-702-003,49,F,White,Y,,8/14/2019,11.10472279,67.2,165,24.68319559,0,Breast,II,Metastatic,6,Complete response,11.00616016,1,Partial response,6.406570842,0,11.10472279,1,4,1,1,1,2,1,75,CYCLE 4 DAY 1,11/11/2019,2.9568789,0,0.8323648
LOXO-TRK-15002-702-003,49,F,White,Y,,8/14/2019,11.10472279,67.2,165,24.68319559,0,Breast,II,Metastatic,6,Complete response,11.00616016,1,Partial response,6.406570842,0,11.10472279,1,7,1,1,1,2,1,70,CYCLE 7 DAY 1,2/5/2020,5.782341,0,0.8323648
LOXO-TRK-15002-702-003,49,F,White,Y,,8/14/2019,11.10472279,67.2,165,24.68319559,0,Breast,II,Metastatic,6,Complete response,11.00616016,1,Partial response,6.406570842,0,11.10472279,1,8,3,1,1,1,2,70,CYCLE 8 DAY 1,2/27/2020,6.5051336,0,0.76038498
LOXO-TRK-15002-702-003,49,F,White,Y,,8/14/2019,11.10472279,67.2,165,24.68319559,0,Breast,II,Metastatic,6,Complete response,11.00616016,1,Partial response,6.406570842,0,11.10472279,1,9,1,1,1,2,1,70,CYCLE 9 DAY 1,3/26/2020,7.4250512,0,0.8323648
LOXO-TRK-15002-702-003,49,F,White,Y,,8/14/2019,11.10472279,67.2,165,24.68319559,0,Breast,II,Metastatic,6,Complete response,11.00616016,1,Partial response,6.406570842,0,11.10472279,1,11,1,1,1,2,1,70,CYCLE 11 DAY 1,5/21/2020,9.2648869,0,0.8323648
LOXO-TRK-15002-702-003,49,F,White,Y,,8/14/2019,11.10472279,67.2,165,24.68319559,0,Breast,II,Metastatic,6,Complete response,11.00616016,1,Partial response,6.406570842,0,11.10472279,1,13,1,1,2,3,2,70,CYCLE 13 DAY 1,7/16/2020,11.104723,0,0.68008983
LOXO-TRK-15002-703-001,46,M,White,Y,,10/20/2017,32.22997947,93.7,174,30.94860616,0,Lung,IV,Metastatic,2,Partial response,27.56468173,1,Partial response,30.32443532,1,32.22997947,1,0,1,1,1,1,3,65,CYCLE 1 DAY 1,10/20/2017,0,1,0.86747533
LOXO-TRK-15002-703-001,46,M,White,Y,,10/20/2017,32.22997947,93.7,174,30.94860616,0,Lung,IV,Metastatic,2,Partial response,27.56468173,1,Partial response,30.32443532,1,32.22997947,1,3,1,1,1,1,1,90,CYCLE 3 DAY 1,12/18/2017,1.9712526,1,0.98082018
LOXO-TRK-15002-703-001,46,M,White,Y,,10/20/2017,32.22997947,93.7,174,30.94860616,0,Lung,IV,Metastatic,2,Partial response,27.56468173,1,Partial response,30.32443532,1,32.22997947,1,5,1,1,1,1,1,85,CYCLE 5 DAY 1,2/9/2018,3.7125256,1,0.98082018
LOXO-TRK-15002-703-001,46,M,White,Y,,10/20/2017,32.22997947,93.7,174,30.94860616,0,Lung,IV,Metastatic,2,Partial response,27.56468173,1,Partial response,30.32443532,1,32.22997947,1,7,1,1,1,1,1,80,CYCLE 7 DAY 1,4/6/2018,5.5523615,1,0.98082018
LOXO-TRK-15002-703-001,46,M,White,Y,,10/20/2017,32.22997947,93.7,174,30.94860616,0,Lung,IV,Metastatic,2,Partial response,27.56468173,1,Partial response,30.32443532,1,32.22997947,1,9,1,1,1,1,1,75,CYCLE 9 DAY 1,6/8/2018,7.6221766,1,0.98082018
LOXO-TRK-15002-703-001,46,M,White,Y,,10/20/2017,32.22997947,93.7,174,30.94860616,0,Lung,IV,Metastatic,2,Partial response,27.56468173,1,Partial response,30.32443532,1,32.22997947,1,11,1,1,1,1,1,80,CYCLE 11 DAY 1,7/27/2018,9.2320328,1,0.98082018
LOXO-TRK-15002-703-001,46,M,White,Y,,10/20/2017,32.22997947,93.7,174,30.94860616,0,Lung,IV,Metastatic,2,Partial response,27.56468173,1,Partial response,30.32443532,1,32.22997947,1,13,1,1,1,1,1,80,CYCLE 13 DAY 1,9/21/2018,11.071869,1,0.98082018
LOXO-TRK-15002-703-001,46,M,White,Y,,10/20/2017,32.22997947,93.7,174,30.94860616,0,Lung,IV,Metastatic,2,Partial response,27.56468173,1,Partial response,30.32443532,1,32.22997947,1,16,1,1,1,1,1,80,CYCLE 16 DAY 1,12/14/2018,13.831622,1,0.98082018
LOXO-TRK-15002-703-001,46,M,White,Y,,10/20/2017,32.22997947,93.7,174,30.94860616,0,Lung,IV,Metastatic,2,Partial response,27.56468173,1,Partial response,30.32443532,1,32.22997947,1,19,1,1,1,1,1,80,CYCLE 19 DAY 1,3/8/2019,16.591375,1,0.98082018
LOXO-TRK-15002-703-001,46,M,White,Y,,10/20/2017,32.22997947,93.7,174,30.94860616,0,Lung,IV,Metastatic,2,Partial response,27.56468173,1,Partial response,30.32443532,1,32.22997947,1,20,1,1,1,1,1,75,CYCLE 20 DAY 1,4/5/2019,17.511293,1,0.98082018
LOXO-TRK-15002-703-001,46,M,White,Y,,10/20/2017,32.22997947,93.7,174,30.94860616,0,Lung,IV,Metastatic,2,Partial response,27.56468173,1,Partial response,30.32443532,1,32.22997947,1,21,1,1,1,1,1,80,CYCLE 21 DAY 1,5/3/2019,18.431211,1,0.98082018
LOXO-TRK-15002-703-001,46,M,White,Y,,10/20/2017,32.22997947,93.7,174,30.94860616,0,Lung,IV,Metastatic,2,Partial response,27.56468173,1,Partial response,30.32443532,1,32.22997947,1,22,1,1,1,1,1,80,CYCLE 22 DAY 1,5/31/2019,19.35113,1,0.98082018
LOXO-TRK-15002-703-001,46,M,White,Y,,10/20/2017,32.22997947,93.7,174,30.94860616,0,Lung,IV,Metastatic,2,Partial response,27.56468173,1,Partial response,30.32443532,1,32.22997947,1,23,1,1,1,1,1,80,CYCLE 23 DAY 1,6/28/2019,20.271048,1,0.98082018
LOXO-TRK-15002-703-001,46,M,White,Y,,10/20/2017,32.22997947,93.7,174,30.94860616,0,Lung,IV,Metastatic,2,Partial response,27.56468173,1,Partial response,30.32443532,1,32.22997947,1,24,1,1,1,1,1,85,CYCLE 24 DAY 1,7/26/2019,21.190966,1,0.98082018
LOXO-TRK-15002-703-001,46,M,White,Y,,10/20/2017,32.22997947,93.7,174,30.94860616,0,Lung,IV,Metastatic,2,Partial response,27.56468173,1,Partial response,30.32443532,1,32.22997947,1,25,1,1,1,1,1,85,CYCLE 25 DAY 1,8/23/2019,22.110884,1,0.98082018
LOXO-TRK-15002-703-001,46,M,White,Y,,10/20/2017,32.22997947,93.7,174,30.94860616,0,Lung,IV,Metastatic,2,Partial response,27.56468173,1,Partial response,30.32443532,1,32.22997947,1,26,1,1,1,1,1,85,CYCLE 26 DAY 1,9/20/2019,23.030802,1,0.98082018
LOXO-TRK-15002-703-001,46,M,White,Y,,10/20/2017,32.22997947,93.7,174,30.94860616,0,Lung,IV,Metastatic,2,Partial response,27.56468173,1,Partial response,30.32443532,1,32.22997947,1,27,1,1,1,1,1,85,CYCLE 27 DAY 1,10/18/2019,23.950718,1,0.98082018
LOXO-TRK-15002-703-001,46,M,White,Y,,10/20/2017,32.22997947,93.7,174,30.94860616,0,Lung,IV,Metastatic,2,Partial response,27.56468173,1,Partial response,30.32443532,1,32.22997947,1,28,1,1,1,1,1,85,CYCLE 28 DAY 1,11/15/2019,24.870636,1,0.98082018
LOXO-TRK-15002-703-001,46,M,White,Y,,10/20/2017,32.22997947,93.7,174,30.94860616,0,Lung,IV,Metastatic,2,Partial response,27.56468173,1,Partial response,30.32443532,1,32.22997947,1,29,1,1,1,1,1,85,CYCLE 29 DAY 1,12/13/2019,25.790554,1,0.98082018
LOXO-TRK-15002-703-001,46,M,White,Y,,10/20/2017,32.22997947,93.7,174,30.94860616,0,Lung,IV,Metastatic,2,Partial response,27.56468173,1,Partial response,30.32443532,1,32.22997947,1,30,1,1,1,1,1,80,CYCLE 30 DAY 1,1/10/2020,26.710472,1,0.98082018
LOXO-TRK-15002-703-001,46,M,White,Y,,10/20/2017,32.22997947,93.7,174,30.94860616,0,Lung,IV,Metastatic,2,Partial response,27.56468173,1,Partial response,30.32443532,1,32.22997947,1,31,1,1,1,1,1,85,CYCLE 31 DAY 1,2/7/2020,27.63039,1,0.98082018
LOXO-TRK-15002-703-001,46,M,White,Y,,10/20/2017,32.22997947,93.7,174,30.94860616,0,Lung,IV,Metastatic,2,Partial response,27.56468173,1,Partial response,30.32443532,1,32.22997947,1,32,1,1,1,1,1,85,CYCLE 32 DAY 1,3/6/2020,28.550308,1,0.98082018
LOXO-TRK-15002-703-001,46,M,White,Y,,10/20/2017,32.22997947,93.7,174,30.94860616,0,Lung,IV,Metastatic,2,Partial response,27.56468173,1,Partial response,30.32443532,1,32.22997947,1,33,1,1,1,1,1,85,CYCLE 33 DAY 1,4/2/2020,29.437372,1,0.98082018
LOXO-TRK-15002-703-001,46,M,White,Y,,10/20/2017,32.22997947,93.7,174,30.94860616,0,Lung,IV,Metastatic,2,Partial response,27.56468173,1,Partial response,30.32443532,1,32.22997947,1,34,1,1,1,1,1,85,CYCLE 34 DAY 1,4/29/2020,30.324436,1,0.98082018
LOXO-TRK-15002-703-001,46,M,White,Y,,10/20/2017,32.22997947,93.7,174,30.94860616,0,Lung,IV,Metastatic,2,Partial response,27.56468173,1,Partial response,30.32443532,1,32.22997947,1,35,1,1,1,1,1,85,CYCLE 35 DAY 1,5/29/2020,31.310062,1,0.98082018
LOXO-TRK-15002-703-001,46,M,White,Y,,10/20/2017,32.22997947,93.7,174,30.94860616,0,Lung,IV,Metastatic,2,Partial response,27.56468173,1,Partial response,30.32443532,1,32.22997947,1,36,1,1,1,1,1,85,CYCLE 36 DAY 1,6/26/2020,32.22998,1,0.98082018
LOXO-TRK-15002-703-002,60,M,White,Y,,9/20/2018,21.19096509,73.6,170,25.46712803,0,Soft tissue sarcoma,II,Locally advanced,0,Complete response,16.55852156,1,Partial response,19.31827515,1,21.19096509,1,0,1,1,1,1,1,100,CYCLE 1 DAY 1,9/20/2018,0,1,0.97889173
LOXO-TRK-15002-703-002,60,M,White,Y,,9/20/2018,21.19096509,73.6,170,25.46712803,0,Soft tissue sarcoma,II,Locally advanced,0,Complete response,16.55852156,1,Partial response,19.31827515,1,21.19096509,1,3,2,1,1,1,1,95,CYCLE 3 DAY 1,11/15/2018,1.87269,1,0.87975502
LOXO-TRK-15002-703-002,60,M,White,Y,,9/20/2018,21.19096509,73.6,170,25.46712803,0,Soft tissue sarcoma,II,Locally advanced,0,Complete response,16.55852156,1,Partial response,19.31827515,1,21.19096509,1,5,2,1,1,1,1,100,CYCLE 5 DAY 1,1/11/2019,3.7453799,1,0.87975502
LOXO-TRK-15002-703-002,60,M,White,Y,,9/20/2018,21.19096509,73.6,170,25.46712803,0,Soft tissue sarcoma,II,Locally advanced,0,Complete response,16.55852156,1,Partial response,19.31827515,1,21.19096509,1,6,2,1,1,1,1,100,CYCLE 6 DAY 1,2/7/2019,4.6324434,1,0.87975502
LOXO-TRK-15002-703-002,60,M,White,Y,,9/20/2018,21.19096509,73.6,170,25.46712803,0,Soft tissue sarcoma,II,Locally advanced,0,Complete response,16.55852156,1,Partial response,19.31827515,1,21.19096509,1,7,2,1,1,1,1,100,CYCLE 7 DAY 1,3/7/2019,5.5523615,1,0.87975502
LOXO-TRK-15002-703-002,60,M,White,Y,,9/20/2018,21.19096509,73.6,170,25.46712803,0,Soft tissue sarcoma,II,Locally advanced,0,Complete response,16.55852156,1,Partial response,19.31827515,1,21.19096509,1,8,2,1,1,1,1,100,CYCLE 8 DAY 1,4/4/2019,6.4722791,1,0.87975502
LOXO-TRK-15002-703-002,60,M,White,Y,,9/20/2018,21.19096509,73.6,170,25.46712803,0,Soft tissue sarcoma,II,Locally advanced,0,Complete response,16.55852156,1,Partial response,19.31827515,1,21.19096509,1,9,2,1,1,1,1,100,CYCLE 9 DAY 1,5/3/2019,7.4250512,1,0.87975502
LOXO-TRK-15002-703-002,60,M,White,Y,,9/20/2018,21.19096509,73.6,170,25.46712803,0,Soft tissue sarcoma,II,Locally advanced,0,Complete response,16.55852156,1,Partial response,19.31827515,1,21.19096509,1,10,2,1,1,1,1,100,CYCLE 10 DAY 1,5/30/2019,8.3121147,1,0.87975502
LOXO-TRK-15002-703-002,60,M,White,Y,,9/20/2018,21.19096509,73.6,170,25.46712803,0,Soft tissue sarcoma,II,Locally advanced,0,Complete response,16.55852156,1,Partial response,19.31827515,1,21.19096509,1,11,1,1,1,1,1,100,CYCLE 11 DAY 1,6/27/2019,9.2320328,1,0.97889173
LOXO-TRK-15002-703-002,60,M,White,Y,,9/20/2018,21.19096509,73.6,170,25.46712803,0,Soft tissue sarcoma,II,Locally advanced,0,Complete response,16.55852156,1,Partial response,19.31827515,1,21.19096509,1,12,2,1,1,1,1,100,CYCLE 12 DAY 1,7/25/2019,10.151951,1,0.87975502
LOXO-TRK-15002-703-002,60,M,White,Y,,9/20/2018,21.19096509,73.6,170,25.46712803,0,Soft tissue sarcoma,II,Locally advanced,0,Complete response,16.55852156,1,Partial response,19.31827515,1,21.19096509,1,13,1,1,1,1,1,100,CYCLE 13 DAY 1,8/22/2019,11.071869,1,0.97889173
LOXO-TRK-15002-703-002,60,M,White,Y,,9/20/2018,21.19096509,73.6,170,25.46712803,0,Soft tissue sarcoma,II,Locally advanced,0,Complete response,16.55852156,1,Partial response,19.31827515,1,21.19096509,1,14,2,1,1,1,1,100,CYCLE 14 DAY 1,9/19/2019,11.991786,1,0.87975502
LOXO-TRK-15002-703-002,60,M,White,Y,,9/20/2018,21.19096509,73.6,170,25.46712803,0,Soft tissue sarcoma,II,Locally advanced,0,Complete response,16.55852156,1,Partial response,19.31827515,1,21.19096509,1,15,1,1,1,1,1,100,CYCLE 15 DAY 1,10/17/2019,12.911704,1,0.97889173
LOXO-TRK-15002-703-002,60,M,White,Y,,9/20/2018,21.19096509,73.6,170,25.46712803,0,Soft tissue sarcoma,II,Locally advanced,0,Complete response,16.55852156,1,Partial response,19.31827515,1,21.19096509,1,16,1,1,1,1,1,100,CYCLE 16 DAY 1,11/14/2019,13.831622,1,0.97889173
LOXO-TRK-15002-703-002,60,M,White,Y,,9/20/2018,21.19096509,73.6,170,25.46712803,0,Soft tissue sarcoma,II,Locally advanced,0,Complete response,16.55852156,1,Partial response,19.31827515,1,21.19096509,1,17,1,1,1,1,1,100,CYCLE 17 DAY 1,12/12/2019,14.75154,1,0.97889173
LOXO-TRK-15002-703-002,60,M,White,Y,,9/20/2018,21.19096509,73.6,170,25.46712803,0,Soft tissue sarcoma,II,Locally advanced,0,Complete response,16.55852156,1,Partial response,19.31827515,1,21.19096509,1,18,1,1,1,1,1,100,CYCLE 18 DAY 1,1/9/2020,15.671458,1,0.97889173
LOXO-TRK-15002-703-002,60,M,White,Y,,9/20/2018,21.19096509,73.6,170,25.46712803,0,Soft tissue sarcoma,II,Locally advanced,0,Complete response,16.55852156,1,Partial response,19.31827515,1,21.19096509,1,19,1,1,1,1,1,100,CYCLE 19 DAY 1,2/6/2020,16.591375,1,0.97889173
LOXO-TRK-15002-703-002,60,M,White,Y,,9/20/2018,21.19096509,73.6,170,25.46712803,0,Soft tissue sarcoma,II,Locally advanced,0,Complete response,16.55852156,1,Partial response,19.31827515,1,21.19096509,1,20,2,1,1,1,1,100,CYCLE 20 DAY 1,3/5/2020,17.511293,1,0.87975502
LOXO-TRK-15002-703-002,60,M,White,Y,,9/20/2018,21.19096509,73.6,170,25.46712803,0,Soft tissue sarcoma,II,Locally advanced,0,Complete response,16.55852156,1,Partial response,19.31827515,1,21.19096509,1,21,1,1,1,1,1,100,CYCLE 21 DAY 1,4/2/2020,18.431211,1,0.97889173
LOXO-TRK-15002-703-002,60,M,White,Y,,9/20/2018,21.19096509,73.6,170,25.46712803,0,Soft tissue sarcoma,II,Locally advanced,0,Complete response,16.55852156,1,Partial response,19.31827515,1,21.19096509,1,22,1,1,1,1,1,100,CYCLE 22 DAY 1,4/29/2020,19.318275,1,0.97889173
LOXO-TRK-15002-703-002,60,M,White,Y,,9/20/2018,21.19096509,73.6,170,25.46712803,0,Soft tissue sarcoma,II,Locally advanced,0,Complete response,16.55852156,1,Partial response,19.31827515,1,21.19096509,1,23,1,1,1,1,1,100,CYCLE 23 DAY 1,5/28/2020,20.271048,1,0.97889173
LOXO-TRK-15002-703-002,60,M,White,Y,,9/20/2018,21.19096509,73.6,170,25.46712803,0,Soft tissue sarcoma,II,Locally advanced,0,Complete response,16.55852156,1,Partial response,19.31827515,1,21.19096509,1,24,1,1,1,1,1,100,CYCLE 24 DAY 1,6/25/2020,21.190966,1,0.97889173
LOXO-TRK-15002-901-001,32,M,White,Y,Disease Progression,8/30/2016,11.23613963,105.5,194,28.0316718,1,GIST,III,Metastatic,2,Partial response,11.137577,0,Partial response,9.232032854,0,36.56673511,1,0,2,1,3,2,3,70,CYCLE 1 DAY 1,8/30/2016,0,1,0.65284634
LOXO-TRK-15002-901-001,32,M,White,Y,Disease Progression,8/30/2016,11.23613963,105.5,194,28.0316718,1,GIST,III,Metastatic,2,Partial response,11.137577,0,Partial response,9.232032854,0,36.56673511,1,3,2,1,1,1,1,95,CYCLE 3 DAY 1,10/26/2016,1.9055442,1,0.88507241
LOXO-TRK-15002-901-001,32,M,White,Y,Disease Progression,8/30/2016,11.23613963,105.5,194,28.0316718,1,GIST,III,Metastatic,2,Partial response,11.137577,0,Partial response,9.232032854,0,36.56673511,1,5,2,1,1,1,1,95,CYCLE 5 DAY 1,12/22/2016,3.778234,1,0.88507241
LOXO-TRK-15002-901-001,32,M,White,Y,Disease Progression,8/30/2016,11.23613963,105.5,194,28.0316718,1,GIST,III,Metastatic,2,Partial response,11.137577,0,Partial response,9.232032854,0,36.56673511,1,7,1,1,1,1,1,100,CYCLE 7 DAY 1,2/15/2017,5.5852156,1,0.98427391
LOXO-TRK-15002-901-001,32,M,White,Y,Disease Progression,8/30/2016,11.23613963,105.5,194,28.0316718,1,GIST,III,Metastatic,2,Partial response,11.137577,0,Partial response,9.232032854,0,36.56673511,1,9,2,1,1,1,1,90,CYCLE 9 DAY 1,4/12/2017,7.4250512,1,0.88507241
LOXO-TRK-15002-901-001,32,M,White,Y,Disease Progression,8/30/2016,11.23613963,105.5,194,28.0316718,1,GIST,III,Metastatic,2,Partial response,11.137577,0,Partial response,9.232032854,0,36.56673511,1,11,1,1,1,1,1,97,CYCLE 11 DAY 1,6/7/2017,9.2648869,1,0.98427391
LOXO-TRK-15002-901-001,32,M,White,Y,Disease Progression,8/30/2016,11.23613963,105.5,194,28.0316718,1,GIST,III,Metastatic,2,Partial response,11.137577,0,Partial response,9.232032854,0,36.56673511,1,13,3,1,1,2,1,84,CYCLE 13 DAY 1,8/4/2017,11.170431,1,0.72249079
LOXO-TRK-15002-901-001,32,M,White,Y,Disease Progression,8/30/2016,11.23613963,105.5,194,28.0316718,1,GIST,III,Metastatic,2,Partial response,11.137577,0,Partial response,9.232032854,0,36.56673511,1,96,2,1,2,2,1,86,END OF TREATMENT,8/8/2017,11.301848,1,0.7330935
LOXO-TRK-15002-901-002,14,M,White,Y,Adverse Event,5/4/2017,33.01848049,41,174,13.54207954,2,Soft tissue sarcoma,Not reported,Metastatic,3,Partial response,33.57700205,1,Complete response,33.57700205,1,37.02669405,1,,,,,,,,,,,1,
LOXO-TRK-15002-901-003,59,F,White,Y,Disease Progression,8/17/2017,7.09650924,115.7,162,44.08626734,1,Melanoma,Not reported,Metastatic,3,Partial response,5.519507187,0,Partial response,5.519507187,0,8.443531827,0,,,,,,,,,,,0,
LOXO-TRK-15002-901-004,52,M,White,Y,,7/17/2018,23.9835729,91,183,27.17310162,0,Lung,IV,Metastatic,5,Partial response,22.11088296,1,Partial response,22.11088296,1,23.9835729,1,0,1,1,2,2,2,70,CYCLE 1 DAY 1,7/17/2018,0,1,0.73205709
LOXO-TRK-15002-901-004,52,M,White,Y,,7/17/2018,23.9835729,91,183,27.17310162,0,Lung,IV,Metastatic,5,Partial response,22.11088296,1,Partial response,22.11088296,1,23.9835729,1,3,1,1,2,3,2,80,CYCLE 3 DAY 1,9/11/2018,1.87269,1,0.67781693
LOXO-TRK-15002-901-004,52,M,White,Y,,7/17/2018,23.9835729,91,183,27.17310162,0,Lung,IV,Metastatic,5,Partial response,22.11088296,1,Partial response,22.11088296,1,23.9835729,1,5,3,1,1,2,2,75,CYCLE 5 DAY 1,11/6/2018,3.7125256,1,0.68016273
LOXO-TRK-15002-901-004,52,M,White,Y,,7/17/2018,23.9835729,91,183,27.17310162,0,Lung,IV,Metastatic,5,Partial response,22.11088296,1,Partial response,22.11088296,1,23.9835729,1,7,2,1,1,3,2,72,CYCLE 7 DAY 1,1/8/2019,5.782341,1,0.68092078
LOXO-TRK-15002-901-004,52,M,White,Y,,7/17/2018,23.9835729,91,183,27.17310162,0,Lung,IV,Metastatic,5,Partial response,22.11088296,1,Partial response,22.11088296,1,23.9835729,1,9,2,1,2,2,2,80,CYCLE 9 DAY 1,2/27/2019,7.4250512,1,0.67980015
LOXO-TRK-15002-901-004,52,M,White,Y,,7/17/2018,23.9835729,91,183,27.17310162,0,Lung,IV,Metastatic,5,Partial response,22.11088296,1,Partial response,22.11088296,1,23.9835729,1,11,2,1,2,2,2,80,CYCLE 11 DAY 1,4/24/2019,9.2648869,1,0.67980015
LOXO-TRK-15002-901-004,52,M,White,Y,,7/17/2018,23.9835729,91,183,27.17310162,0,Lung,IV,Metastatic,5,Partial response,22.11088296,1,Partial response,22.11088296,1,23.9835729,1,13,3,1,2,3,2,70,CYCLE 13 DAY 1,6/19/2019,11.104723,1,0.57791054
LOXO-TRK-15002-901-004,52,M,White,Y,,7/17/2018,23.9835729,91,183,27.17310162,0,Lung,IV,Metastatic,5,Partial response,22.11088296,1,Partial response,22.11088296,1,23.9835729,1,16,3,1,2,2,2,80,CYCLE 16 DAY 1,9/11/2019,13.864476,1,0.62647092
LOXO-TRK-15002-901-004,52,M,White,Y,,7/17/2018,23.9835729,91,183,27.17310162,0,Lung,IV,Metastatic,5,Partial response,22.11088296,1,Partial response,22.11088296,1,23.9835729,1,19,3,2,3,3,3,70,CYCLE 19 DAY 1,12/3/2019,16.591375,1,0.48828587
LOXO-TRK-15002-901-004,52,M,White,Y,,7/17/2018,23.9835729,91,183,27.17310162,0,Lung,IV,Metastatic,5,Partial response,22.11088296,1,Partial response,22.11088296,1,23.9835729,1,22,2,2,3,3,2,75,CYCLE 22 DAY 1,2/26/2020,19.383984,1,0.53544813
LOXO-TRK-15002-901-004,52,M,White,Y,,7/17/2018,23.9835729,91,183,27.17310162,0,Lung,IV,Metastatic,5,Partial response,22.11088296,1,Partial response,22.11088296,1,23.9835729,1,25,2,1,2,3,2,78,CYCLE 25 DAY 1,5/20/2020,22.143738,1,0.62781858
